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Major depressive disorder (MDD) is a heritable and highly debilitating condition with 
antidepressants, first-line treatment, demonstrating low to modest response rates. No 
current biological mechanism substantially explains MDD but both neurostructural 
and neurochemical pathways have been suggested. Further explication of these may 
aid in identifying subgroups of MDD that are better defined by their aetiology. 
Specifically, genetic stratification provides an array of tools to do this, including the 
intermediate phenotype approach which was applied in this thesis. This thesis explores 
genetic overlap with regional brain volume and MDD and the genetic and non-genetic 
components of antidepressant response.  
The first study utilised the most recent published data from ENIGMA (Enhancing 
Neuroimaging Genetics through Meta-analysis) Consortium’s genome-wide 
association study (GWAS) of regional brain volume to examine shared genetic 
architecture between seven subcortical brain volumes and intracranial volume (ICV) 
and MDD. This was explored using linkage disequilibrium score regression (LDSC), 
polygenic risk scoring (PRS) techniques, Mendelian randomisation (MR) analysis and 
BUHMBOX (Breaking Up Heterogeneous Mixture Based On Cross-locus 
correlations). Results indicated that hippocampal volume was positively genetically 
correlated with MDD (rg= 0.46, P= 0.02), although this did not survive multiple 
comparison testing. Additionally, there was evidence for genetic subgrouping in 
Generation Scotland: Scottish Family Health Study (GS:SFHS) MDD cases 
(P=0.00281), however, this was not replicated in two other independent samples. This 
study does not support a shared architecture for regional brain volumes and MDD, 
however, provided some evidence that hippocampal volume and MDD may share 
genetic architecture in a subgroup of individuals, albeit the genetic correlation did not 
survive multiple testing correction and genetic subgroup heterogeneity was not 
replicated.  
To explore antidepressant treatment resistance, the second study utilised prescription 
data in (GS:SFHS) to define a measure of (a) treatment resistance (TR) and (b) stages 
of resistance (SR) by inferring antidepressant switching as non-response. GWAS were 
conducted separately for TR in GS:SFHS and the GENDEP (Genome-based 
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Therapeutic Drugs for Depression) study and then meta-analysed (meta-analysis 
n=4,213, cases=358). For SR, a GWAS on GS:SFHS only was performed (n=3,452). 
Additionally, gene-set enrichment, polygenic risk scoring (PRS) and genetic 
correlation analysis were conducted. No significant locus, gene or gene-set was 
associated with TR or SR, however power analysis indicated that this analysis was 
underpowered. Pedigree-based correlations identified genetic overlap with 
psychological distress, schizotypy and mood disorder traits.  
Finally, the role of neuroticism, psychological resilience and coping styles in 
antidepressant resistance was investigated. Univariate, moderation and mediation 
models were applied using logistic regression and structural equation modelling 
techniques. In univariate models, neuroticism and emotion-orientated coping 
demonstrated significant negative association with antidepressant resistance, whereas 
resilience, task-orientated and avoidance-orientated coping demonstrated significant 
positive association. No moderation of the association between neuroticism and TR 
was detected and no mediating effect of coping styles was found. However, resilience 
was found to partially mediate the association between neuroticism and TR.  
Whilst the first study does not indicate a genetic overlap between regional brain 
volumes and MDD, it demonstrates the utility of the intermediate approach in complex 
disease. Antidepressant resistance was associated with neuroticism both genetically 
and phenotypically, indicating its role as an intermediate phenotype. Nonetheless, 
larger sample sizes are needed to adequately address the components of antidepressant 
resistance. Further work in antidepressant non-response may help to identify biological 








Major depressive disorder (MDD) is a common and disabling condition. Currently 
antidepressant medication is the first therapeutic option for individuals with MDD but 
response rates are low to modest. No current explanations for MDD have adequately 
explained it but both brain structural changes and neurochemical alterations have been 
found. Therefore, examining both brain volumes and the antidepressant response (as 
antidepressants induce chemical changes themselves) could be used to try and explain 
more about MDD individuals. It is not fully understood whether the genetics of MDD 
individuals predispose them to smaller brain volumes or this is a result of the 
environment and/or course of the illness. In this thesis, three studies were completed. 
The first of these examined whether there was any evidence of overlap in the genes 
associated with MDD and the genes associated with larger brain volume in seven 
regions as well as total brain volume. This study found that there was a possible 
subgroup of MDD patients that had genetic overlap with hippocampus but this finding 
was not replicated. No other regions demonstrated strong genetic overlap, although to 
detect weaker correlations, larger sample sizes would be needed. The second study 
looked at antidepressant resistance using prescription records in a cohort taken from 
the general Scottish population. The study examined genetic variants and genetic 
overlap in treatment resistance. Despite this being one of the largest studies to examine 
treatment resistance, sample sizes were too small to identify genes associated however 
genetic overlap was demonstrated with neuroticism, psychological distress, 
schizoptypy and mood disorder traits. Finally, the last study explored the non-genetic 
factors in antidepressant resistance. This used models to look at the effect of 
neuroticism, psychological resilience and coping styles in treatment resistance. The 
study found that neuroticism, resilience and coping styles are all associated with 
antidepressant resistance and that neuroticism may induce treatment resistance by, in 
part, decreasing psychological resilience.  These studies together demonstrate little 
evidence for genetic overlap of brain volumes and MDD but show that neuroticism 
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Chapter 1. Introduction. 
 
1.1 Background of MDD 
Major depressive disorder (MDD) is a highly debilitating condition that contributes a 
large proportion of global disability (Ustün, Ayuso-Mateos, Chatterji, Mathers, & 
Murray, 2004). It is one of the oldest disorders to be formally identified in psychiatry 
(Jackson, 1986) and remains one of the most prevalent psychiatric disorders, however 
its aetiology continues to be elusive. Both psychological and drug interventions are 
used in MDD but antidepressant use is the most common form of treatment. High 
levels of heterogeneity in MDD and the complex contribution and interactions of 
genetic and environmental factors are likely meaningful underlying reasons. The 
economic burden for MDD was estimated at 2.5 trillion US dollars in 2010 with 
numbers expected to rise substantially in the coming years (Bloom et al., 2012). On an 
individual-level, those with serious mental illnesses have been found to earn around 
$16,000 less annually than healthy controls (Kessler et al., 2008). Thus, it is imperative 
to elucidate more about the mechanisms behind the disorder and develop more 
efficacious drugs that better target MDD aetiology.  
Definition of MDD 
Diagnosis of MDD follows the Diagnostic and Statistical Manual of Mental Disorders 
5th edition (DSM-5) (American Psychiatric Association, 2013). It is characterised by 
five or more depressive symptoms that must all persist within at least a two-week 
period. Nine possible depressive symptoms are given in DSM-5 criteria; hence 
multiple combinations of symptoms are inclusive in the same MDD diagnosis likely 
contributing to the substantial heterogeneity. Moreover, it has been hypothesised that 
MDD could incorporate multiple subgroups with varying aetiologies or, alternatively, 
could be a continuum of varying severity (Kendler & Gardner, 1998).  
Many subtypes of MDD have been proposed over a number of years. Traditionally, 
MDD was divided into reactive and endogenous subtypes which refer to stress-induced 
and stress-absent MDD, respectively. The DSM-IV (which preceded DSM-5) 
recognised five symptomatic subtypes of MDD: melancholic, atypical, catatonic, 
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postpartum and seasonal affective disorder. A division between single and recurrent 
episode depression has also been noted with recurrent depression having a higher 
incidence of anxiety comorbidity, higher depression scores and decreased perception 
of satisfactory social support compared with single episode cases (Wilhelm, Parker, 
Dewhurst-Savellis, & Asghari, 1999). Nevertheless, a systemic review of 20 studies 
in MDD subtypes concluded that no current evidence supported the use of 
symptomatic subtypes (van Loo, de Jonge, Romeijn, Kessler, & Schoevers, 2012), 
consequently research is now directed towards stratifying MDD into more 
biologically-evidenced groups. 
Epidemiology of MDD 
In 2011, a cross-national study estimated the 12-month prevalence of major depressive 
episodes at 5.5% and 5.9% and a lifetime prevalence of 14.6% and 11.1% for high to 
low-income countries, respectively (Bromet et al., 2011), however lifetime prevalence 
is subject to recall bias and underestimation (Moffitt et al., 2010; Patten, 2009). A large 
Canadian study reported that 6.6% of past-year MDD individuals reported a suicide 
attempt, 4.8% reported alcohol abuse and 33.1% were taking an antidepressant (Patten 
et al., 2015). Women are twice as likely to be affected than men (Seedat et al., 2009) 
and have been shown to report a lower age of onset and higher comorbidities of panic 
disorder with agoraphobia and anxiety whereas men reported higher comorbidities of 
alcohol dependence/abuse (Schuch, Roest, Nolen, Penninx, & de Jonge, 2014). The 
similarities between the 12-month prevalence as well as similarities in age of onset 
and MDD severity in high and low-income countries demonstrates that MDD is an 
important worldwide phenomenon (Kessler & Bromet, 2013). 
Comorbidities 
MDD has a large number of comorbidities that include other psychiatric disorders and 
some non-psychiatric diseases. For the most part, the mechanisms underlying the 
overlap is unknown although genetic factors are thought to play a role. As 
classification of many of the psychiatric disorders is based on symptoms only, there is 
debate as to the legitimacy of these diagnostic boundaries (Cross-Disorder Group of 
the Psychiatric Genomics Consortium, 2013) which could contribute to the observed 
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overlap. MDD is also known to occur in two common disease groups; cancer, with 
those affected associated with a decreased likelihood of returning to work (Pirl, Greer, 
Temel, Yeap, & Gilman, 2009), and cardiovascular disease, with one in five suffering 
with MDD (Elderon & Whooley, 2013). Furthermore, diseases with co-morbid 
depression are associated with poorer outcomes. For example, in cardiovascular 
disease, depression predicts higher mortality and morbidity in congestive heart failure, 
myocardial infarction and post-surgery patients (Nemeroff & Goldschmidt-Clermont, 
2012). Therefore, understanding the basis for these comorbidities could aid in 
improving patient prognosis. 
1.2. Genetics of MDD 
Familial aggregation of MDD has been described for decades but it is only until 
recently that any genome-wide associations have been documented (Mullins & Lewis, 
2017). The genetic component of depression has been notoriously complex and 
difficult to study. Family-based, twin studies and adoption studies are common 
methods for establishing the existence of a genetic component in disease. However in 
MDD, no high quality adoption studies have been produced (Flint & Kendler, 2014). 
Heritability 
Twin studies have estimated narrow-sense heritability of MDD at 37% (P. Sullivan, 
Neale, & Kendler, 2000). Narrow-sense heritability is the proportion of the trait’s 
phenotypic variance that is attributable to additive genetics. It can be calculated using 
large family-based samples or twin samples however these are susceptible to 
contributions of shared environment. To circumvent this, unrelated samples can be 
used to calculate the single nucleotide polymorphism (SNP) heritability which is the 
variance explained by common genetic variants. Specifically, SNPs are single 
nucleotide base changes that occur at specific regions in the genome and are common 
within the general population. In MDD, the SNP heritability has been calculated at 
21% (RipkeWray, et al., 2013). For the majority of diseases (MDD included), the SNP 
heritability estimates are lower than the narrow-sense heritability estimates and the 
difference between these has been termed the ‘missing heritability’. Explanations for 
this include over-estimations of narrow-sense heritability caused by shared 
environment and the unaccounted variance of rare genetic variants, gene interactions 
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or poorly tagged SNPs in SNP heritability (Wray & Maier, 2014). Understanding the 
contribution of shared environment could enable more accurate heritability estimates. 
A recent study by Zeng et al., (2016) measured the contribution of nuclear family, 
sibling and couple associated environment on MDD in the Generation Scotland cohort 
study (the main cohort used for this thesis). They found that couple-associated 
environment accounted for 14% of the phenotypic variance in addition to common 
variant-associated and pedigree-associated genetics, which accounted for 12% and 
35% respectively (Zeng et al., 2016). This therefore illustrates a high contribution of 
shared couple environment in MDD that may have important implications in the 
planning of future studies. 
Genome-wide association studies 
The past few decades of genome-wide association studies (GWAS) in MDD have been 
less fruitful than in other disease areas until recently, most likely owing to the 
excessive heterogeneity of the disorder. Until two years ago, the largest case-control 
GWAS of MDD, completed by the Psychiatric Genomics Consortium (PGC), on over 
9,000 cases and over 9,000 controls, presented no genome-wide significantly 
associated variants. In the same year, the CHARGE (Cohorts for Heart and Aging 
Research in Genomic Epidemiology) Consortium completed a GWAS on depressive 
symptoms on over 34,000 individuals and similarly produced no significant results. 
Both these studies attributed their lack of findings to insufficient power. 
In 2015, the CONVERGE (China, Oxford and Virginia Commonwealth University 
Experimental Research on Genetic Epidemiology) Consortium published the first 
GWAS to identify genome-wide significant variants. The GWAS was completed on a 
homogenous sample of Chinese women (with over 5000 cases and 5000 controls) with 
severe MDD and identified 2 loci (one near the SIRT1 gene and the other in the intron 
of LHPP) which both replicated in an independent sample (CONVERGE consortium, 
2015). A year later, 23andMe identified 15 loci using self-report data in over 75,000 
individuals and found evidence for the enrichment of the MEIS2 subnetwork which 
has a known role in hippocampal neurogenesis (Hyde et al., 2016). This significant 
progress in MDD has highlighted the importance of sample size in heterogeneous 
disorders. Identifying the genetic underpinnings for MDD may be critical to 
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understanding its underlying biological mechanism and, with the future availability of 
even larger samples, it may be possible to ascertain aetiological pathways, biomarkers 
and therapeutic targets.  
Genetic overlap 
Further exploration into MDD comorbidities has revealed substantial genetic overlap 
with other disorders. The PGC conducted a cross-disorder GWAS looking into the 
shared genetics between five psychiatric disorders: MDD, schizophrenia, autism 
spectrum disorder (ASD), bipolar disorder and attention deficit-hyperactivity disorder 
(ADHD) (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013). The 
analysis found four loci in common across the disorders and further identified a role 
of calcium channel signalling pathways. Additionally, borderline personality disorder 
has also demonstrated genetic overlap with MDD (Witt et al., 2017). Polygenic risk 
scores (PRS) produce an individual genetic score for a loading of a trait and can be 
used to identify genetic overlap. A 2016 Dutch study, assessed the association of PRS 
of psychiatric and metabolic disorders in MDD and subtypes (typical and atypical) 
finding that psychiatric and not metabolic disorders shared overlapping architectures 
and that the two subtypes were partially distinct (Milaneschi et al., 2016). Moreover, 
mania and MDD demonstrate a genetic correlation of 0.65 (McGuffin et al., 2003), 
MDD and alcohol disorders have been demonstrated to have a genetic correlation of 
0.58 (Olvera et al., 2011) and anorexia nervosa and MDD have a shared genetic 
variance of 34% (Wade, Bulik, Neale, & Kendler, 2000). 
In non-psychiatric traits, a review of prior GWAS meta-analyses in cardiometabolic 
traits associated the top findings with reported genetic associations in mood disorders 
(including MDD and bipolar disorder). They identified 24 shared genes between the 
two disease groups including those involved in the hypothalamus-pituitary-adrenal 
(HPA) axis, circadian rhythm, inflammation, neurotransmission and metabolism all of 
which have been previously implicated to be of biological significance in both diseases 
(Amare, Schubert, Klingler-Hoffmann, Cohen-Woods, & Baune, 2017). Analysis of 
the lipidome (referring to all lipids in the human body) in MDD, implicated shared 
genetic aetiology with ether-phosphatidylcholines and omega-6 fatty acid (a precursor 
to inflammatory mediators) (Knowles et al., 2017). Furthermore, genetic overlap 
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between type 2 diabetes and MDD was examined in two large GWAS meta-analysis 
cohorts by identifying overlapping SNPs above the P-value cut-off of <1.0x10-7. After 
further applying pathway analysis, the study described immune responses, cell 
signalling, lipid metabolism and cancer associated pathways shared between the two 
diseases (Ji, Zhuang, & Shen, 2016). Moreover, genetic correlation has been found 
between MDD and heart rate variability; rg= -0.23 P= 0.02 for ultra-low frequency 
heart rates (Su et al., 2010). This therefore demonstrates the utility of examining shared 
genetic architecture in order to understand the pathways underpinning comorbidities. 
1.3. Possible Biological Mechanisms 
Multiple theories have been given as to the aetiology of MDD, however none so far 
have adequately explained it. The role of monoamines, the HPA axis, 
neuroinflammation, other neurotransmitters and neurostructural mechanisms are 
explored here, although it should be mentioned that these are not the only theories for 
causality. 
Monoamine hypothesis 
The monoamine hypothesis is the oldest biological mechanism theorised for 
depression but poorly replicated results and lack of clinical success has led to its loss 
of popularity. Monoamines are neurotransmitters in the central nervous system (CNS) 
that include serotonin, noradrenaline and dopamine. They have a wide array of 
functions but they have all been implicated in the pathology of MDD (Elhwuegi, 
2004). The monoamine theory dates back to the 1950s where the serotonin actions in 
a hallucinogen, lysergic acid diethylamide (LSD), and an antihypertensive agent, 
reserpine, were linked to mental health and MDD (Hirschfeld, 2000). Since then 
research into monoamines and their role in MDD has expanded and prompted the 
generation of monoamine oxidase inhibitors (MAOIs), and later other antidepressants 
(further details on antidepressants are given below). Whilst a decrease in monoamines 
is concurrently found in MDD individuals, animal serotonin knock-out studies have 
not fully captured depression and current antidepressant classes have had limited 
success (Belmaker & Agam, 2008). Explanations for this discrepancy include that 
depression may cause the decrease in monoamines or that another factor is responsible 
for both the reduction in monoamines and onset of MDD (aan het Rot, Mathew, & 
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Charney, 2009). It is possible that stress is such a factor as it has been shown to induce 
a reduction in monoamine levels and is associated with depression onset (Cowen, 
2002). 
The hypothalamus-pituitary-adrenal (HPA) axis 
There is considerable evidence for the involvement of stress in MDD (Tennant, 2002). 
Stress involves the HPA axis which is regulated by a negative feedback loop. In brief, 
a stressful event will stimulate the hypothalamus to release corticotropin-releasing 
hormone (CRH) which binds to receptors on the pituitary gland which in turn releases 
adrenocorticotropic hormone (ACTH). ACTH then binds to the adrenal gland 
releasing cortisol which acts on glucocorticoid receptors in the hippocampus that then 
sends signals to the hypothalamus to decrease CRH. Both cortisol and CRH have been 
strongly associated with MDD and evidence of elevated levels in stress and trauma 
have also been shown (Belmaker & Agam, 2008). Nevertheless, the role of stress and 
the HPA axis has not fully explained the aetiology MDD. Stress levels are not 
necessarily predictive of a depression outcome and cortisol levels have not been found 





Figure 1.1. Diagram representing the hypothalamus-pituitary-adrenal (HPA) 
axis. The HPA axis is regulated by a negative feedback loop that that is initiated by 
the release of glucocorticoids that indirectly signal the hypothalamus to reduce the 
release of CRH. 
Other neurotransmitters and neurotrophins 
Brain-derived neurotrophic factor (BDNF), which is important for neuronal grown and 
survival, has also shown to be reduced in acute and chronic stress and is associated 
with higher cortisol levels (Belmaker & Agam, 2008). Reduced BDNF protein 
expression after chronic stress have been found in the dentate gyrus of the 
hippocampus which chronic antidepressant use has been shown to reverse (Grønli et 
al., 2006; Nair et al., 2007). However, inconsistent results of associations between 
BDNF levels and MDD has led to a lack of support for the BDNF hypothesis as a 
causal pathway for MDD (Groves, 2007). 
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Perhaps one of the most recent theories for MDD aetiology is the glutamate hypothesis. 
Glutamate is the main excitatory neurotransmitter in the brain and binds to the N-
methyl-D-aspartate (NMDA) receptor. Its role in MDD was first noted in 1990 when 
NMDA receptor antagonists were found to have antidepressant-like effects (Trullas & 
Skolnick, 1990). Since then numerous studies have found that NMDA receptor 
antagonists exert fast and effective antidepressant action even in treatment resistant 
individuals (Gerhard, Wohleb, & Duman, 2016). Furthermore, ketamine (an NMDA 
receptor antagonist) has been found to upregulate synaptogenesis and reduce stress-
induced neuronal atrophy (Duman & Li, 2012). Nevertheless, sustained use of 
ketamine can cause neuronal damage and, even at low doses, it can still exert 
psychotomimetic effects (Gerhard et al., 2016). Research into mimicking the effects 
of ketamine and other NMDA receptor antagonists without these adverse effects is 
ongoing (Gerhard et al., 2016). 
Neuroinflammation 
The cytokine hypothesis has also been proposed as an explanation for the aetiology of 
depression and the monoaminergic abnormalities. The presence of cytokines and 
inflammatory processes in MDD was first described in 1990 (Maes et al., 1990) but 
their association since then has become well established (Maes et al., 2009). Increased 
levels of inflammatory cytokines, have been found in the peripheral blood of MDD 
patients (Goldsmith, Rapaport, & Miller, 2016) and inhibition of proinflammatory 
cytokines has been shown to reduce depressive symptoms (Raison, Capuron, & Miller, 
2006). Cytokines are known to induce sickness behaviours (such as fatigue and loss of 
appetite) which bear a notable resemblance to depressive symptoms; it is therefore 
hypothesised that depression could occur when the immune system is upregulated 
(Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008). Stress has also been linked to 
the regulation of inflammation; the HPA axis stimulates glucocorticoids to reduce 
transcription of proinflammatory cytokines and increase anti-inflammatory cytokines. 
However in chronic stress, desensitisation of the glucocorticoid receptors can occur 
which could intensify cytokine activity and in turn exaggerate chronic 
neuroinflammation (Y. K. Kim, Na, Myint, & Leonard, 2016). Furthermore, MDD has 
well established comorbidities with a variety of inflammatory diseases e.g. 
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cardiovascular diseases (Carney et al., 1988) and inflammatory bowel disease (Graff, 
Walker, & Bernstein, 2009). Nevertheless, C-reactive protein, a known inflammatory 
marker, has not been indicated as a causal risk factor for depression (Wium-Andersen, 
Orsted, & Nordestgaard, 2014). Moreover, a 2014 systematic review found a high level 
of heterogeneity in inflammation studies and could not reject the possibility of 
publication bias (Köhler et al., 2014). It is likely that inflammation occurs in a 
subgroup of MDD patients and therefore it has been suggested that future studies 
should focus on identifying patients that may benefit from anti-inflammatory 
intervention (Köhler, Krogh, Mors, & Benros, 2015). 
Neurostructural mechanisms 
Functional and structural brain abnormalities have been associated with MDD 
pathology. However, arguably the most widely studied neurostructural phenomenon 
in MDD causality is hippocampal neurogenesis. Adult neurogenesis (the generation of 
new neurons in the adult brain) is known to occur in two areas of the brain; the 
subventricular zone of the lateral ventricle and subgranular zone of the dentate gyrus 
in the hippocampus (Bond, Ming, & Song, 2015). It is regulated by both intrinsic and 
extrinsic mechanisms. Growth factors, neurotrophins (such as brain-derived 
neurotrophic factor; BDNF), neurotransmitters (e.g. glutamate) and sex hormones are 
among those intrinsic regulators to have been identified (Balu & Lucki, 2009). Other 
brain regions also have an involvement; the basolateral complex of the amygdala plays 
a regulatory role in hippocampal neurogenesis that in turn affects memory (Kirby et 
al., 2012). Genes are also key regulators of neurogenesis (Clark et al., 2011) and 
microglia (neuronal inflammatory agents) have been associated (De Lucia et al., 2016; 
Luo, Ikegaya, & Koyama, 2016). 
The role of hippocampal neurogenesis in depression is still a controversial one and is 
commonly investigating by ablation of hippocampal neurogenesis in mice. High levels 
of stress have been demonstrated to decrease hippocampal neurogenesis in both animal 
and human models (Anacker, 2014) and animal models have demonstrated that 
antidepressants have the ability to increase production of new neurons (Eliwa, 
Belzung, & Surget, 2017). Furthermore, ablation of neurogenesis in the hippocampus 
inhibits antidepressant-induced remission and it has therefore been suggested that 
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neurogenesis mechanisms are essential for antidepressant effects (Surget et al., 2011). 
Diseases that are highly comorbid with MDD have also shown reductions in 
hippocampal neurogenesis: post-traumatic syndrome disorder (PTSD) (Besnard & 
Sahay, 2016), anxiety disorders (Schoenfeld & Cameron, 2015), schizophrenia (Duan 
et al., 2007) and Alzheimer’s Disease (Kent & Mistlberger, 2017). Nonetheless, 
despite some evidence that increasing hippocampal neurogenesis reduces depressive-
like behaviour (Hill, Sahay, & Hen, 2015), the majority of studies report that the 
ablation of new neuronal cells in the hippocampus is not associated with increased 
MDD and therefore not causative (Tanti & Belzung, 2013). Consequently, it has been 
hypothesised that antidepressant action may occur through increasing hippocampal 
neurogenesis causing an alteration in mood (Duman, Nakagawa, & Malberg, 2001) 
rather than targeting the cause of MDD. However, the exact role of neurogenesis in 
MDD and antidepressant response is still unknown. 
Psychosocial factors (referring to the interrelationship of social factors and 
personality/behaviours) are also of significant importance as predictors of depression 
outcome. Associations have been found between the chronicity of depression and the 
HPA axis responsiveness to psychosocial stress (Booij, Bouma, de Jonge, Ormel, & 
Oldehinkel, 2013). In fact, when examining the impact of adolescent depression on 
onset of adult depression, the effect of adolescent depression was significantly reduced 
after accounting for psychosocial factors (McLeod, Horwood, & Fergusson, 2016). 
Personality factors can have a large impact on inter-individual response to stress 
(Lecic-Tosevski, Vukovic, & Stepanovic, 2011). Negative changes in psychosocial 
working environment have been shown to increase depressive symptoms indicating 
that psychosocial factors are important (J. Li et al., 2013). Additionally, psychosocial 
intervention has also been demonstrated to reduce postpartum depression, including 
nurse visits, peer telephone support and psychotherapy (Dennis & Dowswell, 2013). 
Psychosocial intervention strategies have also been shown to improve antidepressant 
adherence (Sirey, Bruce, & Kales, 2010) indicating their benefit in combination with 
pharmacotherapies. 
The above research highlights the necessity for further research into the biological 
mechanisms involved in MDD. Both neurostructural and neurochemical mechanisms 
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have been implicated and it is possible that further investigation of these may elucidate 
more about MDD pathology. This thesis will explore structural neuroimaging, in order 
to determine more about neurostructural abnormalities, and antidepressant response, 
to determine whether differential response relates to variation in the underlying 
neurochemical processes. These subject areas are described in more detail below. 
1.4. Regional Brain Volumes 
Understanding of the processes in the brain has evolved considerably of the last few 
decades, but particularly with regards to emotion and cognition. This is of particular 
relevance as emotional dysregulation and cognitive deficits have been widely 
implicated in poor mental health outcome (Bradley et al., 2011; J. K. Trivedi, 2006). 
Both emotion and cognitive processes are predominantly controlled by complex 
interaction between subcortical and cortical structures (Heatherton & Wagner, 2011; 
Wager, Davidson, Hughes, Lindquist, & Ochsner, 2008) and, although defined as two 
separate entities, are thought to be highly interactive and interdependent (Storbeck & 
Clore, 2007). Specifically, emotional stimulus are generally preferentially 
remembered over neutral ones and they can therefore bias decision making and provide 
motivation whilst cognitive control can inhibit aggression and emotional regulation 
(Pourtois, Notebaert, & Verguts, 2012). Nevertheless, cognitive processes have been 
shown to deteriorate with age whereas emotion functioning remains unaffected (Ebner 
& Fischer, 2014). Emotional dysregulation is widely associated with MDD and has 
further been associated with cognitive inhibition of emotional material (Joormann & 
Gotlib, 2010) thereby implicating brain processes in MDD pathology. This thesis will 
focus on subcortical abnormalities associated with MDD in an aim to explicate the 
potential causality of structural differences in the disorder, however, it is worth 
mentioning that cortical structural differences have also been described in MDD. 
Determining these volumetric alterations could help determine individuals at risk and 
establish biological mechanisms. This section will give a brief overview of the known 
functions and associations of seven subcortical structures; the nucleus accumbens, 
caudate nucleus, putamen and pallidum (part of the basal ganglia), the hippocampus 




Individual subcortical structures are known to be important in a variety of functions 
and are highly interactive between each other and other cortical regions. The nucleus 
accumbens has been traditionally associated with a role as a reward centre but has 
since been related to a variety of behaviours including learning, impulsivity and goal-
orientated actions (Salgado & Kaplitt, 2015). The basal ganglia, composed of both the 
striatum (an interlinking complex of the caudate nucleus and the putamen) and the 
pallidum, has a well-established role in motor functions but has additionally been 
shown to have functions in time estimation, learning, emotions and cognitive function 
(Grahn, Parkinson, & Owen, 2008; Lanciego, Luquin, & Obeso, 2012). Moreover, the 
hippocampus has known functions in memory and cognition (Eichenbaum, 2004) 
whilst both the hippocampus and amygdala are known to play a role in emotions and 
memory (Phelps, 2004). Furthermore, the thalamus has been associated with cognitive 
function (Fama & Sullivan, 2015). Therefore, individual regions may contribute 
differentially to mental health outcomes. 
Association with MDD 
Neuroimaging findings in subcortical volumes in MDD are widely inconsistent. The 
largest single study to date, a UK Biobank study of 354 MDD cases and 803 controls, 
identified no significant differences in subcortical volumes, albeit the authors note 
their sample size as a limiting factor (Shen et al., 2017). In order to enhance sample 
size, a number of meta-analyses have been conducted. The ENIGMA Consortium 
conducted a large meta-analysis of subcortical structures finding that smaller 
hippocampal volume was associated with MDD (Cohen's d= −0.14, P= 4.6x10-4) and 
that this was driven by recurrent MDD (Cohen's d= −0.17, P= 1.1x10-5) (Schmaal et 
al., 2015). This study did not find any significant evidence for an association with any 
other subcortical volume after meta-analysis with 1,728 cases and 7,199 controls. A 
2009 meta-analysis identified moderate reductions in the total volumes of the caudate 
nucleus (Cohen's d= −0.31, P= 0.024), putamen (Cohen's d= −0.48, P= 0.003) and 
hippocampus (Cohen's d= −0.41, P< 0.001)  in an analysis of 2,418 MDD cases and 
1,974 controls (Koolschijn, van Haren, Lensvelt-Mulders, Hulshoff Pol, & Kahn, 
2009). Moreover, subcortical volumes, which are associated with age-related 
volumetric reductions, have been associated with accelerated aging in MDD; volume 
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reductions in the putamen were twice as large than in controls, with reductions of 
16.7mm3/yr in MDD cases (Sacchet, Camacho, Livermore, Thomas, & Gotlib, 2017). 
Nevertheless, in structural neuroimaging studies, reductions in hippocampus have 
been the most widely replicated finding (Arnone, McIntosh, Ebmeier, Munafò, & 
Anderson, 2012).  
Association with Antidepressant response  
Both structural and functional neuroimaging have demonstrated predictive potential in 
antidepressant response indicating their potential clinical utility (Fu, Steiner, & 
Costafreda, 2013). Specifically, the largest meta-analysis to date of hippocampal 
volumes in 374 MDD patients demonstrated smaller volumes were associated with 
antidepressant non-responders in comparison with responders (mean volume 
difference= 260mm3, P= 0.002) (Colle et al., 2016). Furthermore, a study of 39 
patients on fluoxetine found that larger whole brain volumes at trial initiation predicted 
successful response in 89% of cases and further theorised that structural abnormalities 
could specifically predict response to antidepressant treatment whilst functional 
changes could relate to response to cognitive-based therapies (CBT) (Costafreda, Chu, 
Ashburner, & Fu, 2009; Fu et al., 2013). Small sample sizes again severely limit the 
power to detect neuroimaging changes in treatment response studies (M. L. Phillips et 
al., 2015) and further research with larger samples are needed to produce reliable 
associations between antidepressants and subcortical volumes. 
1.5. Antidepressants and MDD 
Antidepressants are the main therapeutic option for individuals with MDD and are the 
third most commonly prescribed drug in the United States (US) (Mojtabai & Olfson, 
2011). For the most part, they can be divided into seven main categories: monoamine 
oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) tetracyclic 
antidepressants (TeCAs), serotonin antagonist and reuptake inhibitors (SARIs), 
selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors 
(NRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). They were first 
approved for the treatment of major depressive disorder in the 1950s with SSRIs, now 
the most widely used antidepressant, introduced in the 1980s (López-Muñoz & Alamo, 
2009). The latest antidepressant to be approved in Europe and the US was vortioxetine 
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in 2013 (Thase, Mahableshwarkar, Dragheim, Loft, & Vieta, 2016). However, 
although each of these antidepressant classes were targeted towards a particular 
























Class Year of 
first 
approval 
Intended Mechanism of Action Examples 
Monoamine oxidase 
inhibitors (MAOIs) 
1952 MAOIs inhibits monoamine oxidase 
which is the enzyme responsible for the 
breakdown of monoamines. 
Monoamine oxidase is present as two 
isoenzymes MAO-A and MAO-B that 
differentially breakdown specific 
monoamines. MAOIs can reversibly or 
irreversibly inhibit both isoforms 








1957 TCAs inhibit reuptake of both serotonin 
and noradrenaline and antagonise the 
histamine H1 receptor (Weber, 
Siddiqui, Wagstaff, & McCormack, 
2010). Their chemical structure 








1971 SNRIs inhibit both the reuptake of 
serotonin and noradrenaline thereby 
increasing their availability at the 






1974 TeCAs structure consists of four rings 
and have various differing effects 
amongst specific drugs. Mirtazapine 
(the most common TeCA prescribed for 
depression) increases serotonergic and 
noradrenergic neurotransmission via 
blocking α2 adrenergic receptors (Davis 






1981 SARIs block the 5-HT2A receptors as 
well as the histamine H1 receptors and 






1987 SSRIs act as selective antagonists at the 
serotonin transporter inhibiting reuptake 







1997 NRIs act as selective antagonists at the 
noradrenaline transporter in a similar 
action to SSRIs. They tend to have 
weak affinity for adrenergic and 




1.2. Major classes of antidepressants. Each class of antidepressant also has its year 





Response to an antidepressant treatment is an improvement in symptoms whereas 
remission is defined as an improvement whereby the individual no longer reaches the 
criteria for major depressive disorder (Israel, 2006). Antidepressant response has been 
measured at about a third of individuals in remission after the first treatment trial (M. 
H. Trivedi et al., 2006) and half after the second treatment trial (A. J. Rush et al., 2006). 
Rush et al., (2006) also found that response rates fell after each treatment step 
indicating that failure to receive remission was a risk for failure to respond the next 
treatment (response after 1st trial= 37%, 2nd trial= 31%, 3rd trial= 14%, 4th trial= 13%) 
(A. J. Rush et al., 2006). Currently the method for determining antidepressant 
prescription is trial and error with the low to modest response rates attributed to clinical 
subtypes of MDD (Domschke et al., 2016). The placebo effect (the simulation of a 
drug whereby improvement is due to personal expectations rather than the drug itself 
(Price, Finniss, & Benedetti, 2008)) is also commonly reported in antidepressants and 
widely debated with perhaps the most controversial study regarding this conducted by 
Kirsch et al., (2008). The study documented the placebo effect in antidepressants, 
finding that it was accountable for response in all but the most severe cases of MDD, 
but this was concluded to be a decreased response to placebo not an increased response 
to medication (Kirsch et al., 2008). The study sparked immediate criticism with it 
being argued that response to antidepressants should be measured as the difference 
between drug and placebo, therefore the interpretation of the paper was in fact that 
drug response increases with depression severity (McAllister-Williams, 2008). 
Furthermore, a re-analysis of the data in 2011, pointed to several failings of this paper, 
including that both venlafaxine and paroxetine reduced depressive symptoms to a level 
that surpassed the thresholds set by the National Institute of Clinical Excellence 
(NICE) (Fountoulakis & Möller, 2011). Nonetheless, this subject is still widely 
debated (Bschor & Kilarski, 2016).  
Mechanisms of action and non-response 
Although the exact mechanism by which antidepressants exert an effect is unknown 
there is some evidence for their actions. Antidepressants were originally used in MDD 
due to their role in increasing monoamines, specifically serotonin. However, 
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monoaminergic increases occur quickly after taking an antidepressant whereas actual 
response (i.e. reduction in depressive symptoms) has been shown to take weeks 
(Andrade & Rao, 2010). Moreover, there is a vast amount of inconsistent evidence that 
exists for the role of serotonin, including no robust evidence that monoaminergic 
decreases are causal (Lacasse & Leo, 2005). It has therefore been proposed that 
antidepressant-induced reduction in depressive symptoms occurs via another 
mechanism. Antidepressants have been shown to cause increases in BDNF levels in 
almost every antidepressant class which have further been associated with 
antidepressant-induced behavioural changes in rodents (Castrén & Kojima, 2017). 
Furthermore, some antidepressants have been shown to reduce glutamatergic action 
by reducing the transmission and release of glutamate in the hippocampus and cortical 
regions (Musazzi, Treccani, Mallei, & Popoli, 2013). Higher inflammatory markers in 
peripheral blood has been shown to predict poor response to current treatments (Uher 
et al., 2014) and antidepressants have also been shown to affect levels of 
proinflammatory cytokines (Więdłocha et al., 2017), indicating a role of the 
inflammatory pathways. Antidepressants have also been shown to reverse stress-
induced reduction in hippocampal neurogenesis (Warner-Schmidt & Duman, 2006) 
and, additionally, SSRIs have been indicated to enhance response to the environment 
which in turn facilitates drug response or non-response (Alboni et al., 2017). 
Nevertheless, no current explanations fully explicate antidepressant action and the 
pathways of response remain elusive. Explicating the mechanisms of action of 
antidepressants could provide an explanation for non-response, help identify more 
effective treatments and may also provide information on MDD causality.  
Genetics 
Familial concordance to differential antidepressant response has been shown 
(Franchini, Serretti, Gasperini, & Smeraldi, 1998) indicating there is a familial burden 
to drug response that could be attributed to genetic or shared environmental 
components. Genetic studies exploring differential responses have not identified any 
robust genetic marker. The main approach for measuring antidepressant response in 
MDD trials is a continuous measure of change in depressive symptoms from baseline, 
which are usually measured by the Montgomery-Asberg Depression Rating Scale 
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(MADRS) or the Hamilton Rating Depression Scale (HRDS). Initial studies of 
candidate genes (such as monoaminergic and neurotrophic polymorphisms) in 
antidepressant response produced poorly replicated results (Fabbri, Porcelli, & 
Serretti, 2014) and prompted a series of GWAS, that are generally considered the gold 
standard in genetic studies as they provide a hypothesis-free alternative. Nevertheless, 
no individual GWAS study or meta-analysis has yet produced any replicated genome-
wide significant result (Biernacka et al., 2015; Cocchi et al., 2016; Garriock et al., 
2010; GENDEP Investigators, MARS Investigators, & STAR*D Investigators, 2013; 
Ising et al., 2009; Q. S. Li, Tian, Seabrook, Drevets, & Narayan, 2016; Myung et al., 
2015; Tansey et al., 2012; Uher et al., 2010). The largest clinically-measured study 
was a meta-analysis between NEWMEDS (Novel Methods leading to New 
Medications in Depression and Schizophrenia) and STAR*D (Sequenced Treatment 
Alternatives to Relieve Depression) which reached nearly 2,900 individuals. 
Antidepressant response was examined in multiple classes as well as an additional 
analysis exploring serotonergic and noradrenergic antidepressants, finding no 
significant genetic variants or pathways (Tansey et al., 2012). The major obstacle in 
these studies is sample size, as GWAS typically require tens of thousands of 
individuals to detect small effects. In order to enhance sample size, the 23andMe study 
applied self-report data to conduct the largest study to date on treatment resistance, 
providing data from 1,311 treatment resistant individuals and nearly 7,795 responder 
controls, but similarly, reported no significant associations. Nonetheless, self-report 
data is not generally considered as reliable as clinically-measured data and self-
reported drug adherence has been shown to be inflated compared to other 
methodologies e.g. pharmacy-refill measures (Stirratt et al., 2015), indicating self-
reported drug data may be subject to error. 
Issues in antidepressant pharmacogenetic research 
Pharmacogenetic studies and clinical trials generally provide small sample sizes. 
Randomised controlled trials (RCTs) are considered the optimum approach to study 
drug response as they give an unbiased comparison of placebo and drug. Nevertheless, 
they have met criticism due to the ethical considerations of distributing a placebo to a 
clinically ill population and are expensive to implement (Naudet, Maria, & Falissard, 
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2011). There are also few clinical trials in pharmacogenetics which have been 
attributed to lack of funding and small patient populations (Moaddeb & Haga, 2013). 
Moreover, it is only recently that pharmacogenomic (genome-wide) studies are 
beginning to be carried out in preference to candidate gene studies. Of note, 
antidepressant studies are also hindered by the placebo response. Whilst most clinical 
trials apply strict thresholds in order to decrease the number of placebo responders, 
they are estimated to account for 35-40% of all antidepressant responders (Furukawa 
et al., 2016). 
Prediction of antidepressant response 
Predicting individuals who may respond to an antidepressant could aid in 
understanding the mechanisms that drive response and non-response. Prediction 
models comprising of multiple clinical and demographic factors have been constructed 
for determining antidepressant remission or resistance. The most recent model was 
able to predict treatment resistance and remission to an accuracy of 0.74 and 0.85, 
respectively, by including as the predictors time between first and last depression 
episode, age and response to first antidepressant treatment, depression severity, 
education, occupation, and others. Nevertheless, none of these factors were significant 
independent predictors (Kautzky et al., 2017). In 2016, a prediction model found that 
depression severity, feeling restless, and reduced energy were the most significant 
predictors of non-remission whilst current employment, total years of education and 
loss of insight into one’s depressive condition were the most significant predictors of 
remission. They reported that a model using 25 predictors of non-response gave an 
accuracy of 0.64 and were able to predict response in two out of three independent 
samples, suggesting that failure in the last sample may be due to their model being 
class-specific (Chekroud et al., 2016). Childhood trauma is the most replicated 
association with antidepressant non-response and, in a meta-analysis of 10 studies with 
over 3,000 participants, childhood maltreatment demonstrated a significant risk factor 
for lack of remission after an antidepressant (OR= 1.43, CI= 1.11–1.83) (Nanni, Uher, 
& Danese, 2012). In fact, it has been found that individuals who have experienced 
childhood trauma respond better to psychotherapies than antidepressants (Wald χ2 = 
6.89, P= 0.0087) (Nemeroff et al., 2003). Specifically, early-life trauma occurring 
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between four and seven years of age  was found to be an important predictor of non-
response (OR= 1.6, P= 0.034) (Williams, Debattista, Duchemin, Schatzberg, & 
Nemeroff, 2016). Therefore, it may be possible to utilise clinical and demographic 
factors in order to elucidate pathways to non-response.  
Is treatment resistant depression a subgroup of MDD? 
Research into polymorphisms in cytochrome P450s (metabolic enzymes) in 
antidepressant response have been inconsistent with positive findings generally 
reported in smaller samples (Wu-Chou, Liu, & Shen, 2016). Although further research 
is warranted in this area, it is also possible that that another mechanism is causing 
variation. Hudson and Pope (1990) theorised that differential antidepressant response 
could be utilised to determine overlapping disorders with the same underlying 
aetiology concluding that obsessive compulsive disorder (OCD), attention deficit 
hyperactivity disorder (ADHD), panic disorder and bulimia likely shared aetiologies 
(Hudson & Pope, 1990). Furthermore, it has been previously speculated that the 
genetic architecture underlying antidepressant response actually demonstrates 
variability in MDD aetiology owing to evidence that the candidate genes associated 
with MDD have also been widely associated with variability in drug response in gene-
environment studies (Keers & Uher, 2012). Nevertheless, results from candidate genes 
should be treated with caution as these have not yet been replicated genome-wide. 
1.6. Project Summary and Aims 
Summary 
Despite recent success of GWAS, the aetiology of MDD remains unexplained. It is 
likely that the current MDD definition encompasses multiple aetiological subgroups 
and that dissecting these subgroups may be key to developing new medicines with 
higher efficacy. The modest heritability of MDD indicates that there are genetic 
underpinnings to the disorder and therefore genetic stratification may be of key value 
to identify subgroups. Given the vast literature on potential biological mechanisms of 
MDD, it is possible that current theories could provide a foundation for aetiological-
based stratification. Two possible explanations of MDD could be explored further, 
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namely neurostructural (pertaining to brain volumes) and neurochemical theories 
(which could be examined by exploring antidepressant response).  
Associations between regional brain volumes and MDD are frequently reported but 
results are often inconsistent. Nevertheless, the role of emotion and cognitive 
processes in MDD have been well documented and further explication of potential 
associations may be beneficial. Antidepressant response rates are low to modest and 
mechanisms behind non-response remain unknown. Genome-wide exploration of 
antidepressant response have yielded no replicated results, with small sample sizes 
likely the reason for this. To date, little is known about treatment resistant MDD and 
the mechanisms that drive it, therefore further studies utilising larger sample sizes are 
necessary. 
Project aims 
This thesis is divided into four main chapters that aim to investigate the above subject 
matter. Firstly, genetic stratification in psychiatric disorders and current methods that 
could be implemented to achieve this will be discussed. The aim of this chapter is to 
provide an overview of progress so far and outline whether genetic stratification in 
psychiatric disorders is achievable. Secondly, considering the inconsistent findings 
between both phenotypic and genetic associations of subcortical brain volumes and 
MDD, this chapter will explore their shared genetics using data from large consortia 
and genome-wide techniques in population- based cohorts. Potential genetic 
subgroups in MDD are also explored using subcortical volume genetic data. Thirdly, 
a genome-wide association study of antidepressant treatment resistance in MDD 
individuals will be examined in the largest study to date (excluding self-report studies). 
Narrow-sense heritability estimates and genetic correlations with associated traits will 
be investigated. Lastly, the impact and interrelationships of neuroticism, psychological 
resilience and coping styles in treatment resistance will be examined. Whilst increased 
neuroticism has been shown to be associated with treatment resistance, the role of 
resilience and coping style has not been previously studied. The next chapter will 




Chapter 2. Genetic Stratification. 
 
2.1. Background 
In Chapter 1, current findings in MDD genetics were reviewed highlighting the high 
genetic overlap and substantial heterogeneity present in the disorder. Considering this 
and the poor to modest antidepressant response rates, it is possible that MDD is 
comprised of several different subgroups of disorders with varying causality. The 
previously reported genetic overlap between neuropsychiatric disorders (Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2013) is especially 
interesting as it implies that current symptom-based diagnostic boundaries may 
encompass overlapping groups of similar aetiology. Nonetheless, no study to date has 
robustly stratified any neuropsychiatric disorder into aetiologically-defined groups, 
which may be essential for the construction of personalised therapies. This chapter will 
explore current methods for genetic stratification and how it can be achieved in 
neuropsychiatric disorders. 
The content for this chapter has been summarised in a manuscript entitled “Towards 
Genetic Stratification of Neuropsychiatric Disorders” and is currently under revision 
at the Journal of Affective Disorders. As first author, I confirm that I composed and 
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Background: Elucidating the genetic architecture underlying complex 
neuropsychiatric disorders has proven challenging, although it is known that these 
disorders have both genetic and environmental influences. Current psychiatric 
classification may group phenotypically similar individuals with diverse aetiologies 
and separate those with common disease mechanisms across diagnostic boundaries. 
Results: In this current review, we discuss approaches for genetic stratification. Taking 
a broad quantitative approach to genomic analysis within and across diagnoses may 
aid establishment of mechanism-based stratification of psychiatric disorders where 
disease identification and future management is guided by genetic discovery. 
Intermediate phenotype approaches and machine learning techniques are currently 
being implemented to genetically stratify neuropsychiatric illness and may lead to 
revised classification and management. 
Limitations: Due to space constraints, this manuscript does not describe every genetic 
stratification technique and there may be others that can also be applied. 
Conclusion: Utilisation of these techniques may stratify neuropsychiatric disorders 












Elucidating the genetic and molecular mechanisms of neuropsychiatric disorders has 
proved to be very challenging, especially for common conditions, such as depression, 
that account for an expanding proportion of disability worldwide (P. Sullivan, Daly, 
& O'Donovan, 2012). Complex disorders (e.g. mood disorders, psychotic disorders, 
neurodegenerative disorders, eating disorders etc.) are caused by a combination of 
multiple genetic and environmental components (Hannan, 2013) and, in contrast to 
Mendelian disorders, have been less tractable to genetic research (Hirschhorn & 
Daly, 2005). This review will focus on common complex disorders examining how 
genetic subgroups can lead to aetiological-based stratification. 
 
The genetic contribution to risk of a disorder is often measured by examining the 
disease risk in relatives of affected individuals. Heritability of neuropsychiatric 
disorders can be calculated using family-based and twin studies and cover a spectrum 
from 0.81 (P. F. Sullivan, Kendler, & Neale, 2003) for schizophrenia to 0.37 (P. 
Sullivan et al., 2000) for depression. Single nucleotide polymorphism (SNP) 
heritability estimates can be used in unrelated samples to measure the contribution of 
common variants but, in apparent contrast, these collectively explain a lower 
percentage of the total phenotypic variance than predicted from twin studies, 0.34 
(International Schizophrenia Consortium et al., 2009) for schizophrenia and 0.21 for 
MDD (RipkeWray, et al., 2013). This ‘missing heritability’ can be explained in part 
by the aggregate effects of many common single nucleotide polymorphisms (SNPs) 
(J Yang, Lee, Goddard, & Visscher, 2011). Numerous studies have not only 
demonstrated the polygenic nature of complex psychiatric disorders (i.e. many 
common variants confer susceptibility in aggregate) but they have also shown that 
genetic liability can be shared across clinically separable disorders (Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013; RipkeO'Dushlaine, et al., 
2013). Explanations for the missing heritability problem include un-typed and 
poorly-imputed common variants, rare variants and interactions between genes 
(epistasis) and genes and environment (Wray & Maier, 2014). Failing to account for 
the effects of shared environment may also contribute to poorly estimated variant 




2.1. Heritability (h2) and SNP h2 of neuropsychiatric disorders. Narrow sense 
heritability figures and the SNP heritability estimated from GWAS for the five major 
neuropsychiatric disorders; schizophrenia h2=0.80, SNP h2=0.34 (International 
Schizophrenia Consortium et al., 2009), autism spectrum disorder h2=0.8, SNP 
h2=0.54 (Gaugler et al., 2014), ADHD h2=0.76, SNP h2=0.31(Saviouk et al., 2011) , 
bipolar disorder h2=0.75, SNP h2=0.38 (Lee, Wray, Goddard, & Visscher, 2011), 
and depression h2=0.36, SNP h2=0.3 (0.28-0.32) (Lubke et al., 2012). The gap 
between the h2 and estimated h2 from GWAS is what is termed the ‘missing 
heritability’ or unexplained heritability. 
 
Phenotypic heterogeneity between individuals with the same disorder, as well as 
longitudinal variation within individuals over time, imposes a major obstacle to the 
study of the neuropsychiatric disorders (Hyman, 2007). The Diagnostic and Statistical 
Manual of Mental Disorders (DSM) is a diagnostic guide for psychiatrists that has met 
much criticism in recent literature due to its categorical distinction of psychiatric 
illnesses (Hyman, 2008; O’Donnell et al., 2014). Whilst it has provided a framework 
for clinical decision making and randomised trials, one of the major drawbacks has 
been the absence of any confirmatory biomarkers from the current diagnostic 
definitions. Many would argue that there has been an over-reliance on diagnosis 
through the identification of symptom clusters and a separation into ‘ill’ and ‘well’ 
based on an arbitrary thresholds (Hyman, 2007, 2008). It is possible, perhaps likely, 
that the current diagnostic categories in fact encompass different subgroups of patients 
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with similar symptoms, but differing aetiologies. This may also explain some of the 
missing heritability (Wray & Maier, 2014) as the variance explained by common SNPs 
can be attenuated by the inclusion of misclassified cases, especially in more common 
psychiatric disorders. Quantitative-trait approaches to genome analysis offers an 
alternative to qualitative disorder-based approaches. Significantly, these methods may 
allow us to re-evaluate the problems of psychiatric classification and distinguish more 
clinically tractable categories to improve patient treatment response and outcome.  
This review will aim to give an overview of genetic stratification of neuropsychiatric 
disorders and the current techniques and will look at future directions for research in 
order to obtain clinically relevant genetic stratification. 
2.2.3. What is genetic stratification and is it achievable? 
Genetic stratification is the subgrouping of individuals based on similar underlying 
genetic architecture. In disease research, this can be useful to identify groups of 
individuals that could have the same disease aetiology. In many complex diseases, 
aetiologies have been difficult to identify prompting an exploration into innovative 
approaches to the problem. Genetic stratification could be key to developing 
personalised medication that more directly target to the mechanism of the disease. 
Genetic risk stratification has been utilised in many different diseases ranging from 
common cancers to Alzheimer’s disease. It is when individuals are considered high-
risk for developing a disease if they carry a particular genetic variant, for instance, the 
BRCA1 and BRCA2 genes confer a very high risk of an individual developing breast 
or ovarian cancer (King, Marks, Mandell, & Group, 2003). If a high-risk variant is 
identified, genetic testing can identify these individuals and allow for early 
intervention e.g. early surgical interventions for BRCA1 or BRCA2 carriers (Finch et 
al., 2006; Kramer et al., 2005). However, in many complex diseases common variants, 
rare variants and environmental factors play a role and the presence or absence of any 
one genetic variant is a weak predictor of the presence or absence of disease. Genetic 
stratification aims to find subgroups of similar genetic architectures that are distinctly 
different from each other. It is currently being implemented in cancer research by The 
Cancer Genome Atlas (TCGA) Pan-cancer project (Weinstein et al., 2013). Cancers 
are generally classified based on the site of origin of the cancer, however, the results 
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of the project have indicated that there are genetic similarities in types of tumours that 
can span across different classes of cancers. This has encouraged a reassessment of 
current classification in cancer to include examination of tumour subtypes that could 
potentially lead to new therapeutics.  
Whilst there has been much interest in this type of stratification in neuropsychiatry, 
subgroups have been difficult to identify. The Research Domain Criteria (RDoC) 
Project was set up in 2009 to identify more neurobiological subgroupings in mental 
illness by utilising seven different units of analysis including genetic analysis 
(Cuthbert & Insel, 2013; Insel et al., 2010). However, this research has yet to yield 
clinically useful subgroups, which is possibly attributable to its reliance on current 
diagnostic criteria (Kozak & Cuthbert, 2016) and very limited access to the tissue of 
interest compared to cancer. Nevertheless, new research and techniques have been 
making ground in psychiatric research. A recent paper examining resting state 
functional magnetic resonance imaging (fMRI) in depression patients identified 4 
subgroups by hierarchical clustering that correlated to distinct symptom profiles 
(Drysdale et al., 2017). This review will examine machine learning techniques, such 
as this, that have been used to some success in genomic analysis as well as genomic 
techniques to examine the overlap and intermediate phenotypes in an aim to further 
dissect psychiatric disorders. 
With increasing evidence suggesting a revision of the current diagnostic criteria and 
the known heritability and co-morbidity of neuropsychiatric disorders, they are ideal 
candidates for genetic stratification. In cancer genomic research, genetic stratification 
is already demonstrating great promise for identification of subgroups therefore 
demonstrating promise for its use in neuropsychiatry. 
2.2.4. Genetic architecture of neuropsychiatric disorders 
In order to genetically stratify a disorder, it is important to first understand its 
underlying architecture. Whilst there is a clear genetic contribution to neuropsychiatric 
disorders, their genetic architectures are incompletely understood (Gratten, Wray, 
Keller, & Visscher, 2014). The effects of individual alleles can be measured via their 
penetrance (the probability of a specific mutation eliciting a disease phenotype) and 
can also be involved in a vast network of interactions. Alleles at different loci may act 
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additively or interact with another (epistasis). All of these effects may also be 
moderated through their interaction with the environment, demonstrating the high 
complexity of this network.  
This high polygenicity and clinical heterogeneity evident in neuropsychiatric disorders 
has fuelled the argument for stratification. Observed pleiotropy between disorders can 
both hinder and help explicate heterogeneity and can be explained as a genetic variant 
having a biological influence on multiple phenotypes (biological pleiotropy), traits 
being causally linked (mediated pleiotropy) or bias that can cause a false association, 
(spurious pleiotropy) (Solovieff, Cotsapas, Lee, Purcell, & Smoller, 2013). Dissecting 
this pleiotropy could be used to indicate genetically distinct subgroups of individuals 
with different underlying neuropsychiatric aetiologies. It is generally believed that the 
missing heritability can be accounted for by interacting genes, rare variants and gene-
environment interaction (Wray & Maier, 2014). Many postulate that understanding the 
vast network of allelic variants and interactions could be an important component in 
understanding the mechanisms of the disorders (Caspi & Moffitt, 2006; Gratten et al., 
2014). The identification of rare high-penetrance variants could be particularly 
valuable as the large biological effects they exert would present effective drug targets. 
Exome sequencing has provided an effective method of identifying rare variants and 
has described variants associated with Mendelian disorders (Ng et al., 2010) with some 
limited early success in complex diseases such as autism (Sanders et al., 2012). 
Reports of gene-gene interactions have become increasingly frequent with 
demonstrations that their effects may exceed that of any single susceptibility gene 
(Kebir et al., 2014; Lai et al., 2015; Moore, 2003). Within psychiatry; evidence for 
epistatic interactions have been demonstrated in depression (Schott et al., 2014) and 
schizophrenia (KK Nicodemus et al., 2010a; KK Nicodemus et al., 2010b; KK 
Nicodemus et al., 2007) and there is emerging evidence that the inclusion of epistatic 
effects may improve prediction of psychiatric traits (KK Nicodemus et al., 2014). 
Environmental exposure to risk factors is also well-established in psychiatry and gene-
environment interactions have attracted particular attention as a potential explanation 
for the inter-individual variability in disorder susceptibility (Duncan & Keller, 2011). 
Different environmental exposures have been shown to interact with different genes 
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to elicit the same psychiatric manifestation whereas it has also been shown that the 
same environment can interact with the same genes and lead to a different psychiatric 
indication (Klengel & Binder, 2013). Klengel and Binder (2013) therefore hypothesise 
that gene-environment interactions can be used to identify clinical psychiatric 
subtypes. The Environmental Genome Project (EGP) was set up to develop tools that 
can stratify individuals based on disease risk utilising integrative information on the 
genome and environmental exposures (Olden, Freudenberg, Dowd, & Shields, 2011). 
Attempts to identify these interactions have met some difficulty with the environment 
being both difficult to define and even more so to classify (Tsuang, Bar, Stone, & 
Faraone, 2004). With this complex underlying architecture, stratification presents a 
very challenging endeavour. 
2.2.5. Genetic overlap and intermediate phenotypes in stratification 
Exploring intermediate phenotypes and genetic overlap of related traits with disorders 
is a popular approach to examine the stratification problem. Intermediate phenotypes 
are phenotypes that are intermediate to a gene and outcome. In psychiatry these are 
often referred to as endophenotypes and definitions can differ between a mediation 
model (whereby the endophenotype is causal) and a liability index model (where the 
endophenotype may share characteristics) (Kendler & Neale, 2010). Endophenotypes 
or intermediate phenotypes have five criteria needed to confirm status which are: (1) 
the phenotype is associated with the illness, (2) it is heritable, (3) it is disease state-
independent, (4) the endophenotype and illness co-segregate within families and (5) 
the endophenotype found in affected family members is found in a non-affected family 
member in a rate higher than in the general population (Gottesman & Gould, 2003). 
However, in the liability-index model the phenotype need not be state-independent, 
can be associated with a range of psychiatric diseases (not only with the illness of 
interest) and do not need to lie on the causal pathway (Flint, Timpson, & Munafò, 
2014; Leuchter, Hunter, Krantz, & Cook, 2014). A method of testing some (but not 
all) of the criteria for intermediate phenotype status is to explore genetic overlap 
between a disorder and a potential intermediate phenotype. This would confirm a 
genetic association between the two phenotypes and indicate the shared genetic 
variation. Nevertheless, genetic overlap could be explained by biological pleiotropy, 
whereby a genetic variant induces both phenotypic outcomes, and therefore 
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investigates an indication for the liability-index model not a mediation model. Other 
psychiatric disorders have been indicated as potential intermediate phenotypes for 
each other. For instance, the Psychiatric Genomics Consortium (PGC) completed a 
cross-disorder GWAS across 5 psychiatric disorders; attention deficit-hyperactivity 
disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder, depression and 
schizophrenia, and identified 4 loci that conferred risk across these disorders (Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2013). This provides further 
support for the need for a quantitative approach to investigate psychiatric disorders. 
Polygenic risk scoring (PRS), LD score regression and BUHMBOX (Breaking Up 
Heterogeneous Mixture Based On Cross-Locus Correlations) are all methods for 
examining genetic overlap. 
 
 
Figure 2.2. Illustration of the use of intermediate phenotypes in dissection of trait 
heterogeneity. Intermediate phenotypes can be used to isolate more homogenous 
groups in disease and aid personalised medicine. 
 
PRS are utilised to infer a polygenic risk architecture and may also be used to measure 
the genetic overlap between disorders (i.e. pleiotropy). They utilise genetic markers’ 
effect sizes estimated by GWAS on an independent training sample, such as those 
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provided by the PGC. Using these marker weights, a new ‘discovery’ sample is then 
genotyped and the product of each reference allele, multiplied by its effect size, is then 
determined across the genome. The ‘risk score’ is then calculated, for each individual 
in the discovery set, using the sum of the allele dosage effect size products (Dudbridge, 
2013a; International Schizophrenia Consortium et al., 2009). PRS have been especially 
effective in neuropsychiatry where the availability of repeatable and objective 
biological correlates of disease is scarce. The first PRS implementation was provided 
in the International Schizophrenia Consortium (ISC) sample. It demonstrated that 
schizophrenia PRS, derived using marker weights from one GWAS, weakly predicted 
the diagnostic status of schizophrenia in a second independent case-control dataset and 
also weakly predicted a diagnosis of bipolar disorder (Craddock, O'Donovan, & Owen, 
2005; International Schizophrenia Consortium et al., 2009). Similarly, depression PRS 
weakly predicted depression status explaining ~1% of the variance, and demonstrated 
genetic overlap with anxiety disorders (Demirkan et al., 2011).  PRS has also been 
used to identify intermediate phenotypes; ADHD PRS (Martin, Hamshere, 
Stergiakouli, O'Donovan, & Thapar, 2014) and ASD PRS (Clarke, Lupton, et al., 
2015) have both been associated with lower cognitive ability. Polygenic risk for 
schizophrenia has also been used to identify neural phenotypes such as prefrontal 
inefficiency; that may provide clues to the underlying neurobiological mechanisms of 
the disorder (Walton et al., 2014). PRS are now being used in an attempt to stratify 
neuropsychiatric disorders into more causally circumscribed diseases. In a recent paper 
examining the comorbidity between depression and migraine, Ligthart et al., (2014) 
found that pure migraine was genetically separate to migraine comorbid with 
depression on the basis of its associations with PRS. Furthermore, the authors 
concluded that migraine comorbid with depression was likely to have occurred as a 
consequence of depression (Ligthart et al., 2014). PRS can also be used to explore 
gene-environment interactions by investigating risk scores associated with specific 
risk factors (Nikolova, Ferrell, Manuck, & Hariri, 2011). For example, childhood 
trauma in individuals with a high polygenic risk for depression were found to be at 
greater risk of developing depression (Peyrot et al., 2014). Furthermore, PRS for 
obesity were found to have a greater effect on individuals with a lifetime diagnosis of 
depression (Clarke, Hall, et al., 2015).  
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Linkage disequilibrium score regression (LDSC), a recent technique developed by 
Bulik-Sullivan et al. (2015), also estimates the proportion of variance in a trait due to 
common SNPs and additionally accounts for inflation due to polygenic signal. In 
LDSC, the chi-square score from GWAS summary statistics is regressed against the 
LD score, sum of LD r2 between variants, and the intercept - 1 is then an estimator of 
the inflation. By utilising LD in this way, it aims to overcome the major problems LD 
causes in genome-wide studies. Simulation results of this study demonstrated that this 
tool was most powerful for polygenic traits, making it of particular interest in 
psychiatry. The score appears to work most efficiently when it is uncorrelated with the 
variance explained per SNP, although this is not always the case (BK Bulik-Sullivan 
et al., 2015a). A highlighted benefit of this technique is that is only requires genetic 
summary statistic data which are usually more widely accessible. Similarly to PRS, 
LDSC can also be adapted to measure genetic correlations between phenotypes by 
looking at the genetic covariance. It is a computationally efficient method that will not 
be biased by sample overlap, unlike genetic variance estimates generated by PRS. 
LDSC was applied to measure genetic correlation between psychiatric disorders and 
notably showed positive genetic correlation between ASD and educational attainment 
and near zero genetic correlation between Alzheimer’s disease and psychiatric illness 
(B Bulik-Sullivan et al., 2015b). This further supports the theory that genetic 
exploration of these disorders could elucidate more about the nature of the illnesses 
and lead to improved stratification. 
BUHMBOX is a recently developed technique, by Han et al. (2015), which can 
distinguish between clinical heterogeneity, defined as two genetically distinct 
subgroups, and true pleiotropy. It does this by utilising genome-wide data to examine 
risk alleles enriched in cases for two phenotypes. True pleiotropy would demonstrate 
enrichment across both phenotypes in cases but not controls whilst enrichment in only 
one of the phenotype cases and absent in the other demonstrates clinical heterogeneity. 
The method was utilised to examine autoimmune genetic sharing, concluding this was 
likely due to true pleiotropy, and was able to distinguish clinical heterogeneity between 
seronegative and seropositive rheumatoid arthritis. The method however does require 
large sample sizes and due to this was underpowered in an analysis on schizophrenia 
and depression (Han et al., 2015). It could provide a powerful technique, especially 
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with increasing sample sizes, in stratification of psychiatric traits into genetic 
subgroups. 
2.2.6. Machine learning in genomic analysis of complex disorders 
Machine learning defines an important set of tools that has gained much attention in 
recent biomedical literature. It is the application of an algorithm that is capable of 
learning from one dataset (usually called the training data) in order to instruct its 
application in another (the test dataset) in an attempt to demonstrate a validated 
relationship. It is therefore imperative for their utilisation that two independent datasets 
are used in order to test the validity of the model.  Many machine learning algorithms 
are flexible to non-additive and non-linear genetic architectures and can provide an 
optimal fit to data containing these types of relationships. Supervised machine learning 
pertains to a method of fitting a model to a labelled dataset with predictors and 
response variables with an aim to accurately predict the response. Unsupervised 
learning refers to a method of fitting a model to data with no response variable (i.e. 
unlabelled data). Supervised methods are by far the most commonly utilised although 
there is a marked increase in the application of both methods within bioinformatics 
(Bhaskar, Hoyle, & Singh, 2006). A recent review summarises the progress machine 





2.3. Supervised and unsupervised machine learning techniques. Supervised and 
unsupervised machine learning methods differ in that they contain labelled and 
unlabelled data, respectively. Models that overfit the training dataset can often not 
perform as well in a test dataset due to modelling noise from the training data. An 
example of each is shown; support vector machines are a supervised learning method 
for classification whereas k-means clustering is considered an unsupervised technique 
 
The accessibility of genome-wide data imposes a heavy computational and multiple 
testing burden, with stringent p-value thresholds required to show statistical 
significance. Parametric statistical techniques can have severe limitations as they rely 
on making distributional assumptions (McKinney, Reif, Ritchie, & Moore, 2006) 
highlighting the need for parametric model enhancements and non-parametric 
alternatives. Owing to their low frequency in the general population, rare variants are 
difficult to identify, but a recent study demonstrated both supervised and unsupervised 
methods had increased power over standard statistical techniques in their detection 
(Lu, Austin, Bonner, Huang, & Cantor, 2014). In psychiatric research, random forest 
(RF), conditional inference forest (CIF), Monte Carlo Logic regression and gradient 
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descent boosting algorithms have also demonstrated potential in the determination of 
interactions; early studies have shown an association between polymorphic DISC, CIT 
and NDEL1 regions and NRG1, ERBB4 and AKT1 in schizophrenia case- control 
analyses (KK Nicodemus et al., 2010a; KK Nicodemus et al., 2010b). 
Machine learning techniques can also be used to identify subgroups of individuals 
within current binary disease categories. These have been infrequently applied to 
psychiatry for genetic classification purposes, but have been effective in cancer 
genomics. For instance, in paediatric acute lymphoblastic leukaemia (ALL), 
hierarchical clustering and principle components analysis (PCA) were applied to a 
gene expression profiling and identified 7 subtypes of the disorder (Ross et al., 2003). 
In acute myeloid leukaemia (ALM) a bayesian machine learning algorithm (Bayesian 
Dirichlet processes) was applied to cytogenetic data, distinguishing 11 genetic 
subgroups of the disorder (Papaemmanuil et al., 2016). Utilising k-mean clustering and 
nonnegative matrix factorisation in transcriptomic data, a group were able to identify 
6 subgroups of gliomas (A. Li et al., 2009). Hierarchical clustering also identified 5 
subgroups of medulloblastoma in gene expression profiling (M. C. Thompson et al., 
2006) and nonnegative matrix factorisation methods identified 3 genomic subgroups 
in copy number analysis using oligonucleotide-based array comparative genomic 
hybridisation in glioblastomas (Maher et al., 2006). Nevertheless, none of these studies 
have yet replicated their findings and it is therefore too early to speculate whether the 
groups identified are of clinical meaningfulness.  
There is increasing evidence to support the ability of machine learning algorithms in 
high dimensional data (Chen & Ishwaran, 2012; J. McCarthy et al., 2004; Vert & 
Jacob, 2008). These tools can be particularly effective at prediction in high dimensions 
and have recently been applied to aid stratification in response to drug treatments. 
Support vector machine (SVM) methods were applied to a high dimensional dataset in 
order to predict response to Methylphenidate in ADHD. Employing genetics and 
neuroimaging results, amongst other information, SVM were able to distinguish the 
non-responder group with an 84.6% accuracy (J. W. Kim, Sharma, & Ryan, 2015). 
Similarly, RF and k-means clustering algorithms were applied to improve prediction 
of non-response to antidepressants and, utilising genomic and clinical predictors, were 
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able to improve prediction in an interaction-based model (Kautzky et al., 2015). 
Machine learning selection of predictors is also being applied to PRS techniques. In 
bipolar disorder a RF algorithm was applied to identify SNP predictors for construction 
of a PRS, demonstrating selection of 289 candidate SNPs enhanced the PRS sensitivity 
















Decision trees are generated on a 
bootstrapped or sub-sampled training 
sample and the best-splitting predictors 
chosen from a set selected at random at 
each split. Each split in the tree considers 
one predictor and the following split made 
using the remaining sample, generating a 
recursively partitioned tree. Many trees 
are grown, generating a forest. The 
prediction error of the model can be tested 
on the left out group from the bootstrapped 
sample (Breiman, 2001; McKinney et al., 
2006).  
 
Unsupervised Clustering In RF clustering, an RF dissimilarity 
measure, a numerical value of similarity 
between observations, is calculated. This 
measure is then utilised to generate 
clusters (Breiman, 2001; Shi & Horvath, 
2006; Shi, Seligson, Belldegrun, Palotie, 
& Horvath, 2005).  
 
Neural Networks Supervised Classification, 
Regression 
Multiple layers of nodes connected by arcs 
with an initial input layer receiving the 
primary information and then connecting 
to varying levels of hidden layers before 
finally an output layer. Each input has a 
weight that is determined by a learning 
algorithm (Benitez, Castro, & Requena, 
1997; McKinney et al., 2006). 
 
Unsupervised Clustering Involves assessing differences between 
weights and inputs in the network. The 
network with minimal difference can then 
adjust surrounding networks. This 
continues until clusters of networks are 






Supervised Classification Reduction of the dimensionality of an N-
dimensional model to a single dimensional 
model by grouping into multifactor 
classes. These multifactor classes could be 
low and high risk categories and are 
usually grouped utilising the Bayes 
classifier and 10-fold cross-validation 
(Cordell, 2009; Pattin et al., 2009; Ritchie, 






    K-means clustering 
 
 
   




Unsupervised Clustering Clustering techniques are unsupervised 
methods utilised to detect patterns in 
datasets (Morris et al., 2011).  
Arguably the most widely used clustering 
algorithm, its function is to minimise the 
distance between data points and their 
closest centre to partition data into k sets. 
The mean is calculated determining the 
next point for the centre until the minimum 
distance is met (Kanungo et al., 2004). 
 
Hierarchical clustering can be 
agglomerative (usually starting in 
individual clusters and merged at each 
step) or divisive (clusters are split at each 
step). Splitting or merging is completed on 
optimisation of a criterion e.g. sum of 
squares, nearest or farthest neighbour 
(Fraley & Raftery, 1998).  
 
LASSO Supervised Classification The LASSO performs variable selection 
and shrinkage. It is utilised in regression 
methods carried out with a penalty 
(usually termed L1). In orthonormal 
designs, subset selection occurs using the 
largest coefficients contributing to the 
absolute value, setting some regression 
coefficients to zero whilst reducing others 
producing more easily interpretable results 
(Tibshirani, 1996). 
 
2.3. Machine learning techniques. Table of various machine learning techniques and 
their methodologies. 
Nonetheless, these techniques are not without their limitations. Due to the large 
datasets dealt with in machine learning, the algorithms can be susceptible to noise 
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within the data causing overfitting and poor predictive ability. Increasing dimensions 
within larger datasets also cause problems with inferring reliable conclusions, the so-
called curse of dimensionality (de Ridder, de Ridder, & Reinders, 2013; Okser et al., 
2014). Both of these limitations are often the reason for machine learning failure. 
Within genetic data, LD can also cause problems due to high genetic correlation (KK. 
Nicodemus, 2011; KK Nicodemus & Malley, 2009). Penalisation strategies such as 
the LASSO and ridge regression techniques are sometimes used in an attempt to 
prevent instability caused by LD (Okser et al., 2014). Moreover, it has been 
hypothesised that parametric techniques could be enhanced by combination with 
current machine learning algorithms (Moore, Asselbergs, & Williams, 2010). It is 
argued that even if machine learning provided a minimal increase in predictive power 
it would significantly improve clinical benefit (Okser, Pahikkala, & Aittokallio, 2013). 
Their use within psychiatry would certainly aid in stratification but these limitations 
are not without merit and therefore caution is warranted. Techniques should be 
comprehensively evaluated before application and results should be independently 














Important genetic influences on the risk of neuropsychiatric disorders have been 
established beyond reasonable doubt and these findings lay the foundation for future 
genetic stratification. Nevertheless, the current classification system within psychiatry 
is sub-optimal and unable to account for both phenotypic and genotypic overlap 
between disorders, as well as the qualitative distinction of ‘ill’ and ‘well’ individuals. 
To further understand the genetic architecture behind these disorders it may be 
beneficial and more parsimonious to examine the quantitative traits underlying clinical 
disorders, without imposing a somewhat arbitrary threshold. Consequently, 
approaching disease stratification through the genetic architectures underlying 
quantitative traits could assist in the identification of more causally circumscribed 
disease entities with greater predictive utility. 
Genomic analysis in complex psychiatric disorders is burdened with high 
heterogeneity and polygenicity. With rare and common genetic variants, epistatic and 
environmental interaction, the architecture behind these disorders is exceptionally 
complex making their genetic dissection especially challenging. Examining genetic 
overlap with related traits and intermediate phenotypes can be examined by PRS, 
LDSC and BUHMBOX, but all of these techniques are reliant on large sample sizes 
for increased power. All the genetic and environmental interactive possibilities lead to 
high dimensional data which traditional parametric technique are typically not 
equipped to deal with. Machine learning provides a potential alternative as it can be 
tailored to cope with high dimensions. Its growing popularity in genomic analysis and 
promising results, especially in cancer genomics, has supported the contention that it 
could be a useful tool in complex traits. 
It is generally considered that we are entering the age of ‘big data’ whereby researchers 
have access to multiple large datasets from differing sources, exerting high demands 
on current computational resources. A lack of confidence in the DSM definitions of 
psychiatric disorders presents additional obstacles to analysis that are imposed by the 
thresholding of clinical syndromes as binary traits. It is likely that the use of 
quantitative traits in combination with binary clinically-diagnosed phenotypes offer a 
more tractable and potentially effective approach to future research. A combination of 
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the above techniques could be effective approaches to tackling the classification 
problem. Through the dissection of their genetic architectures perhaps we can utilise 
large datasets of clinical and genomic data to investigate and validate candidate disease 
taxonomies and match these to case by case clinical management.  
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2.3. Chapter Conclusion 
This chapter summarises the current techniques for genetic stratification and how they 
can be applied within neuropsychiatry. Current advances in cancer, demonstrate the 
utility of genetic stratification as a tool to reduce heterogeneity. Two main approaches 
were discussed; the intermediate phenotype approach and machine learning 
techniques. Intermediate phenotypes (the study of a phenotype that could mediate the 
association between gene and outcome) have been studied in some detail in 
neuropsychiatric diseases but machine learning techniques have been less frequently 
applied. They are more commonly employed in cancer research but represents a useful 
future tool for stratification of psychiatry in large datasets. 
Genetic overlap between MDD and other diseases/disorders has previously been 
documented (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; 
Ji et al., 2016) and lends support to the hypothesis of genetic subgroups. Identifying 
such subgroups could aid in the generation of personalised therapies. Genetic overlap 
also indicates a possible presence of intermediate phenotypes which could be used to 
identify subgroups and possibly biomarkers, given that the most useful biomarkers will 
be those with intermediate proximity between gene and outcome (Leuchter et al., 
2014). To identify phenotype as an intermediate, it must meet several criteria and so 
genetic overlap is only an indication. However, it is an effective method to indicate 
the presence of associated phenotypes that represent candidates for intermediate 
phenotypes. In this thesis, the intermediate phenotype approach will be applied to two 










Chapter 3. Regional Brain Volume and MDD. 
 
3.1. Background 
Differences in regional brain volumes in individuals affected by MDD compared to 
controls have been described previously but results have been inconsistent. A general 
summary of current structural findings was given in Chapter 1. Here, I will comment 
on the genetic associations that have been found between regional brain volumes and 
MDD and describe why a genome-wide approach is needed. 
Much like MDD, subcortical volumes are determined by both genetic and 
environmental components (Wen et al., 2016) and further have been found to be 
influenced by common variants (Hibar et al., 2015). Given that structural abnormalities 
have previously been associated with a higher risk of depression (Koolschijn et al., 
2009; Schmaal et al., 2015), brain volume could be examined as an intermediate 
phenotype between genes and MDD that encode the genetic liability and causally 
impact disease risk. In fact a number of studies have indicated brain volumes and 
imaging phenotypes to have role as intermediate phenotypes in psychiatric disease 
(Honea et al., 2008; Meyer-Lindenberg & Weinberger, 2006). Candidate genes have 
been the most commonly adopted approach to do investigate genetic overlap and 
monoaminergic polymorphisms have been most widely examined. For example, recent 
studies exploring serotonergic polymorphisms have demonstrated moderate 
associations with amygdala volume in a sample of 417 healthy controls and right 
pallidum volume in a sample of 42 MDD cases and 15 healthy controls (Jaworska, 
MacMaster, Foster, & Ramasubbu, 2016; J. Li et al., 2015). Nevertheless, results from 
such studies have been largely inconsistent, reporting both significant associations and 
lack thereof (Won & Ham, 2016). This inconsistency may be due to an increased 
likelihood of reporting false positives due to the bias introduced by a hypothesis-
driven selection of a candidate gene that may or may not be associated with the 
outcome (especially if the candidate gene has not been replicated genome-wide) and 
low sample sizes in neuroimaging studies (Scharinger, Rabl, Pezawas, & Kasper, 
45 
 
2011; P. M. Thompson et al., 2014). This advocates the use of genome-wide 
approaches such as genome-wide association studies (GWAS) (which are hypothesis 
free) and subsequently linkage disequilibrium score regression (LDSC) and polygenic 
risk scoring (PRS) techniques. More recently, a PRS analysis was applied to a sample 
of 938 individuals and the authors reported that PRS of MDD, schizophrenia and 
bipolar disorder were not associated with subcortical volumes (Reus et al., 2017). 
However, a sample of 938 individuals is likely underpowered for a PRS analysis 
(Dudbridge, 2013b). In order to apply genome-wide techniques to examine genetic 
overlap between MDD and regional brain volumes and indicate their potential role as 
intermediate phenotypes, much larger samples are needed. Recent endeavours have 
seen considerable sample increases led by efforts from the ENIGMA (Enhancing 
NeuroImaging Genetics through Meta-Analysis) consortium, using meta-analysed 
data from numerous existing neuroimaging cohorts, and population-based cohorts 
such as UK Biobank, that recently released magnetic resonance imaging (MRI) data 
on 100,000 individuals. In fact, in 2015, the ENIGMA consortium released the first 
ever GWAS of regional brain volumes (Hibar et al., 2015). Equipped with these larger 
samples and more sufficiently powered GWAS, genome-wide approaches could be 
applied in order to determine whether genetic overlap is present and regional brain 
volumes represent potential intermediate phenotypes between genes and MDD 
outcome. 
Using the summary data from the recent ENIGMA GWAS, this following study will 
use LDSC and PRS techniques to determine genetic overlap between regional brain 
volumes and MDD. Additionally, Mendelian Randomisation (MR) and BUHMBOX 
were applied to test for directional association and determine the presence of MDD 
subgroups enriched for alleles associated with regional brain volumes. The content for 
this chapter has been summarised in a manuscript entitled “Do regional brain volumes 
and major depressive disorder share genetic architecture? A study of Generation 
Scotland (n=19 762), UK Biobank (n=24 048) and the English Longitudinal Study of 
Ageing (n=5766)” which has been published in the journal ‘Translational Psychiatry’ 
(Wigmore et al., 2017). I confirm, as the first author, that I carried out the analysis of 




Do regional brain volumes and major depressive disorder
share genetic architecture? A study of Generation Scotland
(n= 19762), UK Biobank (n= 24048) and the English
Longitudinal Study of Ageing (n= 5766)
EM Wigmore1, T-K Clarke1, DM Howard1, MJ Adams1, LS Hall1, Y Zeng1, J Gibson1, G Davies2, AM Fernandez-Pujals1, PA Thomson2,3,
C Hayward3, BH Smith4, LJ Hocking5, S Padmanabhan6, IJ Deary2,7, DJ Porteous3, KK Nicodemus2,3 and AM McIntosh1,2
Major depressive disorder (MDD) is a heritable and highly debilitating condition. It is commonly associated with subcortical
volumetric abnormalities, the most replicated of these being reduced hippocampal volume. Using the most recent published data
from Enhancing Neuroimaging Genetics through Meta-analysis (ENIGMA) consortium’s genome-wide association study of regional
brain volume, we sought to test whether there is shared genetic architecture between seven subcortical brain volumes and
intracranial volume (ICV) and MDD. We explored this using linkage disequilibrium score regression, polygenic risk scoring (PRS)
techniques, Mendelian randomisation (MR) analysis and BUHMBOX. Utilising summary statistics from ENIGMA and Psychiatric
Genomics Consortium, we demonstrated that hippocampal volume was positively genetically correlated with MDD (rG = 0.46,
P= 0.02), although this did not survive multiple comparison testing. None of the other six brain regions studied were genetically
correlated and amygdala volume heritability was too low for analysis. Using PRS analysis, no regional volumetric PRS demonstrated
a significant association with MDD or recurrent MDD. MR analysis in hippocampal volume and MDD identified no causal association,
however, BUHMBOX analysis identified genetic subgrouping in GS:SFHS MDD cases only (P= 0.00281). In this study, we provide
some evidence that hippocampal volume and MDD may share genetic architecture in a subgroup of individuals, albeit the genetic
correlation did not survive multiple testing correction and genetic subgroup heterogeneity was not replicated. In contrast, we
found no evidence to support a shared genetic architecture between MDD and other regional subcortical volumes or ICV.
Translational Psychiatry (2017) 7, e1205; doi:10.1038/tp.2017.148; published online 15 August 2017
INTRODUCTION
Major depressive disorder (MDD) is a debilitating condition that
accounts for a large proportion of disease burden world-wide.1 It
is a complex disorder that is influenced by both genetic and
environmental factors with a heritability of ~ 37% estimated from
twin studies.2 Two recent genome-wide association studies
(GWAS) identified two loci in MDD3 and 15 loci in self-reported
depression4 of genome-wide significance. Nevertheless, the
majority of MDD’s heritability is unaccounted for by currently
identified variants and the mechanisms leading from gene to
clinical phenotype remain elusive.
Reports of lower brain volumes in cross-sectional studies are
common in MDD, but small sample sizes have potentially
contributed to poorly replicated results. Enhancing Neuro-
Imaging Genetics through Meta-Analysis (ENIGMA) completed a
large MDD case–control meta-analysis of subcortical volumes
(n= 8927) demonstrating a significant association between MDD
and reduced hippocampal volume (Cohen’s d=− 0.20).5 Numer-
ous other studies have also demonstrated a link between
hippocampal reduction and MDD, and it is one of the most
robustly associated brain regions.6 Other brain regions have
shown limited and sometimes contradictory evidence for associa-
tion with MDD. Smaller amygdala volume has been associated
with depressive symptoms7,8 and MDD status,9 however larger
amygdala volume has also been associated with the disorder.10 A
2013 meta-analysis concluded that, as well as hippocampus,
smaller putamen and thalamus volumes were associated with late
life MDD, although fewer studies have examined these regions.11
In addition, smaller caudate nucleus volumes have also been
associated with MDD in a meta-analysis.12 The nucleus accumbens
has not been widely associated with MDD status but a smaller
volume has been implicated in the lethality of suicidal acts within
mood disorder sufferers.13 Pallidum volume and intracranial
volume (ICV) have not been associated with MDD in any meta-
analysis to date, as far as we are aware.
Subcortical structural volumes are known to be influenced by
both genetic and environmental factors and have been demon-
strated to be moderately to highly heritable ranging from 0.44 to
0.88.14 The previously reported lower brain volumes in MDD and
the relatively high heritability of these structures means they
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could be of interest as an intermediate phenotype.14 Overlap
between genes involved in MDD and subcortical regions have
been explored previously. The majority of studies have focused on
candidate genes, such as the serotonin transporter (5-HTTLPR),
and findings have often been contradictory.15 As the success of a
candidate gene study is reliant on the correct gene being chosen,
GWAS studies are often considered to be a less biased and more
reliable approach.16 GWAS of regional brain volumes has recently
been completed by the ENIGMA Consortium,17 providing an
important opportunity to examine the genetic overlap between
subcortical brain volumes and ICV with MDD. Indications of
covariation could potentially identify the risk conferring loci
involved in MDD as well as the underlying mechanisms.
In this current study, we examine whether the genetic
architecture of MDD is shared with multiple subcortical brain
regions and ICV. We employed four techniques; the first, linkage
disequilibrium (LD) score regression,18,19 estimates the genetic
correlation between these traits using GWAS summary statistics
from the ENIGMA consortium and Psychiatric Genomics Con-
sortium (PGC). The second method, polygenic risk scoring (PRS),20
utilises ENIGMA summary statistics to generate individual level
polygenic profile scores of each brain region’s volume. We then
calculated the association of PRS (a) with their own volume in UK
Biobank and (b) with MDD status in three population-based
cohorts; Generation Scotland: Scottish Family Health Study (GS:
SFHS), English Longitudinal Study of Ageing (ELSA) and UK
Biobank and (c) with recurrent MDD, MDD episodes, MDD
duration and age of onset in GS:SFHS and UK Biobank. Both (b)
and (c) analyses were adjusted for confounds on an individual
subject level and then combined in a meta-analysis. Third, we
used the Mendelian randomisation method21 to examine a
directional causal relationship between the regional volumes
and MDD, utilising the GWAS significant loci as genetic instru-
ments. Lastly, we used a new software package BUHMBOX22 to
test for the presence of genetic subgroup heterogeneity.
MATERIALS AND METHODS
Cohort descriptions and genotyping
Generation Scotland: Scottish Family Health Study. GS:SFHS is a family-
based cohort with phenotypic data for 24 080 participants (mean
age= 47.6, s.d. = 15.4) of which 20 032 had genotype data. Individuals
were eligible if they had one first-degree relative willing to partake in the
study. Further details on the recruitment for this cohort are available in the
Supplementary Materials and have been described previously.23 Diagnosis
of MDD was made using the structured clinical interview for DSM-IV
disorders (SCID) for those individuals that screened positive during
interview questions (n= 19 762, cases = 2643).24 Individuals with bipolar
disorder (n= 76) were excluded from this study. Information on MDD
episodes and age of onset was also included in the SCID and therefore
recurrent MDD and duration of MDD could be inferred (further details are
given in the Supplementary Materials).
Details of the DNA extraction for GS:SFHS have been previously
described.25 Genotyping was completed at the Wellcome Trust Clinical
Research Facility Genetics Core, Edinburgh (www.wtcrf.ed.ac.uk) using the
Illumina HumanOmniExpressExome -8v1.0 Beadchip (San Diego, CA, USA)
and Infinium chemistry26 and processed using GenomeStudio Analysis
Software v2011.1. Quality Control (QC) utilised the following inclusion
thresholds; missingness per individual o1%, missingness per single-
nucleotide polymorphism (SNP) o1%, Hardy–Weinberg Equilibrium (HWE)
P-value 41× 10− 6, minor allele frequency (MAF) 41%. There were
556 705 SNPs and 19 994 individuals that passed QC criteria.
UK Biobank. UK Biobank is an open resource cohort with phenotypic data
for 502 664 (mean age= 56.5, s.d. = 8.1) between the ages of 40–69
recruited within the United Kingdom between 2006 and 2010, with
genotype data available for 152 734 participants. Our study was conducted
under UK Biobank application 4844. Study design and recruitment has
been described previously27 but, in brief, participants were asked to
complete a touchscreen questionnaire and additional data were collected
by nurse interview. MDD status was based upon putative MDD phenotype
defined by Smith et al.28 (n= 24 048). Participants with mild depressive
symptoms were removed based on this definition and self-reported
bipolar disorder participants (n= 1211) were excluded. Information on
MDD episodes and age of onset was also available, therefore recurrent
MDD and MDD duration was inferred (further details are given in the
Supplementary Materials). Subcortical volumes for nucleus accumbens,
amygdala, caudate nucleus, hippocampus, pallidum, putamen and
thalamus were measured by T1-weighted structural imaging. The UK
Biobank imaging protocol has been described elsewhere (http://biobank.
ctsu.ox.ac.uk/crystal/refer.cgi?id = 1977). The mean of the sum of left and
right volume was taken for each subcortical region. ICV was generated by
the sum of white matter, grey matter and ventricular cerebrospinal fluid
volumes. Imaging data for the eight structures were available for 4446
participants, of which 968 had genetic data available.
Genotyping was completed utilising two Affymetrix arrays (Santa Clara,
CA, USA); BiLEVE (n=49 979) and the UK Biobank Axiom (n= 102 750).
Details have been described previously.29 Initial genotyping QC was
performed by UK Biobank.30 Additional filtering was then applied to
participants with poor heterozygosity or missingness, QC failure, non-
British White ancestry, gender mismatch, genotype missingness o2%, and
relatedness within UK Biobank and to the GS:SFHS sample (r40.0442,
n= 35 752) and ELSA sample (in the meta-analysis with all three cohorts).
SNPs inclusion criteria were HWE P41 × 10− 6 and MAF41%. There were
731 536 SNPs and 152 735 individuals that passed QC criteria.
English Longitudinal Study of Ageing. ELSA is a prospective cohort study of
health and ageing collected in 2002 with six follow-up waves taken at 2-
year intervals. At wave 1 (baseline), phenotypic data were available for
12 003 (mean age= 63.9, s.d. = 10.7) and genotypic data available for 7452
participants. Details of this cohort have been described previously31 and
further information is available in the Supplementary Materials. MDD status
in this study was defined using a shortened form of the Centre of
Epidemiological Studies—Depression scale (CES-D scale) (completed by
5752 participants with genomic data). This consisted of 8 questions, rather
than the original 20, with a ‘no’/‘yes’ response that was converted to a
binary 0/1, respectively, although positive questions, that is, ‘During the
past week, were you happy?’, were scored in reverse; 0 being ‘yes’ and 1
being ‘no’. After summing the scores, a dummy variable of MDD status was
classified as those with a score of 4 or above, as in previous studies.32 Self-
reported ‘manic depressive’ (n= 41) individuals were excluded.
Genotyping was completed in 2013/14 on 7452 participants on the
Illumina Omni 2.5–8 chip and QC and removal of related individuals
(r≥ 0.2, n= 109) was completed at the University College London Genetics
Institute. Further QC was implemented using the same inclusion thresholds
as used for GS:SFHS; SNP inclusion criteria were HWE P41× 10− 6 and
MAF41% and exclusion of related individuals (r4=0.2, n=109). There
were 41.3 million SNPs and 7230 individuals that passed QC criteria.
LD score regression
Genetic correlation of subcortical structures and ICV with MDD were
measured using the LD score regression technique.18,19 In brief, this
technique utilises GWAS summary statistics to estimate the SNP-based
heritability of a trait and genetic correlation between traits, in this study we
used summary data from ENIGMA and PGC. SNPs inclusion criteria were
INFO40.9 and MAF4%1 (further details in Supplementary Materials).
Summary statistics for the regional brain volume GWAS completed by
ENIGMA were downloaded from http://enigma.ini.usc.edu/research/down
load-enigma-gwas-results/. The GWAS was completed using 11 840
participants for eight MRI volumetric measures; nucleus accumbens,
amygdala, caudate nucleus, hippocampus, pallidum, putamen, thalamus
and ICV.17
Summary statistics for the MDD GWAS completed by the MDD Working
Group of the PGC were downloaded from http://www.med.unc.edu/pgc/
downloads. The study examined 9238 MDD cases and 8039 controls.33
Polygenic risk scoring
Construction of PRS was completed in PLINK software.34 PRS utilise effect
sizes from GWAS summary statistics to construct an additive individual
genetic scores in a population.20 Summary statistics were taken from
the ENIGMA GWAS17 (details above) to construct weighted PRS using five
P-value thresholds: 0.01, 0.05, 0.1, 0.5 and 1, after SNPs underwent
clumped-based pruning (r2 = 0.25, 300 kb window). All five thresholds are
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reported in models of subcortical volume and ICV PRS predicting their
respective volume in UK Biobank and the best predictive threshold was
carried forward into models associating MDD status with each subcortical
volume and ICV in all three cohorts. The P-value thresholds carried forward
were; nucleus accumbens: 0.01, amygdala: 0.1, caudate nucleus: 0.5,
hippocampus: 0.01, ICV: 0.5, pallidum: 0.5, putamen: 0.1 and thalamus: 0.05.
Scores for GS:SFHS, UK Biobank and ELSA were computed on the raw
genotypes.
Statistical analysis
Association between regional brain volume PRS and its respective volume.
Models predicting regional brain volumes in UK Biobank were conducted
using linear regression in R version 3.2.3 (www.r-project.org). Models were
adjusted for age, sex and the first 15 principal components (PCs) as well as
for ICV (excepting ICV itself).
Association between regional brain volume PRS and MDD. Mixed linear
model analyses were completed in ASReml-R (http://www.vsni.co.uk/
software/asreml/) for GS:SFHS with MDD status. Mixed linear modelling
was utilised to account for the family structure in GS:SFHS. MDD status was
fitted as the dependent variable and volume PRS fitted as the independent
variable. The model was adjusted for age and sex with the first four PCs
fitted to control for population stratification. An additive relationship
matrix (expected relatedness derived from pedigree information) was
fitted as a random effect to account for the family structure in GS:SFHS.
Wald’s conditional F-test was used to calculate P-values for all fixed effects
and the variance explained was calculated by division of the difference in
the sum of residual variance and additive genetic effect in the null model
(without PRS) with the full model (with PRS). To adjust for the use of linear-
mixed regression models being applied to a binary dependent variable in a
structured data set, the fixed effects and standard errors from the linear
model were transformed utilising a Taylor series approximation35 from the
linear scale to the liability scale (Supplementary Materials).
In unrelated samples (UK Biobank and ELSA) logistic regression utilising
generalised linear models in R version 3.2.3 (www.r-project.org) was used
to test the degree of association between MDD and PRS of subcortical
volumes and ICV. Models were adjusted for age, sex and the first 15 PCs (in
UK Biobank) and first 4 PCs (in ELSA) to control for varying levels of
population stratification present in the samples.
Association between hippocampus volume PRS and MDD traits. As
hippocampal volumetric differences have been more closely associated
with recurrent MDD and early illness onset,5,36 hippocampus PRS
regression analyses were also run with recurrent MDD, number of
episodes, MDD duration and age of onset as dependent variables (for
further details see Supplementary Materials). In GS:SFHS these were run
utilising mixed linear model analysis (as above) to account for the family
structure. As recurrent MDD is a binary trait, this was transformed from the
linear to liability scale using the Taylor series approximation35 (as above).
For testing association in unrelated samples, logistic regression models
were used for binary traits (recurrent MDD) and linear regression for
quantitative traits (number of episodes, MDD duration and age of onset).
Models were adjusted for age, sex and the first 15 PCs to control for
population stratification. These data were not available for ELSA therefore
this was run in UK Biobank only.
Meta-analysis. In order to increase power, fixed effect meta-analysis,
weighted by standard error of the beta values relating PRS scores to MDD
was carried out using the ‘meta’ package (version 4.3-2)37 in R.
Mendelian randomisation
Mendelian randomisation (MR) is an approach that examines genetic
variants in association with an exposure and outcome to determine
causality. In this study if a significant genetic correlation (Po0.05) was
found (indicating pleiotropy) it was carried forward into a two-sample MR
analysis. We utilised the ‘MendelianRandomization’ package (v0.2.0) in R to
conduct both an Inverse-Variance Weighted (IVW) analysis and MR-Egger
regression.21 In brief, the IVW method incorporates multiple SNPs as a
vector of instrumental variables (IVs) and carries out weighted linear
regression analysis between the IVs vector—outcome and IVs vector—
exposure. The analysis is weighted on the inverse variance of the IVs vector
—outcome association and the intercept constrained to zero. We utilised
the effect beta from the genome-wide significant variants from the original
ENIGMA GWAS as the association between variants and exposure and the
effect beta from the same variants in the PGC GWAS as the association
between the variant and outcome. We also tested the association between
the variants and MDD in the GS:SFHS, UK Biobank and ELSA
(Supplementary Materials). If the variant was not available in a data set,
that data set was either removed or the variant in highest LD available in
both data sets was used. The constraint of the intercept at zero in IVW,
however, assumes that all IVs are valid. As this is not always the case, if a
significant association (Po0.05) was indicated in IVW analysis, sensitivity
analysis with MR-Egger regression was conducted. As MR-Egger regression
does not constrain the intercept, it is therefore is not biased by invalid
IVs.38 The same effect beta’s and standard errors were utilised in the
MR-Egger regression. For further details on the methodology see
Supplementary Materials.
BUHMBOX
To further explore correlation between subcortical volume and MDD, we
utilised the technique BUHMBOX.22 This technique tests for the presence
of true pleiotropy and genetic subgroup heterogeneity within cases of a
disease phenotype (phenotype A) by measuring pairwise correlations of
risk alleles with another trait (phenotype B). The presence of phenotype B
risk alleles across all phenotype A cases and not phenotype A controls
provides evidence of true pleiotropy, whereas subgroup heterogeneity is
implicated if phenotype B risk alleles are enriched in a subgroup of
phenotype A cases. Pairwise correlations are combined to generate a
BUHMBOX test statistic for clinical heterogeneity. In this study, if a
significant genetic correlation (Po0.05) was found, we utilised BUHMBOX
to further dissect the genetic relationship between regional brain volume
and MDD. We examined risk alleles associated with the ENIGMA regional
brain volumes as phenotype B with MDD phenotypes in GS:SFHS, UK
Biobank and ELSA as phenotype A. In order to minimise bias caused by
related individuals in GS:SFHS, an unrelated subsample was used
comprising 5659 individuals (786 MDD cases). LD pruning was conducted
using PLINK 1.9039 using --indep-pairwaise with r240.1 and a window size
of 50 SNPs and a sliding winding of five SNPs. The first 4 PCs were fitted in
GS:SFHS and ELSA and the first 15 PCs were fitted in UK Biobank to
account for additional heterogeneity.
Power Analyses
Power analyses for the genetic correlations (rG), calculated using LD score
regression, were completed using the GCTA-GREML power calculator.40 As
LD score regression utilises summary statistics and GCTA, the individual
genotype data, true power is likely to be slightly lower; however, the GCTA-
GREML power calculator gives a close estimate. Results of the power
analysis are presented in Supplementary Table S1.
Simulations of genetic correlations varying from 0.1 to 0.5 between the
brain volume and MDD indicated that, at rG = 0.5, we had power to detect
an association (Po0.05) in all regions. However, genetic correlation was
found to be much lower for many of the regions and therefore we only
had adequate power to detect a correlation between hippocampal volume
and MDD (power = 93%). For the remaining regions, a power curve was
conducted to demonstrate the size of the sample needed for sufficient
power (Figure 1 and Supplementary Figure S2). Results indicate that an
additional ~ 15 000 sample increase in both ENIGMA and PGC samples
would be needed to detect significant genetic correlations between MDD
and either putamen or ICV at the estimates reported in this analysis. To
demonstrate significant genetic correlation between MDD and either
nucleus accumbens or pallidum volumes would require sample size
increases of greater than 100 000 in both samples. Power curves of
simulated genetic correlations (varying from 0.1 to 0.5) were also
constructed to identify the genetic correlation that we would have had
power to detect at the current sample size. Results indicate that this
sample had adequate power to detect a genetic correlation of at least 0.24
for putamen, 0.26 for nucleus caudate, 0.33 for both pallidum and ICV, 0.37
for hippocampus, 0.38 for thalamus and 0.49 for nucleus accumbens.
Power analysis of PRS were completed using AVENGEME.41 Markers were
assumed to be independent and 5% of SNPs were assumed to have an
effect in the training sample. Genetic covariance values were taken from
the LD score regression analysis, however, no value could be computed for
amygdala therefore three hypothetical covariances were tested; 0.50, 0.25
and 0.10. Results of the power analysis are presented in Supplementary
Table S3.
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Figure 1. Power curves were calculated with starting point 0 as the sample size in our analysis. For the genetic correlation power analysis the
power curves demonstrate (a(i)) the sample size increase needed for detecting a significant association at the estimates reported in this
analysis when both samples were increased equally and, for MDD, the proportion of cases and controls was kept constant and (a(ii)) the
genetic correlation that there would be power to detect at the sample size reported in this analysis. For PRS power analysis (b) the sample size
for the training set (ENIGMA) was kept constant while the target set sample size was increased. Amygdala was assumed to have a rG= 0.25 for
the PRS power analysis. Hippocampus had adequate power in the genetic correlation analysis and therefore was not included in the
power curve. ICV, intracranial volume; MDD, major depressive disorder; PRS, polygenic risk scoring.
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Despite a study size of 49 576 individuals, PRS was under-powered in all
analyses. Highest power in the meta-analyses was for hippocampal
volumes (37%). Low SNP heritability and low covariance between traits
account for the low power in the meta-analyses. In the PRS analysis on
their own trait, highest powered was the putamen (23%) at a P-value
threshold of 1. In this analysis a small sample size of 968 individuals likely
reduced power. We therefore conducted a power curve for both the meta-
analysis and PRS in their own trait to indicate the sample size that would
be necessary to have adequate power (Figure 1 and Supplementary
Figure S3). Power curves indicate that a sample increase of ~ 100 000
individuals in the target set would be sufficient power for hippocampus
PRS associated with MDD, however nearly 900 000 for amygdala assuming
a covariance of 0.25 and an increase of over 1 million participants for
nucleus accumbens, pallidum and thalamus.
RESULTS
Genetic correlation
Using LD score regression, we calculated SNP-based heritability
estimates for the seven subcortical regions and ICV with MDD,
utilising summary data from GWAS completed by ENIGMA17 and
PGC,33 respectively. The estimate of the SNP heritability for the
amygdala was non-significant and therefore the amygdala was
not included in any further analysis. SNP heritability estimates for
the remaining subcortical volumes ranged from the SNP
h2 = 0.0855 (s.e. = 0.0438) for the nucleus accumbens to SNP
h2 = 0.297 (s.e. = 0.051) for the putamen (Table 1). MDD SNP
heritability was calculated at 0.204 (s.e. = 0.0386). Genetic correla-
tion between each subcortical region and ICV with MDD was then
calculated. Hippocampal volume demonstrated significant genetic
correlation with MDD (rG = 0.460, s.e. = 0.200, P= 0.0213; Table 1),
although this did not survive multiple testing correction using
false discovery rate adjustment (Supplementary Table S3). No
other subcortical volume or ICV was genetically correlated
with MDD.
Polygenic risk score
Association between regional brain volume PRS and its respective
volume. Subcortical and ICV PRS were calculated in UK Biobank
to examine the association between each regional volume PRS
and its own volume. PRS were positively associated with their
respective volume in four of the eight structures across the five P-
value thresholds; caudate nucleus, ICV, putamen and thalamus. In
addition, hippocampus was significantly associated at a P-value
threshold of 0.01 only. These results retained significance after
multiple test correction across the five thresholds, however only
raw P-values have been reported. Nucleus accumbens, amygdala
and pallidum PRS did not demonstrate any association with their
respective volume. The variance explained by PRS was small for all
volumes, with the largest reported in the caudate nucleus
(R2 = 0.0102, β= 0.117, P= 1.08 × 10− 4; Figure 2 and
Supplementary Table S2).
Association between regional brain volume PRS and MDD. Struc-
tural PRS were selected at the threshold that best predicted its
own volume (nucleus accumbens = 0.01, amygdala = 0.1, caudate
nucleus = 0.5, hippocampus = 0.01, ICV = 0.5, pallidum=0.5, puta-
men= 0.1, thalamus = 0.05) and tested for prediction of MDD
status. No PRS for any volume was significantly associated with
MDD status in any of the cohorts (Supplementary Table S4). In
Table 1. SNP-based heritability (h2) and genetic correlation (rG) of subcortical brain regions and ICV with MDD
SNP heritability Genetic correlation with MDD
Brain region SNP h2 s.e. Z-score rG s.e. Z-score P
Nucleus accumbens 0.0855 0.0438 1.95 0.0458 0.210 0.218 0.828
Caudate nucleus 0.253 0.0432 5.86 0.0752 0.130 0.580 0.562
Hippocampus 0.137 0.0481 2.85 0.460 0.200 2.30 0.0213
ICV 0.167 0.0462 3.61 0.123 0.166 0.739 0.460
Pallidum 0.171 0.049 3.49 − 0.0077 0.158 − 0.0491 0.961
Putamen 0.297 0.051 5.82 0.0986 0.118 0.834 0.404
Thalamus 0.125 0.0401 3.12 − 0.0808 0.177 − 0.457 0.648
Abbreviations: ICV, intracranial volume; MDD, major depressive disorder; SNP, single-nucleotide polymorphism. The heritability of amygdala was nonsignificant













































Figure 2. Significant P-values (o0.05) are indicated with asterisk (*). Nucleus accumbens, amygdala and pallidum PRS were not significantly
associated with their respective volume at any threshold. ICV, intracranial volume; PRS, polygenic risk scoring.
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order to increase power, we completed a meta-analysis of the
summary association statistics from three cohorts. No evidence of
heterogeneity was identified in any of the meta-analyses. We
found no association between any structural PRS and MDD
(Figure 3a and Supplementary Figure S4).
Association between hippocampus volume PRS and MDD traits.
Association between hippocampal volume and recurrent MDD
and early illness onset has been previously reported.5,36 We
therefore examined MDD phenotypes in association with hippo-
campal volume PRS in GS:SFHS and UK Biobank, these data were
not available for the ELSA cohort. There was no association
between hippocampal PRS and recurrent MDD (OR= 0.98,
P= 0.0850) (Figure 3b). Further, hippocampal volume PRS was
not significantly associated with number of episodes (β=
− 0.00390, P= 0.425), MDD duration (β=− 0.00110, P= 0.414) or
age of onset (β= 0.0142, P= 0.291; Supplementary Figure S5).
Mendelian randomisation
To further examine the nominally significant genetic correlation
between hippocampus and MDD, MR analysis was performed to
test for a directional association between hippocampal volume
and MDD. Only two genome-wide significant variants were
identified in the original ENIGMA GWAS (rs61921502 and
rs77956314) and these SNPs were only present in two of the
cohorts (GS:SFHS and UK Biobank). To obtain a value for variant—
outcome in the PGC data set, we selected the SNPs in highest LD
with the two causal variants that were available in both ENGIMA
and PGC summary statistics; rs17765551 and rs7294919. We also
conducted the analysis using values obtained with the causal
variants from meta-analysis with GS:SFHS and UK Biobank. IVW
analysis did not identify evidence for a causal association between
hippocampus variants and MDD in using either PGC MDD as the
outcome nor GS:SFHS and UK Biobank MDD (Supplementary Table
S5), it was therefore not necessary to carry this forward into the
MR-Egger regression model.
BUHMBOX
To further investigate whether the genetic correlation found
between hippocampus volume and MDD could be due to genetic
subgroup heterogeneity, we utilised the software package
BUHMBOX. SNP subsets were used that were associated with
hippocampal volume at a threshold of Po1.0 × 10− 3 and had to
be present in all individuals per cohort therefore 388, 504 and 386
SNPs, and 5659, 7017 and 4118 individuals remained in GS:SFHS,
UK Biobank and ELSA, respectively. Clinical heterogeneity was
found in GS:SFHS MDD cases (Z-score = 2.78, P= 0.00281), demon-
strating excessive pairwise correlations between risk alleles for
hippocampus volume and a subgroup of MDD cases. This survived
false discovery rate multiple testing correction, however, this
finding was not replicated in either UK Biobank or ELSA (Table 2).
DISCUSSION
Previous studies have reported phenotypic associations between
brain volumes and MDD. In this study, we investigated whether
there was evidence of shared genetic architecture between
subcortical brain volumes and ICV with MDD. Results from the
genetic correlation analysis indicate that hippocampal volume and
MDD are partially influenced by common genetic variants
(rG = 0.46, s.e. = 0.200, P= 0.0213), although this did not survive
correction for multiple testing. This positive genetic correlation is
novel, so far as any of the authors are aware, however Mathias
et al.42 demonstrated significant negative correlation between
recurrent MDD and right hippocampal volume measured via
linkage analysis in a sample of 893 individuals. No other brain
regions’ volume showed evidence of shared genetically aetiology
with MDD. Our sample size was adequate to detect a correlation at
rG = 0.5, however, at the values reported in this study, we were
underpowered in all other brain volumes (excluding hippocam-
pus). Power analyses indicate that we had insufficient power to
detect weak to modest genetic correlations in this study. Although
we were able to demonstrate lack of strong genetic correlations
between regional brain volumes (excepting hippocampus) and
Figure 3. Both plots demonstrate a negative correlation with MDD and recurrent MDD with no heterogeneity between cohorts but neither
plot reaches statistical significance. CI, confidence intervals; GS:SFHS, Generation Scotland: Scottish Family Health Study; MDD, major
depressive disorder; OR, odds ratio; seTE, standard errors; TE, treatment effect (regression beta’s); W(fixed), weight of individual studies in fixed
effect meta-analysis.
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MDD, we cannot with confidence exclude the possibility that
they are weakly to modestly correlated. Therefore, further
analysis utilising larger sample sizes (a minimum of 15 000
increase in both samples) would be necessary to draw con-
firmatory conclusions.
Brain volume PRS were not associated with their own volume in
three out of the eight structures and was only associated with
hippocampal volume at P-value threshold 0.01. This is likely due to
the analysis being underpowered to detect an association in a
sample size of 968 participants. Of the PRS that were associated
with their phenotype, the largest proportion of variance explained
was 1% with the majority predicting ~ 0.6%. The proportion of
variance explained is therefore very low although this is fairly
common in PRS studies43 with one of the largest explained
variance by PRS reported in schizophrenia (~7% on the liability
scale).44
Meta-analysis of data from three studies, totalling 49 576
individuals including 11 552 cases, found no evidence of
association between any regional brain volume PRS and MDD,
including the hippocampus. As previous neuroimaging evidence
suggests that decreased hippocampal volumes could occur as a
cause or consequence of recurrent depressive episodes and early
illness onset,5,36 we examined hippocampal volume PRS associa-
tions with recurrent MDD, number of episodes, MDD duration and
age of onset but we observed no significant associations. Despite
the PRS meta-analysis being the largest analysis to date examining
genetic scores for brain volume and MDD, it was severely
underpowered; therefore, we can draw no confirmatory conclu-
sions about the genetic overlap between any structure and MDD
from this analysis. The apparent discrepancy between PRS and our
finding LD score regression is likely due to this lack of power,
however, as LD information is utilised in LD score regression and
SNPs are pruned in PRS calculation, it is also possible that the ‘loss
of information’ involved in calculating PRS contributed. Previous
simulation studies have demonstrated that predictive capabilities
of PRS are greatly enhanced when utilising LD information.45 This
implies that LD pruning may be removing causal SNPs and those
more closely tagging causal variants, resulting in a loss of
information and predictive accuracy.
To further dissect the positive genetic correlation between
hippocampus and MDD, we utilised MR and BUHMBOX techni-
ques. MR was used to determine the causality of genetic variants
in association with hippocampal volume and MDD. We did not
detect a causal association, however, there were only two
genome-wide significant SNPs associated with hippocampal
volume in the original GWAS. Larger numbers of associated
variants increase power in MR analysis38 therefore this was likely a
contributing factor in this analysis. We also applied BUHMBOX
to investigate genetic subgroup heterogeneity and detected
evidence of a subgroup in MDD cases within GS:SFHS. We
did not replicate this finding in UK Biobank or ELSA, however,
MDD cases are not defined using a clinical measure in these
cohorts, whereas GS:SFHS cases are defined using DSM-IV criteria.
The PGC MDD definition also most closely matches that of GS:
SFHS MDD, although the GS:SFHS sample was population-based
rather than identified from a clinically ascertained samples.
This could explain why the findings were associated with these
cohorts and not the others. The observed lack of replication may
then be due to factors related to ascertainment differences and
should therefore be replicated in a clinically determined MDD
sample.
We conclude that hippocampal volume and MDD may share
common genetic factors, although this result did not withstand
multiple testing correction. Animal models have previously
demonstrated that increased stress can drive decreased hippo-
campal neurogenesis (and therefore increased atrophy)46 and this
reduced neurogenesis can lead to depressive-like symptoms.47
Stress is a well-established environmental risk factor associated
with MDD48 and the inhibition of glucocorticoid receptors has
been shown to normalise hippocampal neurogenesis49 and relieve
symptoms in psychotic major depression.50 Furthermore,
increased duration of depression has also been related to more
pronounced hippocampal reductions.51 Our results however
indicated a positive genetic correlation suggesting that genetic
variants determining larger hippocampal volume may be risk
factors for MDD. The clinical heterogeneity found utilising
BUHMBOX in GS:SFHS could provide a possible explanation for
the deviation from literature. If genes for larger hippocampal
volume are present in a subgroup of MDD only, then it is possible
that hippocampal volume atrophy could be associated with a
different subgroup of individuals that are affected through more
environmental pathways. Hippocampal volume has been demon-
strated to be more highly impacted by the environment than
other brain regions52 and is associated with many environmental
factors, for example, stress,48 increased exercise training53 and jet
lag.54 It is therefore possible that the previously reported
decreased hippocampal volume associated with MDD is due to
multiple episodes of depression and that this positive genetic
correlation is due to a role in MDD susceptibility earlier in brain
development. In fact, it has been previously demonstrated that
first episode MDD subjects exhibited marginally larger hippocam-
pal volumes in comparison to healthy controls.55 This could also
provide explanation for the opposing negative genetic correlation
finding by Mathias et al.42 as they examined recurrent MDD.
However, it should be noted that this study did not demonstrate
significant hippocampal atrophy in analysis including controls,55
which has been similarly shown in another study.56 Given that this
positive correlation could be associated with a subgroup of MDD
cases, it is also possible that this is hindering investigations into
hippocampus and all MDD cases. Hippocampal volume changes
are also widely associated with other psychiatric disorders such as
schizophrenia. A similar analysis that examined the genetic
correlation between subcortical volumes and schizophrenia found
no significant correlations.57 This is suggestive that the genetic
correlation observed could be specific to hippocampal volume in
MDD. However, these results are only indicative of a genetic
correlation between the two traits and further research would be
necessary to provide confirmative evidence.
A number of limitations of this study should be noted; first, this
study only explored the effects of common genetic variants and it
Table 2. BUHMBOX results for hippocampus volume and MDD in GS:SFHS, ELSA and UK Biobank
BUHMBOX P Pcorrected Z-score N Cases Controls SNPs N Pleiotropy P Pleiotropy β Pleiotropy s.e.
GS:SFHS 0.00281 0.00843 2.77 5659 786 4873 388 0.0890 − 0.0448 0.0263
UK Biobank 0.893 0.893 − 1.24 7017 2316 4701 504 0.926 − 0.00128 0.0138
ELSA 0.678 0.893 −0.462 4116 544 3572 386 0.650 0.0144 0.0316
Abbreviations: GS:SFHS, Generation Scotland: Scottish Family Health Study; ELSA, English Longitudinal Study of Ageing. Significant results (Po0.05) are shown
in bold.
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may be important to examine rarer variants to generate a more
complete picture, although this will require larger sample sizes.
Second, the lower heritability, higher prevalence and likely
heterogeneity of MDD results in less precise estimates of marker
weights from GWAS,58 decreasing the power to detect genetic
correlations with other phenotypes. Power of the PRS is limited
also by the size of the initial ENIGMA GWAS (n= 11 840), larger
discovery sample sizes greatly improve the accuracy of PRS.44,59
Therefore, larger genome-wide analysis would be necessary to
generate confirmatory conclusions. Third, the estimates for SNP
heritability, calculated using LD score regression, were lower than
have been previously described.60 LD score regression has been
utilised previously to calculate SNP heritability of subcortical
volumes using the ENIGMA summary data with similar low
estimates reported.57
Despite these limitations, we provide some evidence of a
positive genetic correlation between hippocampal volume and
MDD and an indication of MDD subgroup heterogeneity, however,
the genetic correlation did not survive multiple testing correction
and the subgroup heterogeneity was not replicated. We did not
demonstrate an association utilising PRS techniques, however, low
power, low explanation of variance and loss of LD information
were notable limitations. Although we demonstrate a potential
genetic relationship between hippocampal volume and MDD in a
subgroup of individuals, we believe one of the most important
outcomes for the current study is in the planning for future
studies. Sample sizes of ~ 150 000 individuals will be needed to
have sufficient statistical power (40.8) to detect shared genetic
architecture between MDD and hippocampal volume using PRS,
using data sets similar to the one studied. The other regional brain
volumes ranged from needing an additional sample size of
~ 400 000 to in excess of 1 million individuals. Alternatively, further
studies may utilise data from further releases of the ENIGMA
consortium, including larger numbers of participants and more
accurately determined SNP effect sizes. Further research into
subgrouping in the association between hippocampus and MDD
may also be beneficial.
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3.3. Chapter Conclusion 
This study largely indicates a lack of genetic correlation between subcortical volumes 
and MDD, excluding hippocampus which would need to be additionally examined in 
an independent dataset before any confirmatory conclusions can be drawn. It is 
possible that this nominal association in hippocampal volume is a genetic subgroup 
(as indicated by BUHMBOX in GS:SFHS), however given this results contradicts 
previous direction of effect it is also very possible that this correlation is type I error. 
Nevertheless, lack of a genetic correlation for hippocampal volume does not disclude 
the possibility of environmental impact. In fact, a 2009 meta-analysis found that 
hippocampal volume reductions occur after MDD onset (McKinnon, Yucel, Nazarov, 
& MacQueen, 2009) and childhood trauma has been associated with small 
hippocampal volume in MDD (Vythilingam et al., 2002). This study counters the 
previous reports that show an association between candidate genes for MDD and brain 
volumes. The lack of associations provides several different possible interpretations: 
(1) brain volumes and MDD are weakly to modestly correlated at a level that we did 
not have the power to detect with the current sample, (2) brain volume genetic factors 
are not associated with risk for MDD but non-genetic factors are, or (3) regional brain 
volumes are not associated at all with MDD pathology. Further examination of 
environmental effects in regional brain volume and MDD will elucidate more about 
their association. 
Subcortical brain volumes have also been associated with antidepressant response 
therefore a similar analysis exploring antidepressant resistance and subcortical 
volumes would be informative. Nevertheless, given that this analysis was 
underpowered (in all but hippocampus), significantly larger samples for antidepressant 
response would be needed as the largest current GWAS is only ~2,900 individuals 
(Tansey et al., 2012). 
Future studies should investigate the marginal evidence for MDD subgrouping as this 
may explain the inconsistent findings in MDD and neuroimaging studies. Nonetheless, 
this study generally supports a lack of genetic association between regional brain 




Chapter 4. The Genetics of Antidepressant Resistance. 
 
4.1. Background 
In Chapter 1, the high heterogeneity, comorbidities and possible biological 
mechanisms that underlie MDD were explored. Given that no individual biological 
theory has adequately explained MDD, it is possible that the diagnosis may group 
individuals with diverse aetiologies. Furthermore, many of the theories on MDD 
pathology overlap with findings in antidepressant non-response e.g. higher 
inflammatory markers indicate a higher likelihood for non-response (Uher et al., 
2014). Therefore, it is also possible that the causes of antidepressant non-response may 
define different aetiological MDD subgroups. Examining pathways to non-
responsiveness could therefore aid in stratification and explication of biological 
mechanisms.  
Identifying genetic variants associated with antidepressant non-response may facilitate 
our understanding of antidepressant mechanisms, stratify individuals into more 
aetiologically circumscribed subgroups and inform the construction of personalised 
treatments. The most common methodology for studying non-response is a continuous 
assessment of reduction in baseline depression symptoms during treatment measured 
by scales such as the Montgomery-Asberg Depression Rating (MADRS) and Hamilton 
Rating Depression Scale (HRSD). Nevertheless, these studies are conducted as clinical 
trials which are highly regulated, require significant resources and staffing and are 
prone to under-recruitment and premature termination. Clinical trials are therefore 
prone to small sample sizes (Moaddeb & Haga, 2013; Naudet et al., 2011) and are 
likely to be underpowered, especially for genetic studies. Alternate approaches to 
obtaining sufficient sample sizes for genetic studies of treatment response are therefore 
needed. Both self-report response data and electronic health records provide possible 
alternatives as these represent cheaper substitutes that can be applied with relative ease 
to large samples. However, these techniques typically provide less detailed 
information about individual drug response than a continuous approach. Previous 
studies utilising these approaches have deduced binary responder/non-responder or 
responder/resistant status. For example, 23andMe applied information from a self-
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report questionnaire on response whereby assessment of an individual’s response to 
an antidepressant was ranked on a scale from “Not at all” or 0 to “A fair amount” or 
3. Treatment non-response was then defined as a score less than or equal to 1 and was 
used to deduce non-response to selective serotonin reuptake inhibitors (SSRIs) and 
bupropion and additionally treatment resistance (which was non-response to more than 
2 antidepressants and additionally never reporting a score of more than 3) (Q. S. Li et 
al., 2016). Additionally, using electronic health records, treatment resistant depression 
was defined in an antidepressant-user population as non-response to two or more 
antidepressants using a previously validated natural language processing (NLP) tool 
(O'Dushlaine et al., 2014). The NLP tool utilised longitudinal data from clinic visits 
and prescription records to define treatment resistance and then compared their 
outcomes with the International Classification of Diseases 9 (ICD-9) codes reporting 
an area under the curve (AUC) of 0.85-0.88 (Perlis et al., 2012). 
The largest current genome-wide association study (GWAS) on antidepressant 
response is a meta-analysis conducted by NEWMEDS and STAR*D that measured 
response continuously as reduction in symptoms using both the MADRS and HRSD-
17 scales (Tansey et al., 2012). No significant genetic associations or pathway 
enrichment was detected and an additional PRS analysis found no significant 
prediction of NEWMEDS PRS in STAR*D. The largest current GWAS on 
antidepressant treatment resistance (measured as a binary outcome) was completed by 
23andMe using self-report data (detailed above) but similarly found no significantly 
associated genetic variants (Q. S. Li et al., 2016). Nonetheless, analysis refined to 
specific antidepressant classes have described associated variants; a meta-analysis of 
over 1,354 individuals identified a variant located in an intergenic region on 
chromosome 5 (near pseudogene LOC643401) associated with 2-week outcomes with 
citalopram and escitalopram (GENDEP Investigators et al., 2013). Additionally, a 
further 23andMe analysis found an intergenic variant located between genes GPRIN3 
and SNCA associated with bupropion response (Q. S. Li et al., 2016); bupropion is a 
noradrenaline-dopamine reuptake inhibitor but is not currently indicated for MDD in 
the National Health Service (NHS)  (Joint Formulary Committee, 2017). Furthermore, 
through gene-set enrichment, they identified circadian rhythm, long-term depression 
and vascular endothelial growth factor pathways.  
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This chapter will explore treatment resistance (TR) in a population-based cohort using 
prescription records gained by linkage to NHS electronic health records whilst also 
examining antidepressant resistance in a semi-quantitative scale, stages of resistance 
(SR). This analysis will be, in part, a proof of principle study to demonstrate the use 
of health records in large biobanks, which have becoming increasing popular in recent 
years. Genome-wide association study, gene and gene-set enrichment were conducted. 
Moreover, to explore whether any traits that have previously been associated with 
depression could meet some of the criteria for intermediate phenotypes for treatment 
resistance, polygenic risk score (PRS) analysis and genetic correlations were also 
performed. The content for this chapter has been summarised in a manuscript entitled 
“Genome-wide association study of antidepressant treatment resistance in a 
population-based cohort using health service prescription data and meta-analysis with 
GENDEP” which has been submitted for publication. I confirm, as the first author, 
that I carried out the analysis of the data (excepting the GENDEP GWAS which was 
conducted by GENDEP themselves due to access restrictions) and wrote the following 
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Antidepressants demonstrate modest response rates in the treatment of major 
depressive disorder (MDD). Despite previous genome-wide association studies 
(GWAS), the genetic factors underlying non-response are unknown. Using 
prescription data in a population and family-based cohort (Generation Scotland: 
Scottish Family Health Study; GS:SFHS), we sought to define a measure of (a) 
treatment resistance and (b) stages of resistance  by inferring antidepressant switching 
as non-response to treatment. GWAS were conducted separately for treatment 
resistance in GS:SFHS and the Genome-based Therapeutic Drugs for Depression 
(GENDEP) study and then meta-analysed (meta-analysis n=4,213, cases=358). For 
SR, a GWAS on GS:SFHS only was performed (n=3,452). Additionally, we conducted 
gene-set enrichment, polygenic risk scoring (PRS) and genetic correlation analysis. 
We did not identify any significant loci, genes or gene-sets associated with treatment 
resistance or stages of resistance. Significant positive genetic correlations of treatment 
resistance and stages of resistance with neuroticism, psychological distress, schizotypy 
and mood disorder traits were identified. These findings suggest that larger sample 
sizes are needed to identify the genetic architecture of antidepressant treatment 
response, and that population based observational studies may provide a tractable 












Major depressive disorder (MDD) is a disabling condition with a high global impact 
(Collaborators, 2015; Ustün et al., 2004). Antidepressants are the first-line treatment 
for MDD patients but response is modest with only approximately 50% achieving 
remission after completing two treatments (A. Rush et al., 2006). The mechanisms 
underlying antidepressant resistance remain elusive, but are of key value if more 
effective therapies are to be identified and developed. 
Genome-wide association studies (GWAS) of antidepressant treatment response have 
yet to establish any replicated genetic variants (Biernacka et al., 2015; Cocchi et al., 
2016; Garriock et al., 2010; Ising et al., 2009; Myung et al., 2015; Tansey et al., 2012; 
Uher et al., 2010). Two large meta-analyses similarly reported no genome-wide 
significant associated variants. The first, a meta-analysis of the GENDEP (Genome-
based Therapeutic Drugs for Depression), MARS (Munich Antidepressant Response 
Study) and the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) 
(GENDEP Investigators et al., 2013) studies comprised of 2,256 individuals, and the 
second, between the NEWMEDS (Novel Methods Leading to New Medications in 
Depression and Schizophrenia) and STAR*D (Tansey et al., 2012) projects comprised 
of 2,897 MDD individuals. An additional analysis in the first meta-analysis restricted 
to citalopram or escitalopram did, however, identify an intergenic variant (5q.15.1) 
(GENDEP Investigators et al., 2013). The largest GWAS to date examining treatment 
resistance (TR=1,311) versus responders (n=7,795) was conducted by 23andMe 
utilising self-report information, however, no significantly associated genetic variants 
were reported. Nevertheless, one variant (4.q22.1) was found in association with 
bupropion response (Q. S. Li et al., 2016). Numerous candidate genes have also been 
investigated but the results are inconsistent (Fabbri et al., 2014). Furthermore, the 
largest polygenic risk score (PRS) analysis in antidepressant response to date, (which 
utilised GENDEP/STAR*D data) yielded no significant associations for response 
itself, MDD or schizophrenia (García-González et al., 2017).  
Discovering genomic variants associated with resistance to antidepressants could 
advance personal treatment, help identify resistant individuals earlier and inform our 
understanding of MDD. A recent systematic review reported non-response was 
62 
 
associated with illness severity including higher suicide risk, number of 
hospitalisations and antidepressant dosage, but not cognitive ability (De Carlo, Calati, 
& Serretti, 2016). In fact, several phenotypic associations have been found in treatment 
resistant individuals; more comorbidities and suicide attempts (Amital, Fostick, 
Silberman, Beckman, & Spivak, 2008), increased neuroticism and decreased 
extraversion, openness and conscientiousness (McGirr, Van den Eynde, 
Chachamovich, Fleck, & Berlim, 2014; Takahashi et al., 2013). Identifying genetic 
loci may therefore help to identify resistant individuals earlier and enable timelier 
intervention. 
Pharmacogenetic studies are particularly susceptible to small sample sizes (Bacanu, 
Whittaker, & Nelson, 2012) and low statistical power. Numerous studies have 
indicated the need for large sample sizes in genetic studies (Baker, 2014; Bergen & 
Petryshen, 2012). The recent 23andMe study maximised sample size by utilising self-
report questionnaires (Q. S. Li et al., 2016), whilst other groups have examined 
treatment resistance in both MDD or schizophrenia by using prescription data 
(O'Dushlaine et al., 2014; Ruderfer et al., 2016; Wimberley et al., 2016). 
In the present study, we employed a complementary approach utilising prescription 
data in a population and family-based cohort (Generation Scotland: Scottish Family 
Health Study; GS:SFHS) to define a dichotomous and a semi-quantitative measure of 
antidepressant resistance; treatment resistance and stages of resistance, respectively. 
We conducted a GWAS of treatment resistance with meta-analysis with the GENDEP 
cohort and SR in GS:SFHS only and calculated narrow-sense heritability estimates. 
Gene and gene-set enrichment analysis on both traits were also conducted and we 
further examined genetic correlations. We also utilised PRS techniques to examine 
pleiotropy between the genetic liability of MDD, schizophrenia and bipolar disorder 








Generation Scotland: Scottish Family Health Study 
GS:SFHS is a family and population-based cohort of over 24,000 individuals (mean 
age=47.6, s.d.=15.4) within Scotland. Participants were eligible if they were aged 
above 18 years and had a first-degree relative also willing to participate in the cohort. 
Recruitment has been described in detail elsewhere (B. Smith et al., 2006; B. H. Smith 
et al., 2013). Genotype data were available for 20,032 participants and data on mood, 
cognitive function and personality traits were obtained through interview (see 
Supplementary Materials).  
Prescription data were available through data linkage to the Prescribing Information 
System (PIS) administered by National Health Service (NHS) Scotland Information 
Services Division. Written informed consent for linkage was obtained for 98% of 
GS:SFHS. Further information regarding the prescription records are found in the 
Supplementary Materials (see Supplemental Table S1 and S2). Records were 
excluded if the daily dose was below the minimum recommendations given by the 
British National Formulary (BNF) for MDD (Joint Formulary Committee, 2017) and 
the duration was below 6 weeks of continuous treatment (as this is considered adequate 
duration (Fava, 2003; Souery et al., 1999)). Following this pruning, we totalled the 
number of different antidepressants prescribed to each individual. This was then used 
as a measure of non-response, assuming that switching to a different antidepressant 
reflected failure or lack of clinical response. Drug switching due to side effects is 
expected to take place before the 6th week of treatment. Individuals with schizophrenia, 
schizoaffective disorder and bipolar disorder were excluded (n=164).  
Defining treatment resistance and stages of resistance 
Treatment resistance was assessed in GS:SFHS using only individuals that had been 
prescribed at least one antidepressant at an adequate dose and duration (n=3,452). Case 
status for treatment resistance was defined as those individuals who had been 
prescribed more than 2 antidepressants providing 250 treatment resistant cases and 
3,202 non-treatment resistant controls. There have been significant difficulties 
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defining treatment resistant depression in research but the general consensus is that it 
should be defined as non-response to more than two antidepressants (Conway, George, 
& Sackeim, 2016).  
Individual response to antidepressants decreases with more unsuccessful trials (A. 
Rush et al., 2006), it has therefore been suggested that a semi-quantitative stages of 
resistance phenotype might be more informative than a dichotomous approach (Ruhé, 
van Rooijen, Spijker, Peeters, & Schene, 2012). Stages of resistance was defined as 
the number of different antidepressants prescribed given an adequate dose and 
duration. It was coded 1-4 with all individuals receiving more than 4 different 
antidepressants assigned a value of 4. This definition included 3,452 individuals on 
antidepressants (2557, 645, 186 and 64 on 1, 2, 3 and 4+ antidepressants, respectively).  
Genome-based Therapeutic Drugs for Depression 
GENDEP is a 12-week study that examined antidepressant response in 867 individuals 
(mean age=42.7, s.d.=11.6) taking escitalopram and noritriptyline. Response was 
measured by the Montgomery–Åsberg Depression Rating Scale (MADRS) 
(Montgomery & Asberg, 1979). Treatment resistance was defined as those who did 
not respond to more than 2 antidepressant therapies including GENDEP treatments 
and previous treatments (cases: 109, controls: 668), as described in a previous study 
(Iniesta, Malki, et al., 2016). A full description of the cohort is provided in 
Supplemental Table S3. 
Genotyping, Imputation and Quality Control procedures 
Generation Scotland: Scottish Family Health Study 
Blood samples were stored and genotyped at the Wellcome Trust Clinical Research 
Facility, Edinburgh (www.wtcrf.ed.ac.uk). Details of the DNA extraction and 
genotyping have been given elsewhere (Kerr et al., 2013). Imputation to a combined 
reference panel of 1000 Genomes Phase 1 Version 3 and the UK10K haplotype 
reference panels was completed using Minimac3 and phasing was conducted utilising 
SHAPEIT2 (Nagy et al., 2017). Quality Control (QC) inclusion criteria were INFO > 
0.9, missingness per single nucleotide polymorphism (SNP) or individual < 1%, 
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Hardy-Weinberg equilibrium (HWE) P value cut-off of 1x10-6, minor allele frequency 
(MAF) > 1%. 7,395,460 SNPs and 3,452 individuals (and 250 cases for treatment 
resistance) passed QC criteria. 
Genome-based Therapeutic Drugs for Depression 
DNA was extracted from blood samples and genotyped using the Illumina 
Human610quad bead chip (Illumina, Inc., San Diego). Imputation to the Haplotype 
Reference Consortium (HRC) data version 1 reference panel (S. McCarthy et al., 2016) 
was completed using Minimac3. QC exclusion criteria were poor imputation quality 
r2<0.3 (using the Markov Chain method (Y. Li, Willer, Ding, Scheet, & Abecasis, 
2010)), missingness per SNP > 5%, missingness per individual > 3%, MAF < 1%, 
related individuals (identity-by-descent > 0.188). Individuals with gender 
discrepancies, abnormal heterozygosity and population outliers were excluded. 
7,518,836 SNPs and 761 individuals (108 cases) passed QC criteria. 
Statistical Analysis 
Genome-wide association study 
GWAS in GS:SFHS on treatment resistance and stages of resistance were completed 
utilising linear mixed model analysis in GCTA (Genome-wide Complex Trait 
Analysis) (J Yang et al., 2011). Age, sex and the first four multidimensional scaling 
(MDS) components were fitted as covariates and, to account for the family structure 
in GS:SFHS, genetic relationship matrices (GRMs) were fitted as random effects (see 
Supplementary Materials). To counter the loss of power that is caused by inclusion of 
a candidate SNP as both a random effect (in the GRM) and a fixed effect, the leave-
one-chromosome-out method was utilised (J. Yang, Zaitlen, Goddard, Visscher, & 
Price, 2014). Due to the use of linear mixed models on a binary trait, treatment 
resistance, Taylor series transformation (Cortes et al., 2013) was used to convert beta 
and standard error values from the linear scale to the liability scale (see Supplementary 
Materials).  
GWAS in GENDEP was completed on unrelated individuals utilising logistic 
regression in PLINK (Purcell et al., 2007). Models were corrected for age, centre, 
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baseline severity and the first four principal components, to control for population 
stratification. 
Meta-analysis between GS:SFHS and GENDEP in treatment resistance was completed 
in METAL (Willer, Li, & Abecasis, 2010) with the inverse variance weighted method. 
A total of 7,120,598 SNPs were in common across both samples. 
Gene and gene-set enrichment analysis 
Gene and gene-set analysis were completed using MAGMA (v1.04) (de Leeuw, Mooij, 
Heskes, & Posthuma, 2015) (further details in Supplementary Materials). Individual 
level data were utilised for analysis of both treatment resistance and stages of 
resistance in GS:SFHS and summary statistics data used for analysis in GENDEP TR. 
Treatment resistance in GS:SFHS and GENDEP was then meta-analysed in MAGMA 
using fixed effect meta-analysis. To map SNPs to gene and biologically-meaningful 
gene sets, SNPs were annotated using NCBI 37.3 and, for the gene set analysis, gene-
annotation files from BIOCARTA (http://www.biocarta.com/), KEGG (Okuda et al., 
2008) and REACTOME (Croft et al., 2014; Fabregat et al., 2016) were taken from the 
Molecular Signatures Database (MSigDB) v5.2. Gene sets were corrected for multiple 
testing using the MAGMA default setting correcting for 10,000 permutations. 
Pedigree-based heritability 
Pedigree-based heritability of treatment resistance and stages of resistance was 
calculated in R using MCMCglmm (Hadfield, 2010). This was achieved by 
constructing a variance component matrix that takes into account all pedigree 
information and then fitting it into a univariate model as a random effect. MCMCglmm 
uses a Bayesian framework to estimate heritability. For TR, the logit link function was 
used to account for the binary nature of the phenotype. 
Genetic correlation analysis 
Genetic correlations were calculated using a bivariate analysis in ASReml-R 
(http://www.vsni.co.uk/software/asreml/). In order to assess the similarity between 
treatment resistance and stages of resistance, genetic correlation between the two was 
examined. Further, correlations between treatment resistance and stages of resistance 
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were examined with eight personality and cognitive variables; neuroticism, 
extraversion, schizotypal personality questionnaire (SPQ), mood disorder 
questionnaire (MDQ), general cognitive ability (‘g’, formed from a number of varied 
cognitive test scores), Scottish Index of Multiple Deprivation (SIMD), education and 
the general health questionnaire (GHQ). The ASReml-R method was utilised as it can 
account for the family structure in GS:SFHS. Genetic correlation measurements were 
calculated between pedigree-based heritabilities as the sample sizes were too small to 
conduct SNP-based correlations. More information on the variables and methods used 
can be found in the Supplementary Materials.  
Polygenic risk scoring analysis 
PRS were constructed utilising PLINK (Purcell et al., 2007). This method has been 
previously described (International Schizophrenia Consortium et al., 2009) and further 
information is available in the Supplementary Materials. Summary statistics taken 
from the Psychiatric Genomics Consortium (PGC) were used to construct PRS for 
MDD (unpublished data, see Supplementary Materials), schizophrenia (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014) and bipolar disorder 
(Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011) in the 
GS:SFHS cohort to examine genetic liability to the disorders in a treatment resistant 
population. PRS were reported across five P value thresholds (0.01, 0.05, 0.1, 0.5 and 
1).  
Association of PRS to the trait was analysed by linear mixed model analysis in 
ASReml-R (http://www.vsni.co.uk/software/asreml/) with treatment resistance or 
stages of resistance as the dependent variable and PRS as the independent variable. All 
models were adjusted for age, sex, and the first four MDS components and, to account 
for related individuals, an additive relationship matrix (expected relatedness derived 
from pedigree information) was fitted as a random effect. Wald’s conditional F-test 
was used to derive P values for all fixed effects (see Supplementary Materials). Taylor 
series approximation (Cortes et al., 2013) was used for the treatment resistance 
variable, as above. 
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AVENGEME (Palla & Dudbridge, 2015) was used to calculate power in the PRS 
analysis assuming 5% of SNPs had an effect in the training sample and all markers 
























Genome-wide association study 
In the treatment resistance meta-analysis of 4,213 individuals (cases=358, 
controls=3,855) no SNP reached genome-wide significance (P > 5x10-8). The most 
significant SNP identified was an intergenic variant located at 10p26.13 (lead SNP 







4.1. Manhattan and Q-Q plots of the GWAS of antidepressant treatment 
resistance in (a) GS:SFHS, (b) GENDEP and (c) the meta-analysis between these 
two cohorts. Genome-wide significance level (P<5x10-8) is represented by a red line 
and suggestive threshold (P<1x10-5) is represented by a blue line. 
In the GWAS of stages of resistance in GS:SFHS (n=3,452) no SNP reached genome-
wide significance (P > 5x10-8). The most significant SNP identified was an intergenic 





4.2. Manhattan and Q-Q plots of the GWAS of antidepressant stages of 
resistance. Genome-wide significance level (P<5x10-8) is represented by a red line 
and suggestive threshold (P<1x10-5) is represented by a blue line. 
 
The top four loci for each GWAS below a P value of 5x10-7 for the treatment resistance 
meta-analysis and stages of resistance can be found in Table 4.3. Heterogeneity 
statistics for the treatment resistance meta-analysis are also reported, we found either 
no evidence or nominal evidence of heterogeneity between GS:SFHS and GENDEP 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Gene and gene-set enrichment analysis 
Gene-based analysis with MAGMA did not identify any genes significantly associated 
after false discovery rate (FDR) multiple testing correction. Similarly, in the gene-set 
analysis no gene-set passed multiple testing correction over 10,000 permutations. The 
most significant genes and gene-sets are listed in Supplemental Table S4. 
Pedigree-based heritability and genetic correlations 
Pedigree-based heritability was calculated in GS:SFHS at 0.60 (CI=0.22-0.87) for 
treatment resistance and 0.27 (CI=0.24-0.31) for stages of resistance.  Genetic 
correlation between treatment resistance and stages of resistance was calculated at 0.90 
(P=0.0034). 
Significant positive genetic correlations were found between treatment resistance and 
neuroticism (rg=0.66, PFDR=0.0091), MDQ (rg=0.86, PFDR=0.0072) and GHQ 
(rg=0.96, PFDR=8.8x10
-5). For stages of resistance they were identified between 
neuroticism (rg=0.51, PFDR=0.023), SPQ (rg=0.44, PFDR=0.036), MDQ (rg=0.69, 
PFDR=0.027) and GHQ (rg=0.71, PFDR=0.0011). All these correlations survived 

































Genetic liability of psychiatric traits with treatment resistance and stages of resistance 























































































































































































































































































































































































































































































































































































































































































































































































































Treatment resistance and stages of resistance were positively and nominally associated 
with MDD PRS at P value thresholds (PT) 0.1, 0.5 and 1, and treatment resistance only 
with schizophrenia PRS at PT=0.01. There were no significant associations between 
treatment resistance or stages of resistance with bipolar disorder PRS (Table 4.5). No 
result survived FDR correction and power analyses indicated we were underpowered 
to detect an association between MDD and bipolar disorder PRS with treatment 
resistance and stages of resistance. Schizophrenia PRS was powered to detect an 
association at all thresholds in both treatment resistance and stages of resistance given 
a genetic correlation of 0.5. At a genetic correlation of 0.25, stages of resistance had 
adequate power at all thresholds whilst treatment resistance was only powered at PT 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We utilised antidepressant prescription records to explore common genetic factors in 
treatment resistance and stages of resistance in a population and family-based cohort 
of 3,452 individuals. In the treatment resistance GWAS meta-analysis, the most 
significant locus was located at 10q26.13 at P= 3.3x10-7; lead SNP rs188352979. This 
SNP is intergenic and lies in between genes ACADSB and HMX3. ACADSB encodes 
short/branched chain specific acyl-CoA dehydrogenase (SBCAD) which is an enzyme 
involved in the metabolism of fatty acids (Rozen et al., 1994). HMX3 is a transcription 
factor that is involved in the specification of neuronal cells needed for hypothalamus 
development and hypothalamic-pituitary-adrenal (HPA) axis (Wang, Grimmer, Van 
De Water, & Lufkin, 2004). Disruptions in the HPA axis are known to be associated 
with MDD, MDD severity and antidepressant response (Papiol et al., 2007; Pariante 
& Lightman, 2008). A single locus at 10q22.1 was associated with SR at P=1.71x10-
7, lead SNP rs116902282. This is an intergenic variant that lies between functional 
genes C10orf35 and COL13A1. C10orf35 is a protein coding gene that has previously 
been associated with uterine leiomyoma (Ling, Wu, Fu, Tan, & Xu, 2015). COL13A1 
encodes the alpha chain of one of the nonfibrillar collagens. No variant in either 
analysis reached the required threshold for genome-wide statistical significance 
(P>5x10-8). Gene and gene-set enrichment did not identify any significant associations 
with either treatment resistance or stages of resistance. Nonetheless, modest to high 
pedigree-based heritability estimates indicate that 60% of the variance in treatment 
resistance and 27% of the variance in stages of resistance can be explained by genetics, 
although these estimates had large confidence intervals. This indicates that further 
exploration into genetic contributions in antidepressant resistance may be beneficial. 
The genetic correlation between treatment resistance and stages of resistance (rg=0.90) 
demonstrates that these two measures capture similar genetic variation. This is further 
shown in the similarity of the genetic correlation measures with cognitive and 
behavioural measures, albeit stages of resistance is a quantitative trait and is therefore 
higher powered in this analysis. Treatment resistance was significantly and positively 
genetically correlated with neuroticism (rg=0.66), MDQ (rg=0.86) and GHQ (rg=0.96) 
indicating overlapping genetic architecture between these traits. In stages of resistance, 
78 
 
these same traits also demonstrated significant genetic correlation; neuroticism 
(rg=0.51), MDQ (rg=0.69) and GHQ (rg=0.71), and we additionally identified a 
significant genetic correlation with SPQ (rg=0.44). The MDQ and SPQ correlation 
indicates that more resistant individuals may share genetic components with 
schizotypy and mood disorder personality traits. Genetic overlap between 
psychological distress and antidepressant resistance is indicative that individuals 
susceptible to distress are associated with a poorer outcome in antidepressants and 
should be further investigated. We did not find any correlation in treatment treatment 
resistance or stages of resistance with general intelligence, education or social 
deprivation trait, however, a lack of power due to small sample size (n=3,452 with 
only 250 cases in treatment resistance) was likely to be a major contributing factor. 
We have only identified modest to high correlations therefore it may be possible that 
we are underpowered to detect weak to modest correlations. It is also worth noting that 
whilst these traits were measured prior to the treatment resistance definition, 
individuals may have been diagnosed with depression and/or taking antidepressants 
prior to this as we only have prescription data from 2009. Therefore, it is not possible 
to determine cause or effect in these associations. These phenotypes have also been 
previously associated with depression severity, e.g. higher psychological distress is 
associated with higher depressive symptoms (Marchand, Durand, Juster, & Lupien, 
2014). However, studies on treatment resistance and MDD have been largely 
contradictory. Whilst some have found that higher severity is associated with treatment 
resistance (Souery et al., 2007) others have found treatment responders are associated 
with clinical severity (Fournier et al., 2010). Additionally, some studies have found no 
association between the two (Rabinowitz et al., 2016). 
Using PRS, we investigated whether poor response to antidepressants indicate a higher 
liability to other mental disorders (schizophrenia or bipolar disorder) as well as higher 
genetic loading of MDD itself. We did not find any significant association with 
treatment resistance or stages of resistance, however, power with the current sample 
size was only adequate in analysis with schizophrenia PRS at a genetic correlation of 
0.5 and additionally 0.25 for stages of resistance. Results for MDD and bipolar 
disorder PRS should therefore be treated with caution, although the nominal 
associations between MDD PRS and stages of resistance may be worth further 
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investigation with larger sample sizes.  
One of the strengths of this study was that it used data taken from a population-based 
cohort and is a good representation of antidepressant users in a MDD sample in the 
general Scottish population. Nevertheless, certain limitations of this study should be 
noted. Although currently diagnosed schizophrenia and bipolar patients were removed 
prior to this analysis and minimum dose was matched to that of MDD 
recommendations, it is possible that individuals were prescribed the antidepressant for 
other conditions e.g. anxiety disorders, obsessive compulsive disorder (OCD), 
posttraumatic stress disorder (PTSD) and panic disorders, and may have had a 
misdiagnosis in the first instance. It was not possible to account for the use of 
psychotherapy or electroconvulsive therapy (ECT; which is advised in patients with 
severe MDD). We were also only able to obtain prescription records over a six-year 
period meaning there are likely to be some individuals who had prescriptions before 
this period. Furthermore, because we integrate prescribing data across a number of 
different antidepressant drugs and classes, specific associations with treatment 
resistance within or between classes of prescribed compounds may have been missed. 
In the meta-analysis, it should also be noted that the samples had differing covariates, 
e.g. baseline severity in the GENDEP sample but not GS:SFHS. Prescription records 
are also susceptible to low drug adherence which are known to be a problem in 
antidepressant treatment. Specifically, 20% of treatment resistant individuals are 
thought to represent non-compliant individuals (Souery & Mendlewicz, 1998) and it 
is therefore possible that low drug concordance is contributing to an individual’s 
treatment resistance status and therefore is a notable limitation. Additionally, the cross-
sectional nature of the treatment resistance definition in GS:SFHS means that any trait 
association is subject to change throughout the time-period that the definition was 
constructed. Moreover, it is difficult to assess cause or effect given that treatment 
resistant individuals may have already failed to respond to two antidepressants prior 
the definition construction. 
Despite an increased sample size compared to those reported in previous clinical 
studies of antidepressant response (n=2,897), our numbers are still small for a GWAS 
and it is likely that we were underpowered. With an increasing availability of 
electronic records in large biobanks and numerous smaller antidepressant studies, a 
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collaborative effort approach may be required in order to increase sample size for 
adequate power. To replicate our analysis with adequate power (>0.8) at a MAF of 
0.01, it would require a sample size of 7,596 cases for treatment resistance and 9,660 
total sample for stages of resistance assuming an OR of 1.6 and beta of 0.3, 
respectively (Supplemental Table S6; power calculations were completed using 
QUANTO v1.2). 
With increasing accessibility of electronic health records (Jensen, Jensen, & Brunak, 
2012), access to prescription records is becoming possible. In this study, we explored 
the possibility of utilising this prescription data to examine resistance to antidepressant 
treatment by inferring drug switching as non-response. We have provided evidence 
that resistant individuals have a high genetic correlation with neuroticism, 
psychological distress, schizotypy and mood disorder traits. Furthermore, we 
demonstrate the need for larger cohorts and collaboration in order to maximise sample 
size. This study demonstrates the value of this method; as larger cohort sizes become 
available, the results of such studies could further inform clinical and research 
applications.  
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4.3. Chapter Conclusion 
Although this current analysis is relatively small for a GWAS, it demonstrates the 
potential utility of population-based cohorts and electronic health records for 
pharmacogenomic studies. In this study, we demonstrate that 7,596 treatment 
resistance cases would be necessary to be adequately powered to detect a genetic 
variant with an OR= 1.6 and a MAF= 1% whereas this study was underpowered with 
358. The emerging large national biobanks, such as UK Biobank, represent examples 
whereby sample sizes could overcome current power issues. Additionally, meta-
analysis between existing cohorts and these biobanks could also be applied in order to 
achieve well-powered genome-wide analysis that more accurately reflects the effect 
of common variants.  
Although common variants have been demonstrated to contribute a proportion of the 
variance in antidepressant response (GENDEP Investigators et al., 2013), it may also 
be advantageous to examine rare variants. A 2013 analysis examined exome 
sequencing data in two samples of patients taking escitalopram (n=116 and n=394) 
identifying a variant in the BMP5 gene associated with worse treatment response 
(Tammiste et al., 2013). Nonetheless, the sample here was small and association 
analysis of rare variants typically requires large sample sizes (B. Li & Leal, 2008), 
arguably greater than those required for a GWAS (Sham & Purcell, 2014). 
Furthermore, it has been reported that women preferentially respond to SSRIs in 
comparison to men, (Berlanga & Flores-Ramos, 2006; Kornstein et al., 2000) 
therefore, given the availability of adequately sized samples, gender-stratified GWAS 
may further elucidate this. 
The genetic correlations identified here, indicate that these traits may be of interest as 
potential intermediate phenotypes in antidepressant treatment resistance, therefore, 
further evidence and specific intermediate phenotype exploration may be of interest 
to confirm this. For example, it is possible that treatment resistant depression 
represents a subgroup of depression with higher neuroticism that may play a 
biological role in non-response. Intermediate phenotypes have been described in 
multiple psychiatric conditions including MDD, schizophrenia and alcoholism 
(Hornung & Heim, 2014; Oreland et al., 2017; Tan, Callicott, & Weinberger, 2008) 
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and have been suggested to be effective tool in identification of genetic subgroups in 
psychiatric disorders (Flint et al., 2014). Genetic overlap between two phenotypes 
indicates that the phenotypes may have an important causal relationship, although 
further research is needed to confirm this. Efforts in antidepressant treatment 
resistance have, for the most part, focused on monoaminergic candidate genes 
(Leuchter et al., 2014). For instance, the serotonin transporter (5-HTTLPR) is related 
to the amygdala-cingulate feedback circuit involved in emotion regulation (Pezawas 
et al., 2005) and appears to modulate amygdala responses to negative stimuli 
(Dannlowski et al., 2010). Additionally, the noradrenaline transporter (NET) and 5-
HT1A polymorphisms have been associated with hippocampal volume in treatment 
resistant individuals (J. L. Phillips et al., 2015). Nevertheless, candidate gene-studies 
are prone to selection bias (bias introduced by hypothesis-driven selection of a gene) 
and associations between antidepressant response monoaminergic genes are poorly 
replicated (Fabbri et al., 2014). An alternative approach would be to use summary 
data from GWAS to measure genetic correlations in common variants (as in Chapter 
3). However, even with the increase in numbers we report here, numbers are 
currently too small to run these using current LDSC techniques (which typically 
require a minimum of 5,000 individuals). In this study, we demonstrate pedigree-
based genetic correlations, which account for all genetic variance including common 
variants, rare variants and gene interactions, therefore providing evidence for 
intermediate phenotypes between genes and treatment resistant outcome. 
Nevertheless, this approach is prone to overestimation due to shared environment 
(Manolio et al., 2009). Should interindividual variability in antidepressant response 
represent clinical depression subgroups, further explication of intermediate 











In Chapter 4, neuroticism was identified as a potential intermediate phenotype 
whereby higher neuroticism may mediate the effect of risk alleles on antidepressant 
treatment resistance. The role of neuroticism as a genetic intermediate phenotype has 
previously been reported in MDD. Neuroticism polygenic risk score (PRS) has 
demonstrated a positive association with MDD status (de Moor et al., 2015) and 
neuroticism and MDD were positively genetically correlated (rg= 0.64) in an analysis 
conducted using linkage disequilibrium score regression (LDSC) (D. J. Smith et al., 
2016). Therefore, it may be of value to further explicate the mechanism by which 
neuroticism is related to antidepressant resistance.  
The role of stress is well-established in MDD and is estimated to precede a depressive 
episode in roughly 70% of cases as well as play a causal role in 20-50% of cases 
(Hammen, 2005; Monroe & Harkness, 2005). Stress is implicated in most causal 
explanations for MDD, for example hypothalamus-pituitary-adrenal (HPA) axis 
dysregulation (Belmaker & Agam, 2008), inflammatory mechanisms (Dantzer et al., 
2008) and the brain-derived neurotrophic factor (BDNF) hypothesis (Belmaker & 
Agam, 2008), amongst others (covered in more detail in Chapter 1). However, there is 
currently no steadfast explanation for the variability in mental health outcome after a 
stressful experience. It has been theorised that personality traits, such as neuroticism, 
can influence response to stress which, in turn, can induce MDD (Yoon, Maltby, & 
Joormann, 2013). Neuroticism is one of five personality constructs that form the five-
factor model, which also include extraversion, conscientiousness, agreeableness and 
openness to experience (Goldberg, 1993) but is arguably the personality trait that is 
most widely associated with negative mental health outcomes. Specifically, it has been 
shown to positively associate with MDD (Kendler, Kuhn, & Prescott, 2004), higher 
stress vulnerability (Schneider, 2004) and negatively associate with subjective well-
being (Steel, Schmidt, & Shultz, 2008). Higher levels of neuroticism has been shown 
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to increase perceived stress (Gramstad, Gjestad, & Haver, 2013) and encourage less 
adaptive stress coping strategies, such as increased emotional and avoidant/escape-
focused coping and reduced task/problem-focused coping (Bolger, 1990; Watson & 
Hubbard, 1996).  
Many factors are known to affect responses to stress and the term resilience is often 
used as a general term to describe an ability to bounce back from adversity, although 
there is no one universally accepted definition (Southwick & Charney, 2012). Higher 
resilience is thought to protect individuals from MDD and other mental health 
outcomes (Wu et al., 2013). Specifically, it has been found that a higher resilience 
reduces the severity of depression after a traumatic event (Wingo et al., 2010). 
Resilience is a construct that comprising of many factors including coping style in 
response to stress. Maladaptive coping styles (such as emotional coping) have been 
associated with an increased risk for MDD (Horwitz, Hill, & King, 2011). Coping style 
has been shown not only to predict later depression but also to be predictive of 
depressive symptoms (Murberg & Bru, 2005). Moreover, coping styles are thought to 
moderate response to stressful life events; for instance, it has been found that 
depression can lead to a poor assessment of coping which further leads to the sufferer 
feeling overwhelmed in stressful situations (Orzechowska, Zajączkowska, 
Talarowska, & Gałecki, 2013). It is possible that all these factors could independently 
impact MDD or interact to elicit the disorder. 
Models to explore the relationships between neuroticism, stress and MDD have 
primarily focused on mediation and moderation studies which, in larger samples, are 
sometimes separated by gender on account of neuroticism being higher in women 
(Weisberg, Deyoung, & Hirsh, 2011). For instance, the pathway between neuroticism 
and MDD was found to be mediated by stress in a sample of 3,950 individuals, 
whereby neuroticism increased stress which then induced depressive symptoms (male 
coefficient= -0.071, P<0.001, female coefficient= -0.039, P<0.001). However, 
neuroticism was also directly associated in the same model (male coefficient= 0.077, 
P<0.001, female coefficient= 0.077, P<0.001), meaning the mediation was only partial 
and it was associated with the outcome both directly and indirectly (S. E. Kim et al., 
2016). Moreover, neuroticism has also been shown to moderate the relationship 
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between cumulative stress with depressive symptoms in a sample from the general 
population (n= 563) and a replication clinical depression and anxiety study sample (n= 
2,274), in which the combined effect of cumulative stress and neuroticism 
strengthened the association with MDD (discovery beta= 0.013, P<0.001, replication 
beta = 0.367, P<0.001) (Vinkers et al., 2014). Maladaptive coping styles (such as 
emotional coping) have also been shown to mediate the relationship between 
neuroticism and MDD in a sample of 533 individuals (pathway from neuroticism to 
maladaptive coping: beta= 0.64, P<0.001; pathway from maladaptive coping to 
depression: beta= 0.61, P<0.001) (Yoon et al., 2013) indicating a possible pathway by 
which neuroticism can induce stress vulnerability and then depressive outcome.  
Higher levels of both neuroticism and childhood maltreatment have also been shown 
to predict poorer response to antidepressants (Bock, Bukh, Vinberg, Gether, & 
Kessing, 2010; Nanni et al., 2012; Quilty, Meusel, & Bagby, 2008), yet their 
interrelationships have not yet been explored. The largest analysis to date examining 
neuroticism in antidepressant responder and non-responders was conducted on 649 
individuals and reported significantly higher neuroticism in non-responders (t = 13.89, 
P< .01). As neuroticism has been associated with both MDD and antidepressant non-
response, it is possible that perhaps treatment resistant individuals represent a 
subgroup of depressed individuals with a higher level of neuroticism. Consequently, a 
different approach to such individuals may elicit more effective treatment outcomes. 
Furthermore, explicating the pathways from neuroticism to outcome may help 
elucidate more proximal processes involved in antidepressant treatment resistance. 
This chapter will explore the associations between antidepressant treatment resistance 
and neuroticism, psychological resilience and coping styles as well as the 
interrelationships between them. The content for this chapter has been summarised in 
a manuscript entitled “Antidepressant treatment resistance and the impact of 
neuroticism, psychological resilience and coping style” which has been submitted for 
publication. I confirm, as the first author, that I carried out the analysis of the data and 
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Background: Antidepressant response rates are modest with only 50% of individuals 
achieving symptomatic remission after two adequate treatment trials. Higher 
neuroticism is associated with poor response to antidepressants but the role of 
psychological resilience and coping styles have been incompletely studied. This study 
examined neuroticism, psychological resilience and coping styles in antidepressant 
resistance and their potential mediating and moderating effects. 
Methods: Using prescribing records in the Generation Scotland cohort, antidepressant 
treatment resistance (TR) was defined as non-response to two adequate treatment trials 
whereby switching to a different antidepressant was a proxy for non-response. The 
independent effects of neuroticism, psychological resilience and coping styles (task-
orientated, emotion-orientated, and avoidance-orientated coping) on TR were 
examined in addition to their moderation and mediation effects. 
Results: Neuroticism and emotion-orientated coping were independently positively 
associated with TR whereas psychological resilience, task-orientated and avoidance-
orientated coping were negatively associated. No moderation effect of resilience or 
coping style on neuroticism was identified. Mediation analysis suggested that the 
positive association between neuroticism and TR is partially mediated by lower 
resilience, although no effect of task, emotion or avoidance-orientated coping was 
found. 
Conclusions: Neuroticism, lower psychological resilience and less adaptive coping 
styles are each associated with TR. The effects of coping styles in TR present 
potentially modifiable risk factors. In addition to the stress-ameliorating effects of 
psychological resilience observed for the onset of MDD, our research shows that these 








Antidepressants are the main therapeutic treatment for major depressive disorder 
(MDD); however, response rates are modest with only a third of individuals in 
remission after completion of one adequate antidepressant trial (M. H. Trivedi et al., 
2006) and half after the completion of two (A. Rush et al., 2006). Early improvement 
in MDD symptomatology whilst taking an antidepressant has been demonstrated to 
predict subsequent remission (Lam, 2012). Nonetheless, the mechanisms of depression 
and antidepressant resistance remain poorly understood. Psychological factors 
affecting treatment response might represent potentially modifiable influences that 
have so far received relatively little attention in the published literature. 
Antidepressant treatment resistance (TR) is commonly defined as failure to respond to 
more than two treatment trials given adequate dose and duration (Conway et al., 2016). 
Determining the potentially modifiable psychological factors conferring TR may have 
important benefits for the patient’s health, their families and society. Several studies 
have employed multiple sociodemographic and clinical factors to construct prediction 
models for TR (Chekroud et al., 2016; Kautzky et al., 2017; Perlis, 2013). Most 
antidepressants act through the monoaminergic system and increase neurotransmitter 
levels such as serotonin. Neuroticism has been shown to positively associate with the 
higher serotonin transporter binding (Takano et al., 2007), the target of selective 
serotonin reuptake inhibitors (SSRIs). Higher neuroticism has been associated with 
risk for MDD (Kendler et al., 2004; Lyness, Duberstein, King, Cox, & Caine, 1998) 
and poor treatment outcomes in both first and second antidepressant trials (Bock et al., 
2010; Quilty, De Fruyt, et al., 2008). Moreover, greater reduction in neuroticism score 
has been shown to significantly mediate clinical response to SSRIs (Quilty, Meusel, et 
al., 2008). Although Quilty et al., (2008b) demonstrated the mediation was specific to 
SSRIs, it indicates that clinical response to antidepressants may be secondary to 
reductions in neuroticism. 
Psychological resilience is generally considered to be the ability to recover or ‘bounce 
back’ from stress. Lower resilience is associated with affective disorders including 
MDD (T. Hu, Zhang, & Wang, 2015) and has been shown to negatively associate with 
neuroticism (Campbell-Sills, Cohan, & Stein, 2006). Furthermore, resilience has been 
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demonstrated to mediate the effects of neuroticism on happiness and positive affect 
(Wei, Wang, Liu, & Zhang, 2014). Early symptom improvement has been used as a 
proxy for resilience to MDD, with findings suggesting that it is associated with 
subsequent treatment outcome (Wagner et al., 2017). However, psychological 
resilience has been little studied with regard to TR, which is likely due to the broadness 
of its definition and complexities in its measurement (Windle, Bennett, & Noyes, 
2011). As yet, no study has investigated whether a quantitative measure of resilience 
is associated with TR.  
Personality traits have been demonstrated to predispose an individual towards a 
particular coping style, specifically, higher neuroticism has been shown to increase the 
risk for unhealthy coping styles (Drapeau, Cerel, & Moore, 2016). This can in turn 
increase liability to stress (Afshar et al., 2015) which has been associated with a 
reduced hippocampal neurogenesis that is known to be reversed by antidepressants 
(Warner-Schmidt & Duman, 2006). Despite the known effect of neuroticism on 
antidepressant response, no study to date has explored the interrelationships between 
neuroticism, psychological resilience and coping style in TR, to our knowledge. It is 
both possible that the association between high neuroticism and treatment resistance 
occurs via resilience or coping style pathways (mediation) or that higher resilience or 
different coping styles reduce the impact of high neuroticism on treatment resistance 
and vice versa (moderation). Neuroticism is generally considered to remain relatively 
stable in adulthood (Lucas & Donnellan, 2011), although in the presence of depression 
and anxiety it has been demonstrated to be subject to small changes (Karsten et al., 
2012). In this present analysis, we will treat neuroticism as stable trait. 
In this study, we explore neuroticism, resilience (measured by the Brief Resilience 
Scale) and coping styles (task, emotional and avoidance-orientated) in association with 
TR in a large population-based cohort (Generation Scotland: Scottish Family Health 
Study; GS:SFHS). Using logistic regression, we examined the independent association 
and moderating effects of resilience and coping styles on the association between 
neuroticism and TR. We also used structural equation modelling to examine the 





Cohort Description and genotyping 
Generation Scotland: Scottish Family Health Study 
GS:SFHS is a family and population-based cohort recruited at random from Scottish 
medical practices between 2006-2011. At baseline, GS:SFHS recruited 24,090 
individuals (mean age= 47.6, s.d.= 15.4) to the study and conducted a battery of mental 
health, cognitive, psychosocial and biological testing. In 2014, participants were re-
contacted and asked to participate in a follow-up study examining mental health and 
resilience. A total of 9,618 individuals (mean age= 56.4, s.d.= 13.3) responded to 
follow-up and provided self-report measures of stressful life events, resilience and 
coping styles. Full details of the initial recruitment and follow-up have been given 
elsewhere (Navrady et al., 2017; B. Smith et al., 2006; B. H. Smith et al., 2013) and 
further information is provided in the Supplementary Materials. 
Defining Treatment Resistance 
Prescription data was available through linkage to the Prescribing Information System 
(PIS) (Alvarez-Madrazo, McTaggart, Nangle, Nicholson, & Bennie, 2016) 
administered by National Health Service (NHS) Scotland Information Services 
Division. PIS is a database of all Scottish NHS prescriptions for payments for 
medications excluding hospital dispensed prescriptions and over-the-counter 
medications (Prescription indication was not included and prescription records were 
available between February 2009 and April 2015, see Supplementary Materials). 98% 
gave consent for record linkage at the initial interview. To measure TR, all 
antidepressant users were extracted (frequency table in Supplementary Table S1) and 
thresholds of dose and duration applied. Daily dose was calculated for each 
prescription entry and all those that fell below British National Formulary (BNF) (Joint 
Formulary Committee, 2017) recommendations for MDD were removed, as this is the 
medication reference book for the NHS. Duration of antidepressant use was also 
calculated and prescriptions that fell below 6 weeks were removed (see Supplementary 
Materials) giving a total of 3,839 individuals taking antidepressants in GS:SFHS. 
Individuals with schizophrenia, schizoaffective disorder and bipolar disorder were 
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excluded (n=164). TR cases were defined as individuals who had been prescribed more 
than two antidepressants and controls were individuals who had been prescribed one 
or two antidepressants. A sample of unrelated individuals was used for all analysis 
therefore a total of 2,390 controls and 262 cases were available. 
Neuroticism, resilience and coping style variables 
Neuroticism was measured at initial clinic visit using the Eysenck Personality 
Questionnaire Short Form-Revised (EPQ-SF) (Eysenck, 1991). The neuroticism 
subsection consisted of 12 items which were answered “no” or “yes” (0 and 1, 
respectively), therefore individuals received a score ranging from 0 to 12 with higher 
scores indicating higher neuroticism (mean=3.8, total n=19,758).  
Resilience was measured at follow-up using the Brief Resilience Scale (BRS) (B. W. 
Smith et al., 2008); a self-report measure assessing an individual’s ability to recover 
from stress. The BRS consists of six statements (e.g. “I tend to bounce back quickly 
after hard times”) rated on a 5-point scale from “Strongly agree” to “Strongly 
disagree”. The BRS was converted to a numeric 1 to 5 scale, with reverse scoring of 
even-numbered items, and the average of the sum of the six questions was taken 
(mean=3.6, total n=9,411). The BRS has previously been found to demonstrate good 
internal consistency and test-retest reliability (B. W. Smith et al., 2008). 
Coping styles were measured at follow-up by the Coping Inventory for Stressful 
Situations (CISS) (Cosway, Endler, Sadler, & Deary, 2000; Endler & Parker, 1990) 
which consists of a list of 48 statements (e.g. “Schedule my time better”) grouped into 
three overarching coping styles; task-orientated coping, emotion-orientated coping and 
avoidance-orientated coping. Individuals ranked each in terms of relevance to 
themselves in situations when they are under stress from 1 (“Not at all”) to 5 (“Very 
much”). The scores for each coping style sub-scale  were then summed (task-
orientated: mean=54.3, total n=8,980, emotion-orientated: mean=37.6, total n=9,130 
and avoidance-orientated: mean=39.4, total n=9,070). The CISS has proven a robust 
measure of assessing situation-specific coping strategies, with a stable factor structure 
and high construct validity (Endler & Parker, 1990). 
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It should be drawn to the readers attention that the neuroticism was measured between 
2006-2011, treatment resistance was defined between 2009-2015 and coping styles 
were measured between 2014-2017. This should therefore be considered an important 
limitation in the following analysis. 
Statistical Analysis 
Independent associations 
Univariate analysis of TR was performed using logistic regression in generalised linear 
models in R version 3.2.3 (www.r-project.org). TR was fitted as a binary outcome in 
all models and neuroticism, BRS, task-orientated, emotion-orientated and avoidance-
orientated coping were fitted as the independent predictors. As TR was taken over a ~ 
6-year time period and all independent variables taken at a single time point, 
independent variables were adjusted for age at measurement before being fitted to the 
model, and TR was adjusted for current age and sex. Variance explained was 
calculated using McFadden pseudo R2. Results were corrected for multiple testing 
using false discovery rate (FDR) over the five models. 
Moderation 
Bivariate generalised linear models were computed to examine moderating effects and 
possible interactions. TR was fitted as a dichotomous outcome and neuroticism was 
tested for interactions with BRS, neuroticism, task-orientated, emotion-orientated and 
avoidance-orientated coping. The main effect of each variable in addition to their 
interaction was investigated. As above, predictor variables were adjusted for age at 
measurement prior to being modelled and TR was covaried for current age and sex.  
Full model with treatment resistant outcome 
The variables were assessed in a full model to assess their association as independent 
variables with TR outcome. Due to the co-linearity of the three coping styles these 
were assessed in three separate models. This analysis was completed using the 
structural equation modelling package ‘lavaan’ (Rosseel, 2012) in R using the 
WLSMV (weighted least squares, mean and variance adjusted) estimation and 
standardised betas are reported in the model. Neuroticism, resilience and each coping 
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style were assessed as independent predictors of TR and the correlations between each 
variable is reported. 
Mediation 
Mediational analyses were completed using the structural equation modelling package 
‘lavaan’ (Rosseel, 2012) in R. WLSMV estimation was used to model the binary TR 
outcome in all analyses; standardised betas were reported throughout. For each model, 
the direct association between TR and neuroticism (path c) was examined and the 
mediating associations between neuroticism and resilience or coping style (path a) and 
then resilience or coping style and TR (path b) were examined independently in each 
model (Figure 5.1). Significant a and b paths suggest significant model mediation. 
BRS and coping style variables were measured as latent constructs, with the variance 
of each fixed to 1 for comparability of the models. Fit statistics to determine the fit of 
each model are reported; comparative fit index (CFI; good fit > 0.95), Tucker-Lewis 
index (TLI; good fit > 0.95) and root mean square error of approximation (RMSEA; 


















































































































































































A Pearson’s correlation matrix between TR, neuroticism, resilience and coping styles 









































































































































































































































































































































































































































































































Standardised beta coefficients from the logistic and probit (structural equation 
modelling mediation) regression models are reported throughout for consistency and 
comparison between models. A positive beta coefficient indicates a greater association 
with TR and can be interpreted as the probability that TR=1 conditioned on the 
covariates in the model. 
Independent associations 
All univariate associations demonstrated significant association with TR; neuroticism 
(PFDR= 6.0x10
-9, beta= 0.47, R2= 0.20), BRS (PFDR= 6.0x10
-8, beta= -0.66, R2= 0.049), 
task-orientated (PFDR= 0.018, beta= -0.020, R
2= 0.0089), emotion-orientated (PFDR= 
0.00016, beta= 0.036, R2= 0.025) and avoidance-orientated coping (PFDR= 0.00027, 
beta= -0.041, R2= 0.021; Table 5.3). 
 
 PFDR Beta R
2 N (cases) 
Neuroticism 6.0x10-9 0.47 0.20 2390 (262) 
BRS 6.0x10-8 -0.66 0.049 1255 (96) 
Task-orientated coping 0.018 -0.020 0.0089 1176 (89) 
Emotion-orientated coping 0.00016 0.036 0.025 1216 (95) 
Avoidance-orientated coping 0.00027 -0.041 0.021 1208 (98) 
 
Table 5.3. Independent associations of stressful life events, coping styles and 
resilience on antidepressant resistance. Significant values (PFDR<0.05) are shown in 
bold. Abbreviations: BRS, Brief Resilience Scale; FDR, false discovery rate. 
 
Moderation 
No evidence of moderation was identified in any model. After fitting both neuroticism 
and resilience, BRS and not neuroticism was significantly associated with TR. 
Neuroticism was significantly associated with TR after correcting for the three coping 
styles whereas only avoidance-orientated coping style was significantly associated 
























































































































































































































































































































































































































































































Full results are detailed in Figure 5.5. 
Model with task-orientated coping 
The model included the effects of task-orientated coping, BRS and neuroticism on TR 
whilst also reporting each correlation coefficient between the independent variables. 
The fit statistics for this model indicated a good model fit (CFI= 0.99, TLI= 0.98, 
RMSEA= 0.030). 
Model with emotion-orientated coping 
The model included the effects of emotion-orientated coping, BRS and neuroticism on 
TR whilst also reporting each correlation coefficient between the independent 
variables. The fit statistics for this model indicated a good model fit (CFI= 0.98, TLI= 
0.98, RMSEA= 0.037). 
Model with avoidance-orientated coping 
The model included the effects of avoidance-orientated coping, BRS and neuroticism 
on TR whilst also reporting each correlation coefficient between the independent 
variables. The fit statistics for this model indicated a poor model fit (CFI= 0.85, TLI= 


































































































































































































































For each mediation model, a significant indirect association (paths a and b) represents 
evidence of mediation and both a significant indirect and direct association (path c) 
represents evidence of partial mediation. For the individual path effect sizes (a, b and 





























































































































































































































































































































































































Full tabulated results for mediation models are given in Supplemental Table 2 and 
all fit statistics are given in Supplementary Table S3. All factor loadings for the latent 
variables are given in Supplementary Tables S4-7. 
BRS as the mediator 
A direct path between neuroticism and TR (path c) was found when including the 
mediating effect of BRS and accounted for 4.8% of the variance. The indirect path 
(path ab) was also significant (PFDR= 3.4x10
-5) and indicated that lower BRS partially 
mediates 43% of the association between neuroticism and TR. The fit statistics for this 
model indicated a good model fit (CFI= 0.97, TLI= 0.96, RMSEA= 0.048). 
Task-orientated coping as the mediator 
A direct path between neuroticism and TR (path c) was found when including the 
mediating effect of task-orientated coping and accounted for 7.1% of the variance. The 
indirect path (path ab) was not significant (PFDR= 0.062) and indicated that task-
orientated coping did not mediate the association between neuroticism and TR. The fit 
statistics for this model indicated a good model fit (CFI= 1.0, TLI= 1.0, RMSEA= 
0.013). 
Emotion-orientated coping as the mediator 
A direct path between neuroticism and TR (path c) was found when including the 
mediating effect of emotion-orientated coping and accounted for 6.4% of the variance. 
The indirect path (path ab) was not significant (PFDR= 0.062) and indicated that 
emotion-orientated coping did not mediate the association between neuroticism and 
TR. The fit statistics for this model indicated a good model fit (CFI= 0.98, TLI= 0.97, 
RMSEA= 0.036). 
Avoidance-orientated coping as the mediator 
A direct path between neuroticism and TR (path c) was found when including the 
mediating effect of avoidance-orientated coping and accounted for 7.3% of the 
variance. The indirect path (path ab) was significant (PFDR= 0.016) and indicated that 
lower avoidance-orientated coping partially mediates 11% of the association between 
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neuroticism and TR. However, the fit statistics for this model indicated a poor model 
























To our knowledge, this is the first study to examine the mediating and moderating 
effects of resilience and coping style of neuroticism’s association with antidepressant 
treatment resistance. An initial independent association analysis demonstrated that all 
variables were significantly associated with TR. Neuroticism was positively associated 
with TR and explained 20% of the variance, replicating previous findings (Bock et al., 
2010; Quilty, De Fruyt, et al., 2008). Our results indicated that lower resilience was 
associated with a higher probability of a TR outcome and explained 5% of the 
variance. Furthermore, both task-orientated and avoidance-orientated coping were 
negatively associated with TR (explaining 1% and 2% of the variance, respectively) 
whilst emotion-orientated coping was positively associated with TR (explaining 3% 
of the variation).  
Resilience has not been previously associated with TR using a quantitative measure, 
although previous studies have demonstrated that higher resilience (measured by the 
resilience scale for adolescents) is associated with fewer depressive symptoms 
(Hjemdal, Aune, Reinfjell, Stiles, & Friborg, 2007). Similar directions of effect have 
been reported in MDD with task-orientated and emotion-orientated coping 
(McWilliams, Cox, & Enns, 2003), but inconsistent results have been reported for 
avoidance-orientated coping. Whilst some studies have reported avoidance-orientated 
coping as a risk factor for depression and depressive symptoms (Silverstein et al., 
2016; Tan-Kristanto & Kiropoulos, 2015), others have demonstrated an association 
with positive emotions in the short-term but negative outcome in the long term (M. M. 
Smith, Saklofske, Keefer, & Tremblay, 2016). In this study, we demonstrate that 
higher avoidance-orientated coping was associated with antidepressant responders. 
The impact of coping style on TR has never been previously reported.  
In the full models of the variables, neuroticism was no longer significantly associated 
with TR after accounting for task-orientated coping and resilience whereas emotion-
orientated coping was not associated with TR after accounting for resilience and 
neuroticism. Avoidance orientated coping, neuroticism and resilience were all 
significantly associated with TR but this model was not a good fit to the data. These 
results indicate that the variables were not independently associated when accounting 
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for each other which could be explained by correlation between the variables or 
interaction. Given that coping style and neuroticism were weakly correlated and 
coping style and resilience modestly correlated, this result indicates that there could 
be interaction between the predictors. 
We found no significant moderation of neuroticism on TR by coping styles or 
resilience. Mediation analysis indicated that resilience partially mediated the 
association between neuroticism and TR. Specifically, resilience was found to mediate 
43% of the association. However, as this mediation was only partial, neuroticism 
remained independently directly associated with TR. We demonstrate that low 
neuroticism is associated with an increased likelihood of resilience and a decreased 
likelihood of a TR outcome. Neither task-orientated or emotion-orientated coping 
mediated the effect of neuroticism on TR but was associated with neuroticism itself in 
both instances. This therefore suggests that neuroticism was accounting for the effect 
of task-orientated and emotion-orientated coping on TR. Additionally, whilst 
mediating effects of avoidance-orientated coping were found, the model’s poor fit 
statistics mean these results should be discounted. It is perhaps surprising, considering 
previous research demonstrating associations with maladaptive coping and 
neuroticism in over 4,600 individuals (Afshar et al., 2015), emotion-orientated and 
avoidance-orientated coping were not mediators. 
In this study, we assume that neuroticism is stable over the lifetime but it has been 
shown that neuroticism is liable to changes with changes depression (Chow & BW, 
2014) and stressful life events can modestly increase neuroticism (Riese et al., 2013). 
Moreover, changes in neuroticism trait levels can occur whilst on SSRI treatment 
(Quilty, Meusel, et al., 2008). Nonetheless, Renner et al., (2013) found that 
neuroticism score is not likely altered after undergoing treatment with various 
antidepressants (Renner, Penninx, Peeters, Cuijpers, & Huibers, 2013). Considering 
these inconsistent results, additional studies examining neuroticism changes over the 
course of antidepressant treatment may be beneficial. It is possible that treatment 
resistant individuals have a higher depression severity which is more difficult to treat 
with traditional antidepressants. In fact, neuroticism has been shown to be associated 
with higher depression symptom severity and the relationship was mediated by 
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maladaptive coping styles (Yoon et al., 2013). However, whilst some studies have 
indicated antidepressants are more successful in a clinically severe population rather 
than mild or modest depression (Fournier et al., 2010) others have reported no 
difference between severity groups (Rabinowitz et al., 2016).  
One of the most widely reported theories for the mechanism by which neuroticism 
increases risk for depression is through increasing an individual’s liability to stress 
(Klein, Kotov, & Bufferd, 2011) and chronic stress has been shown to moderate its 
effect on the course of depressive symptoms (Brown & Rosellini, 2011). Stress is 
involved in several hypothesized biological mechanisms of depression including the 
brain-derived neurotrophic factor (BDNF) hypothesis, the cytokine hypothesis and 
hippocampal neurogenesis (Stepan et al., 2015; Warner-Schmidt & Duman, 2006) 
which have all been implicated in antidepressant response (Björkholm & Monteggia, 
2016; Eliwa et al., 2017; Uher et al., 2014). In fact, it has been shown that 
antidepressants are only able to exert an effect if hippocampal neurogenesis 
mechanisms are intact (Surget et al., 2011). As resilience and coping styles effect 
response to stress, their role in the neuroticism could also be related to stressful life 
events. Nevertheless, neuroticism was only partially mediated by resilience meaning 
that this could only explain the association in part. Further research into neuroticism’s 
relationship with stress and its biological mechanisms in TR would be beneficial.  
We replicate the finding that neuroticism is important in the prediction of TR and 
further add that resilience partially mediates this mechanism. It has been previously 
demonstrated that both task-orientated and emotion-orientated coping are significant 
contributors to resilience (Campbell-Sills et al., 2006) and therefore, resilience is likely 
a construct that incorporates coping style. Although replication and further research is 
necessary before making any clinical recommendations, the results of this study 
indicate that modifying coping style could facilitate response to antidepressants. 
Coping styles have been previously reported as modifiable (Cairns, Yap, Pilkington, 
& Jorm, 2014). 
Certain limitations in this study deserve consideration. Firstly, it should be highlighted 
that the sample size in this analysis was small (largest sample for 
moderation/mediation analysis: 954 non-TR controls and 82 TR cases), therefore, 
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further analysis utilising larger sample sizes may be beneficial especially in generating 
more accurate effect sizes. Prescription records in GS:SFHS were only available for a 
six-year period meaning that antidepressant prescriptions prior to 2009 were not 
captured. Furthermore, although exclusions on dose were carried out using BNF 
recommendations for MDD and schizophrenia, schizoaffective and bipolar individuals 
removed, it is possible that individuals could have been prescribed antidepressants for 
other indications including anxiety disorders, post-traumatic stress disorder, obsessive 
compulsive disorders, panic disorders and non-psychiatric indications. It is also 
possible that drug switching occurred due to adverse effects, however, this is thought 
to occur prior to six weeks which was the minimum duration in this study. Finally, 
neuroticism, TR and coping styles were all measured at different time points; 
neuroticism was measured between 2006-2011, TR was defined between 2009-2015 
and coping styles were measured between 2014-2017. Although TR would have been 
defined subsequent to measures of neuroticism for most individuals, it was defined 
retrospectively to coping styles. Evidence has shown that coping styles can be 
marginally modified (Nielsen & Knardahl, 2014), specifically, maladaptive coping 
styles (emotion and avoidance coping styles) have been shown to be more susceptible 
to change in comparison to adaptive coping styles (task-orientated coping) (Franken, 
Hendriks, Haffmans, & van der Meer, 2001). Relatively few studies have explored the 
effect of antidepressant treatment on coping style itself. A small study of 16 dysthymic 
patients, 17 MDD patients and 18 controls reported that depression recovery after 
SSRI treatment is associated with a decreased reliance on emotion-orientated coping 
(Ravindran, Griffiths, Waddell, & Anisman, 1995). Additionally, vortioxetine has 
been shown to restore adaptive coping in stressed rats (Hatherall, Sánchez, & Morilak, 
2017). Nevertheless, no large study exploring the effect of antidepressants on coping 
style longitudinally has been carried out. Therefore, careful interpretation should be 
applied and change in coping style during antidepressant treatment should be further 
examined.  
In conclusion, we demonstrate that neuroticism, resilience and coping styles are each 
independently associated with a TR outcome (as shown in the univariate analysis), 
presenting potentially modifiable risk factors. Furthermore, we demonstrate that 
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5.3. Chapter Conclusion 
This study represents the largest analysis of neuroticism in antidepressant resistance 
to date and replicates previous findings of positive associations between neuroticism 
and TR whilst also demonstrating an additional a role of coping styles and resilience 
on TR. No coping styles (task-orientated, emotion-orientated or avoidance-orientated 
coping) mediated the relationship between neuroticism and TR but lower resilience 
partially mediated the effects of higher neuroticism. Partial mediation between of 
stress on the association between neuroticism and depressive symptoms has previously 
been reported (S. E. Kim et al., 2016). This is indicative that although neuroticism 
influences MDD and antidepressant resistance through stress-related risk factors, there 
may be other biological components involved. Kim et al., (2016) also demonstrated 
that females show higher levels of neuroticism which contributed to more depressive 
symptoms compared to men (S. E. Kim et al., 2016). Gender differences were not 
explored here due to modest sample size; however, future studies would benefit from 
sample size enhancements and further explication of potential gender effects. 
Neuroticism has been negatively associated with the placebo effect as individuals with 
higher neuroticism are more inclined towards negative attitudes to pharmacological 
treatments (Jakšić, Aukst-Margetić, & Jakovljević, 2013). Previous research has 
shown higher placebo effect to be associated with mild-moderate responders (Kirsch 
et al., 2008). Clinical trials reduce the likelihood of placebo responders by selecting 
more severe depression cases and by randomising people blindly to treatments. In this 
present study, depression severity was not accounted for and antidepressant users in 
the general population were examined, therefore it is likely that there are placebo 
responders within this sample. The association between neuroticism and treatment 
resistant therefore could be partially attributed to this. 
Neuroticism demonstrates a significant predictor of antidepressant treatment 
resistance, explaining 20% of the variance in TR. However, the mechanism for this 
association is still unexplained. Future studies would benefit from larger samples to 
explore the effect of stress-related traits as well as the role of the placebo effect. 
112 
 
Chapter 6. Discussion. 
 
6.1. Summary 
This thesis presents three studies that seek to investigate intermediate phenotypes in 
MDD with a view to reducing the causal heterogeneity associated with the clinical 
phenotype. Given the previous literature documenting the high heterogeneity and 
modest heritability of MDD, genetic stratification illustrates a potentially effective 
technique to divide MDD into aetiologically-defined groups (Chapter 2). This thesis 
had two main objectives; (1) explicating the genetic overlap between regional brain 
volumes and MDD, and (2) enhancing current sample sizes in pharmacogenetic studies 
to identify potential mechanisms underlying MDD stratified by treatment response. In 
Chapter 3, the intermediate phenotype approach was adopted whereby regional brain 
volumes and MDD were examined for both overlap and subgrouping. In Chapters 4 
and 5, antidepressant treatment resistance was examined using genetic and non-genetic 
approaches in order to explicate pathways to non-responsiveness. Here, I will briefly 
summarise the results and main findings. 
Regional brain volume and MDD 
Previous work researching subcortical volumes and MDD primarily explored the 
effects of candidate genes (which are prone to selection bias). Therefore, the genome-
wide approach applied in this thesis provides a hypothesis-free approach that is less 
susceptible to selection bias, and for which there are established methods for 
controlling for population stratification and false positives. Sample sizes were 
adequate to reject a modest to high genetic correlation between all volumes (excepting 
hippocampal volume) and MDD therefore not supporting previous findings of a 
potential genetic overlap, although this work does not exclude the possibility of a low 
to modest genetic correlation. Nevertheless, the general literature supports an 
association between brain volume and MDD. It is therefore possible, if not likely, that 
there is an environmental component that affects brain volume in MDD patients. In 
fact previous studies have found that the effect of early life adversity on MDD was 
partially mediated by smaller hippocampal volume (Rao et al., 2010). Gene-
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environment interaction could also explain the phenotypic associations and previous 
research has indicated its role in brain volumes in MDD patients, however this research 
has also primarily focused on candidate genes (Frodl et al., 2010; Verhagen et al., 
2010). 
The positive genetic correlation between hippocampal volume and MDD reported in 
this chapter was not significant after correcting for multiple testing. Given this and that 
it is in the opposite direction to previously reported associations, it is possible that this 
finding represents type I error. An alternate explanation to this is that, as indicated in 
the BUHMBOX analysis, the positive correlation is present in a subgroup of MDD 
patients, nevertheless, this did not replicate in two other independent cohorts. 
Therefore, further analysis is needed in order to evaluate the role of hippocampal 
volume in MDD. 
In summary, the lack of strong genetic correlation reported in Chapter 3 does not 
support the function of regional brain volumes as intermediate phenotypes for MDD. 
Nevertheless, environmental influences, such as stressful life events, may still be 
important in the role of regional brain volumes in MDD pathology and genetic 
correlation may still be present at levels lower than we had power to detect.  
Factors involved in antidepressant treatment resistance 
The largest current meta-analysis in antidepressant non-response (in a clinical 
sample) is comprised of ~2,900 individuals (Tansey et al., 2012). In Chapter 4, 
antidepressant resistance was defined using prescription records in a population-
based cohort and meta-analysed with GENDEP with the aim of surpassing this 
number and allowing the application of techniques for exploring genetic overlap and 
intermediate phenotypes. No variants, genes, pathways or PRS associated with 
treatment resistance or stages of resistance, but PRS analysis was only adequately 
powered to determine an association between schizophrenia PRS and stages of 
resistance. However, this study was in part a proof-of-concept study demonstrating 
the use of prescription records in antidepressant analysis. Other biobanks with access 
to prescription records may have sufficient numbers for a well-powered genome-
wide association study in treatment resistance. 
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Pedigree-based genetic correlations were found between neuroticism, psychological 
distress, mood disorder personality and schizotypal personality (in stages of 
resistance only) indicating that exploring them as potential intermediate phenotypes 
may be beneficial. Similarly, neuroticism, coping styles and resilience were all 
associated with treatment resistance outcome in Chapter 5. To confirm intermediate 
phenotype status, these would have to be explored in further detail. The genetic and 
phenotypic associations here could also indicate the presence of pleiotropy. 
Pleiotropy can be biological (a gene or variant having an influence on multiple 
traits), mediated (a gene or variant influencing one trait in order to affect another) or 
spurious (false association). A causal pathway from gene through intermediate 
phenotype would have to be established. Should these phenotypes demonstrate to be 
intermediaries, several suggestions could explain their relationship. It is possible that 
the intermediate phenotypes could represent a subgroup of individuals and further 
explication could identify aetiological subgroups, whilst is also possible that they 
could represents misclassification, whereby those with high mood disorder 
personality could be misclassified bipolar cases. Further explication of the 
mechanisms driving the genetic correlation would be necessary to provide an 
explanation for the relationships. 
In summary, these studies demonstrate strong support for the association of 
neuroticism with antidepressant resistance with it being both phenotypically associated 
(explaining 20% of the variance) and genetically correlated (rg= 0.66 and rg= 0.51 
with TR and SR, respectively). The partial mediation of resilience indicates that 
although stress-associated factors may have a part role in neuroticism’s association 
with TR they do not fully explain it. 
6.2. Limitations 
The majority of limitations have been addressed in each individual chapter, therefore 
here, I will only comment on the main limitations. Additionally, an overview of the 
limitations related to the definition of antidepressant resistance will be explored. 
The major contributing limitation to almost every analysis in this thesis was 
insufficient power, despite each chapter providing some of the largest reported sample 
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sizes. In Chapter 3, power was insufficient to detect a genetic correlation of less than 
0.24 for the putamen and 0.49 for the nucleus accumbens. Therefore, to adequately 
assess the presence of genetic correlations below these values, it would be necessary 
to replicate utilising data from larger samples. In Chapter 4, to detect an allele with a 
MAF of 5% and an OR of 1.6, analysis of TR would need 1,624 cases whereas we 
reported effects with 358 cases. Furthermore, in Chapter 5, the sample size for 
moderation and mediation only consisted of a maximum of 82 cases. Nevertheless, 
these were the largest available samples at the time of analysis therefore future 
investigations would benefit from significantly enhancing sample sizes in clinical 
trials, or drawing together larger samples through meta- and mega-analysis. 
The role of the placebo effect is a common complication within antidepressant 
response studies as identification of placebo responders is exceedingly difficult. 
Considering it was not possible to select individuals based on depression severity in 
GS:SFHS (a commonly used approach to reduce placebo responders in clinical trials), 
it is likely that placebo responders are present in our sample. As a result, this makes 
the association with neuroticism potentially more difficult to interpret. Individuals 
with higher neuroticism scores are more prone to pharmacophobia (Jakšić et al., 2013) 
and, consequently, neuroticism may be negatively associated with treatment resistance 
due to lower neuroticism scores in treatment responders driven by the placebo effect. 
Placebo responders have been shown to account for 35-40% of antidepressant response 
(Furukawa et al., 2016), but their occurrence is still widely debated (Bschor & Kilarski, 
2016). 
Neuroticism was explored as a stable trait throughout this thesis, however, neuroticism 
is subject to changes in certain disease states. Specifically, neuroticism score has been 
shown to increase after a stressful life event (Riese et al., 2013). Additionally, changes 
in neuroticism have been shown to occur with changes in depression (Chow & BW, 
2014) whilst changes in neuroticism on antidepressants has also been shown to be 
subject to change (Quilty, Meusel, et al., 2008). It may therefore be more valuable to 
measure neuroticism longitudinally with depression to assess trait change associated 
with illness.  
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Finally, employing the intermediate phenotypes approach is not without its caveats. 
The involvement of epistasis and gene-environment interactions are not accounted for 
utilising these approaches but are both likely to be involved in the genetic architecture 
of MDD (Lopizzo et al., 2015; Schott et al., 2014). Moreover, these techniques are 
reliant on GWAS data which require large sample sizes to be representative of the 
genetic architecture of a trait. It is necessary then that adequately sized samples are 
available for each examined trait which is often not the case. GWAS also only 
examines common variants that confer relatively small effects in comparison to rare 
variants. The most accurate approach to a genetic study would be one that incorporates 
common variants, rare variants, epistasis and gene-environment interactions. 
However, no approach to date has yet been able to achieve this task. Consequently, 
intermediate phenotypes remain an effective approach to analyse the current data and 
identify potential clinical subgroups. 
Defining antidepressant resistance in a population-based cohort 
Electronic health records can contain a multitude of information including varying 
levels of details from prescription records. Nevertheless, prescription records often do 
not contain response data meaning the approach of inferring response after adequate 
treatment, whilst practical and necessary, may have limitations. An adequate 
antidepressant treatment is usually defined as one that reaches a minimum dose 
threshold and minimum duration, which are defined by clinical guidelines in each 
country. Clinical prescription guidelines in the UK are detailed in the British National 
Formulary (BNF). For antidepressants, the BNF currently recommends a minimum 
duration of four weeks (Joint Formulary Committee, 2017) with studies showing that 
response can occur between four and six weeks (Hansen, Gartlehner, Lohr, Gaynes, & 
Carey, 2005). Consequently, a maximum of six weeks on an antidepressant is 
considered to be more than satisfactory to elicit response and has been labelled the 
‘turning point’ whereby additional treatment options such as administering a higher 
dose or different antidepressant are considered (Blier, 2009). Nevertheless, it has 
historically been shown that, due to interindividual variability in response, longer 
treatments and higher doses in non-response may be effective in some patients 
(Targum, 2014). In this thesis, BNF recommendations for daily dose were used to 
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ensure the minimum dose required for clinical effect. A six-week threshold was also 
adopted in order to apply a more conservative approach whilst also accounting for any 
individuals that may have switched drugs due to side effects. Nonetheless, it is possible 
that these exclusion thresholds removed those that would have been eligible for 
inclusion, if more detailed phenotyping information had been available. Furthermore, 
no information on drug response was available in the prescription records, therefore, 
drug switching was used to infer failure to a drug. This method has been applied before 
in treatment resistant schizophrenia and in treatment resistant depression (O'Dushlaine 
et al., 2014; Ruderfer et al., 2016; Wimberley et al., 2016), but is prone to error. For 
instance, it is possible that the individuals switched drugs due to side effects or never 
completed their antidepressant prescription, low adherence to antidepressants is 
commonly reported (Keyloun et al., 2017; Leggett, Ganoczy, Zivin, & Valenstein, 
2016). An additional limitation to this method is that it does not account for 
combination therapies. Although in the UK it is generally considered that combination 
therapies are trialled after failure of a second single antidepressant trial (Joint 
Formulary Committee, 2017), at which point, by the definition in thesis, they would 
already be considered treatment resistant. 
In antidepressant response, there is disparity between studies defining treatment 
resistance. Non-response after one and two trials  have been proposed for TR (Souery 
et al., 1999). In 2006, the STAR*D trial described an inflection point in response after 
two treatments (A. J. Rush et al., 2006), consequently, general consensus is that it 
should be described as non-response to more than two adequate treatment trials 
(Conway et al., 2016).  However, it has been additionally proposed that a staging 
model of antidepressant response more accurately describes resistance whereby stages 
are given based on number of antidepressant trials, class of antidepressant, dose and 
duration. Several different staging models have been suggested (Conway et al., 2016; 
McIntyre et al., 2014) but these have received criticism for amalgamating multiple 
classes and increasing heterogeneity in the trait (Fogelson & Leuchter, 2017). 
Nevertheless, no general consensus has been reached on the effectiveness of between-
class switching as switching between different antidepressant classes has not generally 
shown different efficacy than switching within the same class (Souery et al., 2011). 
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6.3. Future Work 
Although the work in this thesis does not generally support the role of subcortical 
volumes as genetic intermediate phenotypes for MDD, meta-analyses have generally 
supported a phenotypic association, albeit results have been somewhat inconsistent 
(Schmaal et al., 2015; Sexton, Mackay, & Ebmeier, 2013). Relative contributions of 
genetic and environmental factors differ per brain region, but in general brain volumes 
have been reported to be associated with both shared and independent environments 
(Blokland, de Zubicaray, McMahon, & Wright, 2012) therefore additional exploration 
into an environmental effect to may explain the association. Furthermore, given the 
ascertainment differences between the samples applied to BUHMBOX in Chapter 3, 
it would be advantageous to replicate the study in a clinically defined sample to 
determine the presence of a true subgroup. Moreover, the ENIGMA consortium is 
currently conducting a large GWAS meta-analysis of cortical volumes, therefore 
similar genome-wide approaches could be applied to cortical structures. 
The major obstacle to pharmacogenomic investigation of antidepressant treatment 
resistance is sample size. In this thesis, an approach to circumvent small sample sizes 
in pharmacogenomic research is demonstrated whereby antidepressant treatment 
resistance is defined utilising prescription records. This is arguably a better approach 
than self-report methods as these methods rely on retrospective accounts of individuals 
which are typically less reliable. Access to electronic health records is becoming 
increasingly available in large national biobanks. The first recorded national biobank 
was formed in Iceland but since its outset, several nation-wide cohorts have been 
established; Singapore, Sweden, Denmark, Japan and others (Mitchell, 2010). In the 
UK for instance, UK Biobank has genetic data collected for 500,000 individuals with 
access to medical records becoming available to researchers with the next few months. 
Prior to the ENIGMA project, neuroimaging research was prone to similar 
complications as pharmacogenomic research. By utilising meta-analysis and 
enhancing sample sizes in biobanks, research in neuroimaging is now reaching an 
appropriate number for genome-wide investigations. In antidepressant 
pharmacogenomics, a large collaborative meta-analysis (such as ENIGMA), utilising 
the cohorts already available along with data from the national biobanks, may 
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demonstrate an effective method to increase numbers to allow genome-wide analysis 
to be possible. 
Subsequent to these sample increases, multiple further approaches could be applied to 
explicate antidepressant resistance. Firstly, it would be beneficial to generate an 
empirical definition of treatment resistance and/or a staging model so it may be applied 
to future research. Secondly, it may be beneficial to examine regional brain volumes 
as an intermediate phenotype to antidepressant resistance (using similar approaches as 
Chapter 3) as regional brain volumes have been previously associated with 
antidepressant non-response (Fu et al., 2013). Thirdly, genomic information (such as 
PRS) could be assessed within mediation models in order to examine the pathways 
from genes to outcome. Fourth, exploration into potential gender differences in 
antidepressant response is warranted as previous studies have shown that women 
preferentially respond to SSRIs whereas men typically respond better to tricyclic 
antidepressants (Kornstein et al., 2000). Lastly, change in neuroticism and coping style 
during antidepressant treatment should also be investigated as neuroticism change has 
been shown to be mediate SSRI response (Quilty, Meusel, et al., 2008). Furthermore, 
resilience only partially explained the mechanism by which neuroticism induced 
antidepressant non-response indicating alternative pathways should be explored. 
In both MDD and antidepressant resistance the effects of rare variants should be 
examined, once adequate numbers have been reached. The role of rare variants may 
be of value as they typically confer larger effects in a subpopulation of individuals. 
Consequently, they provide more effective targets for pharmaceutical intervention 
with their biological consequences eluding more about the pathology of the disease. 
Moreover, rare variant analysis may aid in genetic stratification given that these 
variants are only present in population subgroups.  
Epigenetics and their role in MDD and antidepressant resistance also provide future 
potential. Epigenetics is the occurrence of processes such as methylation which can 
turn a gene “on” or “off”. It is instigated by an external modification, such as a 
stressful event, that leads to change in the function/structure of DNA. Numerous 
studies have demonstrated that early adversity has subsequent epigenetic effects 
especially amongst genes involved in the HPA axis, serotonin transporter and BDNF 
120 
 
(Jawahar, Murgatroyd, Harrison, & Baune, 2015; Menke & Binder, 2014). 
Furthermore, epigenetics mechanisms are known to play a role in antidepressant 
response. Antidepressant non-responders have exhibited lower BDNF messenger 
ribonucleic acid (mRNA) expression levels than responders and treatment with a 
SSRI caused an increase in methylation with methylation differences predicting drug 
response (Menke & Binder, 2014). Future analysis may benefit from a better 
understanding of the epigenetic factors involved in MDD and antidepressant 
resistance. 
To confirm intermediate phenotype status, further research would be required. 
Intermediate phenotypes need to meet several criteria, including being associated 
with the disease of interest and being significantly heritable. There are two models of 
intermediate phenotype status, the mediation model and the liability-index model. In 
order to test the mediation model it would be necessary to demonstrate a causal 
association with the disease. Analysis such as mendelian randomisation could be 
utilised to determine this. For the liability-index model the two phenotypes do not 
need to be associated causally and a pleiotropic relationship could explain their 
relationship, by indicating that a subset of genes cause both traits. Although 
significant genetic correlation indicates a relationship, further exploration into which 
model best explains the relationship is needed. To further explore the intermediate 
phenotype status of neuroticism and which model best explores the relationship, 
further analysis with techniques such as mendelian randomisation would be 
necessary. 
This thesis has focused on the intermediate phenotype approach to genetic 
stratification, but it may also be valuable to apply machine learning approaches. 
Regular advancements in these techniques are likely to equip them to be invaluable 
tools for prospective use. Machine learning methodologies are becoming increasingly 
popular in cancer research and are infrequently being applied to psychiatric research. 
Genetic stratification using both these methodologies could significantly benefit both 
MDD and antidepressant treatment resistance. 
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6.4. Potential clinical applications 
MDD is a highly complex and heterogeneous disorder that is attributed to multiple 
genetic and environmental components, and this thesis demonstrates only some. 
Individually each component contributes only a little of the total variance of MDD but 
together this could additively explain much more. It has therefore been proposed that 
prediction models could be used to identify patients at high risk of developing MDD. 
For instance, MDD prediction models in children have demonstrated area-under-
curves (AUC) of between 0.70 and 0.72 using social factors, comorbidities, symptoms 
and drug and alcohol misuse (Nichols, Ryan, Connor, Birchwood, & Marshall, 2016). 
Similar models have been constructed in treatment resistant depression, the most 
recent of which reported a prediction accuracy of 0.74 for treatment resistance and 
0.85 for treatment remission (Kautzky et al., 2017). The addition of genetics in these 
models may also increase accuracy especially with further understanding of gene-
environment interactions. By identifying high risk individuals, early intervention 
strategies could be implemented to target the individual prior to the onset of the illness. 
Similarly, by identifying those that are less likely to respond to antidepressants, 
alternative treatment methods can be implemented. A similar prediction model of 
response to psychotherapies may also be beneficial. 
Given larger sample sizes, GWAS analysis in treatment resistant depression may have 
power to detect genetic associations. This could reveal mechanisms to non-response 
which may define separate aetiology. With this information, it may be possible to 
construct pharmacotherapies that target the underlying mechanism of disease. 
Common genetics are often criticised for low effect sizes, however, the effect of statins 
on cholesterol is 20 times stronger than the effect reported for HMCGR (the statin 
receptor) genetic variants from GWAS analysis (Barrett, Dunham, & Birney, 2015). 
This highlights the importance of these kinds of studies for elucidating potential 
mechanisms and producing more effective and targeted treatments. 
6.5. General Conclusion 
Genetic stratification of MDD may aid in identifying more aetiologically-defined 
subgroups that can be better targeted by treatments. This thesis demonstrates 
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application of the intermediate approach with two objectives: assessing the genetic 
overlap between regional brain volumes and MDD and exploring antidepressant 
treatment resistance. No genetic overlap between regional brain volume and MDD was 
identified and therefore these results do not support the role of subcortical brain 
volumes as intermediate phenotypes. However, neuroticism was indicated as an 
intermediate phenotype in antidepressant resistance. Furthermore, its association was 
partially mediated by resilience. This work in this thesis highlights the importance of 
large sample sizes. The most important next steps for explicating antidepressant 
resistance will be enhancing current sample sizes and advocates the initiation of an 
international consortium to meta-analyse current data and recruit larger biobanks. Only 
after this, will it be possible to explicate the biological mechanisms that underlie non-
response and use this information to stratify MDD. Explication and application of 
genetic stratification using the techniques described here may aid in reducing the 
heterogeneity of MDD and assist in the generation of more targeted treatments. 
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Cohort descriptions and MDD phenotype 
GS:SFHS: GS:SFHS is a cohort of 24,080 participants collected from Scottish 
medical practices between 2006 and 2011. Participants were recruited at random and 
were eligible if they were over 18 years of age and had one first-degree relative also 
willing to participate. Genotype data was available for 20,032 participants which after 
QC was reduced to 19,994 (males=8,158, females=11,698). 2,643 participants (13.4%) 
were given a diagnosis of MDD after SCID interview with 17,119 controls. Episode 
data was available for 2,643 cases and was coded from 0 to 40 episodes with anyone 
above that value (including those who had more episodes than they could recall) given 
the value 41. Age of onset information was available for 2,631 cases. For recurrent 
MDD, single episode MDD were excluded leaving 1,319 cases. MDD duration was 
calculated by age of onset subtracted from age of participant. 
UK Biobank: UK Biobank is an open access cohort of 502,664 individuals collected 
from across the United Kingdom between 2006 and 2010. Participants were eligible if 
they were between the age of 40 and 69. After QC, genotype data was available for 
152,734. Related individuals and GS and ELSA participants were excluded from this 
sample leaving 116,909 individuals (males=55,410, females=61,499). 8,146 MDD 
cases (33.9%) were available in this sample and 15,886 controls, a large number of 
controls were excluded due incomplete or missing data explaining the higher 
proportion of cases. MDD episode data was available for 6,466 individuals and coded 
as for GS:SFHS, therefore, recurrent MDD (excluding any single episode MDD) 
included 4,612 cases. Age of diagnosis of MDD was available for 1,316 cases and 
MDD duration derived as described above. 
ELSA: ELSA is comprised of 12,003 individuals at wave 1 that were collected from 
the English population. Participants were eligible if they were aged 50 or over. 
Genotype data was available for 7,412 unrelated individuals which was reduced to 
7,230 after QC. 757 MDD cases (13.1%) and 5,009 controls had available genotype 
data in wave 1 of the data. Wave 1 was selected for analysis as this had the largest 
sample size of MDD cases (males=2,662, females=3,196). Episode data and age of 
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onset of MDD was not available in ELSA therefore we could not infer recurrent MDD 
status or MDD duration. 
LD score regression 
Only SNPs that overlapped with HapMap Project Phrase 3 SNPs were included for 
calculation of SNP heritability and genetic correlations and the following thresholds 
were applied; INFO > 0.9, MAF > 1%, missingness of 0 and strand-ambiguous SNPs 
were excluded. For further details on this method please see original paper (B Bulik-
Sullivan et al., 2015b; BK Bulik-Sullivan et al., 2015a). The intercept in this analysis 
was not constrained and multiple comparison testing was completed utilising false 
discovery rate (FDR). 
Polygenic Profiling 
To generate PRS in each cohort, SNPs were excluded on the following thresholds; 
MAF < 1%, Hardy Weinberg equilibrium p>1x10-6, missingness per individual <1%, 
missingness per SNP <1%. Principle components were generated utilising the genome-
wide complex trait analysis (GCTA) tool (Yang, Lee, Goddard, & Visscher, 2011) to 
control for population stratification and strand-ambiguous SNPs were removed. 
Clump based LD pruning was performed (r2 0.25, 300kb window). For further details 
on this method please see original paper (International Schizophrenia Consortium et 
al., 2009). 
Taylor Series Transformation 
The Taylor series transformation (Cortes et al., 2013) is a method of converting a linear 




, where P represents the prevalence of the trait (in this case MDD) 
in the general population and beta is the beta coefficient from the linear association 
model. 




Instrumental variables (IVs) were constructed of SNPs that reached genome-wide 
significant in the ENIGMA GWAS. As hippocampal volume was the only brain 
structure to demonstrate nominally significant genetic correlation, MR analysis was 
only completed on this subcortical structure. Two SNPs reached genome-wide 
significance in the original GWAS; rs61921502 and rs7294919. These SNPs were not 
available in the MDD PGC GWAS summary statistics and therefore the SNPs in 
highest LD available in both datasets (ENIGMA and PGC) were selected. rs17765551 
was in LD with rs61921502 (R2=0.51) and rs77956314 was in LD with rs7294919 
(R2=0.86). 
ENIGMA SNPs (rs61921502 and rs7294919) were present in both GS:SFHS and UK 
Biobank however not in ELSA. This dataset was therefore excluded. The genetic 
variants were extracted using PLINK (Purcell et al., 2007) and coded as 0,1 or 2. These 
variants were then carried forward into an association analysis. 
Association in GS:SFHS and UK Biobank 
Following the same model used to measure the association between PRS and MDD, 
variant – exposure association was measured using mixed linear models in AS-Reml-
R in GS:SFHS and logistic regression in UK Biobank. Fixed-effect meta-analysis 
between the 2 datasets for each SNP association was conducted using the ‘meta’ 
package in R.  
Mendelian Randomisation (MR) analysis 
We conducted MR analysis using the method outline by Bowden et al., (2015) which 
utilises 2 techniques; the Inverse Variance Weighted (IVW) method and MR-Egger 
regression (Bowden, Davey Smith, & Burgess, 2015). MR makes three assumptions 
of instrumental variables (IVs); (1) that the IVs are associated with the exposure, (2) 
that the IVs are not associated with any confounders and (3) that the association 
between outcome and exposure is conditional on the IVs (e.g. the IVs do not have a 
direct effect on the outcome). Any deviation from these assumptions would mean the 
IVs are invalid. Whilst the IVW method considers that the assumptions are true, MR-
Egger regression relaxes these assumptions to account for directional pleiotropy. It 
uses a weaker assumption known as the Instrument Strength Independent of Direct 
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effect (InSIDE) which is the condition that the correlation between IVs – exposure and 
direct effect of IVs – outcome is zero. If the intercept differs from zero, then the model 
contains invalid IVs and the IVW estimate will be biased.  
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Supplemental Table S1. Power analyses. 
 a) 
 
 b i) 
 GCTA-GREML Power Calculator 
 Simulation rG= 0.5 Measured rG 
Accumbens 0.81 0.060 
Amygdala - - 
Caudate 1.00 0.13 
Hippocampus 0.96 0.93 
ICV 0.98 0.20 
Pallidum 0.98 0.051 
Putamen 1.00 0.22 
Thalamus 0.94 0.097 
 PRS in association of own 
structure 
MDD PRS Meta-Analysis 
 PRS 
thresholds 


















































































GCTA-GREML power calculator was used to calculate (a) power for genetic 
correlation at the measured correlation and at a simulated rg=0.5. AVENGEME was 
used to predict power of PRS in (b i) the meta-analysis between subcortical structures 
and MDD and in prediction of own structure in UK Biobank (b ii) the meta-analysis 
between depression traits and hippocampal volume. Covariance was measured, were 
possible, utilising LD score regression between ENIGMA subcortical structures and 
PGC MDD. If covariance could not be calculated, covariances of 50%, 25% and 10% 
have been reported. SNP heritability values were calculated from LD score regression 
were possible, otherwise values from published sources were used. Abbreviations: 
GCTA, genome-wide complex trait analysis; GREML, genomic-relatedness-matrix 




























































Supplemental Table S2. Linear regression analysis of polygenic score for regional 
brain volume and their respective volume in UK Biobank.  
  Respective total brain region volume 
 PRS Threshold P value Stats 




























































































































































































β= 0.0758  






































Five P value thresholds were used; 0.01, 0.05, 0.1, 0.5 and 1. Significant values 



























































































































































































































































































































































































































Supplemental Table S4. Mixed model analysis of Subcortical volumetric and ICV 
PRS with MDD in all 3 cohorts. 
PRS Study P value beta s.e. 
Nucleus accumbens GS 0.485 -0.0181 0.0218 
  UKB 0.284 -0.0151 0.0141 
  ELSA 0.659 0.0175 0.0395 
Amygdala GS 0.327 -0.0285 0.0217 
  UKB 0.962 0.000694 0.0146 
  ELSA 0.208 -0.0500 0.0398 
Caudate nucleus GS 0.246 0.0197 0.0224 
  UKB 0.396 -0.0135 0.0159 
  ELSA 0.114 -0.0630 0.0398 
Hippocampus GS 0.782 -0.00299 0.0211 
  UKB 0.601 -0.00732 0.0140 
  ELSA 0.571 -0.0222 0.0392 
ICV GS 0.395 0.0179 0.0225 
  UKB 0.280 -0.0160 0.0148 
  ELSA 0.0995 0.0652 0.0396 
Pallidum GS 0.752 -0.00808 0.0221 
  UKB 0.250 0.0178 0.0155 
  ELSA 0.658 0.0176 0.0398 
Putamen GS 0.303 -0.0246 0.0218 
  UKB 0.215 0.0231 0.0186 
  ELSA 0.695 -0.0161 0.0410 
Thalamus GS 0.451 -0.0192 0.0219 
  UKB 0.836 0.00293 0.0142 
  ELSA 0.222 -0.0482 0.0395 
 
Best P value threshold for PRS were carried forward in this analysis; Nucleus 
accumbens=0.01, Amygdala= 0.1, Caudate nucleus=0.5, Hippocampus=0.01, 
ICV=0.5, Pallidum=0.5, Putamen=0.1, Thalamus=0.05. No PRS demonstrated a 
significant association with MDD in any cohort. Abbreviations: PRS, polygenic risk 
scores; ICV, intracranial volume; GS, Generation Scotland; UKB, UK Biobank; 










Supplemental Table S5. MR analysis using IVW method.  
 Inverse-Variance Weighted method 
 P value Beta SE 
Hippocampus-GS&UKB MDD 0.361 0.0100 0.005 
Hippocampus-PGC MDD 0.077 0.004 0.007 
 
Abbreviations: GS, Generation Scotland; UKB, UK Bioabank; PGC, Psychiatric 



































Figure S2. Power curves for genetic correlation analysis a) increasing sample size 


















Power curves were calculated with starting point 0 as the sample size in our analysis. 
For increasing the sample for MDD it was assumed the ratio of cases and controls 
remained the same therefore a sample increase of 1000 would include 500 cases and 





Figure S3. Power curves for PRS analyses a) subcortical PRS associated with 
their respective structures at a P value threshold of (i) 1 and (ii) 0.01 and b) 
subcortical PRS associated with recurrent MDD, age of onset, episodes and 
duration. 
























Power curves assumed training sample size (ENIGMA subcortical volumes) remained 
constant and sample size for the target data set was increased from point 0 (the sample 
at which this analysis was conducted). Amygdala, recurrent MDD, episodes, age of 














Figure S4. Meta-analysis forest plots of mixed model analysis of subcortical 
volume PRS and MDD in Generation Scotland: Scottish Family Health Study 
(GS:SFHS), UK Biobank and English Longitudinal Study of Ageing (ELSA). 
S3.  a) Nucleus Accumbens PRS 
 b) Amygdala PRS 
  








d) ICV PRS 
 
 e) Pallidum PRS 
   






g) Thalamus PRS 
   
No heterogeneity was reported between cohorts but no regional brain PRS is 
significantly associated with MDD. Abbreviations: TE; treatment effect (regression 
beta’s); seTE, standard errors; OR, odds ratio; CI, confidence intervals; W(fixed), 


















Figure S5. Meta-analysis forest plots of mixed model analysis of hippocampal 
volume PRS and MDD episodes, MDD duration and age of onset in GS:SFHS and 
UK Biobank.  




c) Age of Onset
 
No heterogeneity was reported between cohorts but hippocampal volume PRS was not 
significantly associated with number of MDD episodes (a), MDD duration (b) or age 
of onset (c). Abbreviations: TE; treatment effect (regression beta’s); seTE, standard 
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Generation Scotland: Scottish Family Health Study (GS:SFHS): GS:SFHS is a 
cohort of 24,080 participants, aged between 18 and 98 (mean age=47.6, s.d.=15.4), 
recruited from Scottish medical practices between 2006 and 2011. Participants were 
recruited at random after individuals were identified via their Community Health 
Number and it was a requirement for participants to also have a first-degree relative 
over the age of 18 willing to participate. Data on mood, cognition and personality were 
obtained through questionnaires and genotype data was obtained for 20,032 
individuals (after QC n=19,994). Schizophrenia and bipolar individuals were 
identified through record linkage to the Scottish Morbidity Record, general hospital 
inpatient, general hospital outpatient and psychiatric inpatient/outpatient data 
(SMR00, SMR01, SMR04). Prescription data was available through the Prescribing 
Information System (PIS) which records all Scottish NHS prescriptions for payments 
for medications prescribed by general practitioners (GPs), nurses, pharmacists and 
hospitals where the medication was dispensed in the community (hospital dispensed 
prescriptions are not included). Records were available for the period between April 
2009 and February 2015. 
Prescription records in GS:SFHS 
Information available from prescription records included the dose of the prescription 
given, amount of drug dispensed and prescription instructions. From this, a daily dose 
was calculated based on the dose of the prescription and the instructions for daily 
intake. Prescription instructions were sometimes given as a range, where this was the 
case, e.g. “1-2 tablets per day”, the lower range was selected to calculate daily dose to 
ensure an individual was taking at least an adequate dose. For calculations regarding 
duration of prescription, the upper range was selected to ensure an adequate duration. 
Duration on the antidepressant was calculated based on the dispensed amount and daily 
dose. Entries were then distinguished into prescription episodes. i.e. periods where the 
same antidepressant had been prescribed continuously for at least 6 weeks. All 
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prescription episodes that fell below this were excluded. Duration of a drug was 
calculated additively based on a continuous prescription. Date of drug dispense was 
available at month and year only therefore when determining a continuous prescription 
time point a 31 day margin was given. British National Formulary (BNF) guidelines 
differ for elderly patients (age>64 years) therefore age at prescription was considered 
when excluding those below the minimum dose (a total of 29,942 entries excluded). 
BNF guidelines recommend that at least 4 weeks of treatment should be completed 
before considering switching the antidepressant due to lack of efficacy however we 
applied a stricter threshold of at least 6 weeks.  
Defining stages of resistance (SR) 
Our definition is loosely based on the Massachusetts General Hospital’s staging 
(MGH-S) method(Fava, 2003) which has been previously recommended as a useful 
research tool(Hazari, Christmas, & Matthews, 2013). However, this method has met 
criticism for arbitrarily weighting stages on dose optimisation/drug augmentation and 
electroconvulsive therapy (ECT)(Berlim & Turecki, 2007). Therefore, our staging 
method was purely based on antidepressant switching given an adequate duration and 
dose. 
Cognitive and personality traits in GS:SFHS 
To obtain ‘g’ (general intelligence) a principle component analysis (PCA) was 
conducted in cognitive tests. 4 Cognitive tests were assessed; digit symbol coding, 
vocabulary, verbal fluency and logical memory. Digit symbol coding was measured 
using the Wechsler digit symbol substitution task(Wechsler, 1998) to measure 
participants processing speed. For vocabulary, the Mill Hill vocabulary scale(Raven, 
Raven, & Court, 1998) (combined junior and senior synonyms) was used and, to test 
executive functioning, a 1 minute letter-based verbal fluency test was used with letters 
C, F and L(Lezak, 1995). Logical memory was assessed by summation of the 
immediate and delayed score for recall of a paragraph in the Wechsler logical memory 
test(Wechsler, 1998). The first unrotated principle component was utilised as ‘g’ and 
explained 41% of the total variance between the 4 tests. 
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Neuroticism and extraversion were assessed using the Eysenck Personality 
Questionnaire Short Form-Revised(Eysenck, 1991) with a score ranging 0-12. 
Schizotypal personality and mood disorders were measured by the schizotypal 
personality questionnaire (SPQ) version B(Raine & Benishay, 1995) and mood 
disorder questionnaire (MDQ)(Hirschfeld, 2002), respectively. Higher scores 
indicated higher expression of the personality trait. The general health questionnaire 
28 (GHQ)(Goldberg & Hillier, 1979) was used as a measure of psychological distress 
with 28 questions scored from 0 (“not at all”) to 3 (“much more than usual”).  
To measure social deprivation, the Scottish Index of Multiple Deprivation 
(SIMD)(Payne & G, 2012) was used. In brief, this ranks areas according to crime, 
housing, education, income, health and geographical access. Each area then receives a 
rank from 1 to 6,505 which is then converted to a quintile, 1 being most deprived and 
5 being least deprived. Education was scored as years in full-time education and ranged 
from 0-10. 
Construction of Genetic Relationship Matrices (GRMs) 
Two GRMs were fitted utilising the method created by Zaitlen et al. (2013) The first 
GRM included pairwise relationship coefficients for all individuals and the second 
included off-diagonal elements of pairs of individuals who had a relationship 
coefficient < 0.05 set to 0. This therefore excluded pairs of individuals that have a most 
recent common ancestor of approximately four generations distant, assuming no 
inbreeding. This method has been demonstrated to account for potential upward biases 
due to excessive relationships, thus allowing the inclusion of closely and distantly 
related individuals in genetic analyses(Zaitlen et al., 2013). 
Taylor series transformation 
The Taylor series transformation(Cortes et al., 2013) is used to convert a linear beta to 
an odds ratio (OR) using the formula 𝑂𝑅 =  
𝑃+𝑏𝑒𝑡𝑎/(1−𝑃−𝑏𝑒𝑡𝑎)
𝑃/(1−𝑃)
, where P indicates the 
trait prevalence in the general population and beta is the beta coefficient from the linear 
association model. 
Gene and gene-set enrichment using MAGMA 
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MAGMA(de Leeuw, Mooij, Heskes, & Posthuma, 2015) uses multiple regression to 
identify gene-sets that are associated with the phenotype while accounting for linkage 
disequilibrium (LD) between markers by combing SNP P values. The LD reference 
panel used was the European-ancestry subjects from 1000 Genomes Project(Abecasis 
et al., 2012). Both individual level genotype data and summary statistics can be used 
as input, however individual level genotype data are considered the preferred choice. 
Polygenic risk scores (PRS) 
PRS is an additive SNP score constructed per individual weighted by the effect size 
from a training set (GWAS summary statistics). Due to the application of linkage 
disequilibrium (LD) pruning, PRS were constructed utilising genotyped data rather 
than imputed. Data was quality controlled (QC) using the following thresholds; minor 
allele frequency (MAF) > 1%, Hardy Weinberg equilibrium (HWE) p>1x10-6, 
missingness per individual <1%, missingness per SNP <1%.  Clump based pruning 
was used (r2=0.25, 300kb window) and strand-ambiguous SNPs were removed. Multi-
dimensional scaling (MDS) components were created in PLINK(Purcell et al., 2007) 
to control for population stratification. Further details on this method can be found in 
the original paper(International Schizophrenia Consortium et al., 2009). 
Trait variance explained by the PRS was calculated using (var(x × β))/var(y), where x 
was the standardized PGS, β was the corresponding regression coefficient and y was 
the phenotype(Nakagawa & Schielzeth, 2013) 
Psychiatric Genomics Consortium (PGC) MDD GWAS summary statistics 
Unpublished data was used to construct PRS in GS:SFHS using the latest PGC release 
for MDD. The sample consisted of 51,865 MDD cases and 112,200 controls. 
Genetic Correlation 
Genetic correlations (rg) is defined as 𝑟𝑔 =  
𝑐𝑜𝑣𝐺
√𝑉𝐺𝑖 ∗𝑉𝐺𝑗
 where covG is the additive 
covariance, VGi is the additive variance of the personality or cognitive variable and VGj 
is the additive variance of TR or SR. Significance was calculated using the likelihood 
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ratio test to compare the model against a null model (model assuming no covariance 
between the traits). 
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Supplemental Table S1. Full list of antidepressants being prescribed in GS:SFHS.  



































































Supplemental Table S2. Description of GS:SFHS subjects included in TR study. 
 
Variable TR (n=250) Non-TR (n=3,202) 
Age  45.04±13.96 47.32±13.92 




3 for 186 individuals (67.2%) 
4 for 46 individuals (18.4%) 
5 for 13 individuals (5.2%) 
6 for 1 individuals (0.4%) 
7 for 2 individuals (0.8%) 
8 for 2 individuals (0.8%) 
1 for 2557 individuals (79.9%) 
2 for 645 individuals (20.1%) 
N of previous 
SSRI treatments  
0 for 8 individuals (3.2%) 
1 for 53 individuals (21.2%) 
2 for 118 individuals (47.2%) 
3 for 69 individuals (27.6%) 
4 for 2 individuals (0.8%) 
0 for 539 individuals (16.8%) 
1 for 2333 individuals (72.9%) 
2 for 330 individuals (10.3%) 
N of previous 
TCA treatments  
0 for 200 individuals (80%) 
1 for 41 individuals (16.4%) 
2 for 9 individuals (3.6%) 
0 for 2993 individuals (93.5%) 
1 for 206 individuals (6.4%) 
2 for 3 individuals (0.1%) 
N of previous 
MAOI 
antidepressants 
0 for 244 individuals (97.6%) 
1 for 6 individuals (2.4%) 
0 for 3193 individuals (99.7%)  
1 for 9 individuals (2.8%) 




0 for 202 individuals (80.8%) 
1 for 139 individuals (55.6%) 
2 for 51 individuals (20.4%) 
3 for 12 individuals (4.8%) 
0 for 2645 individuals (82.6%) 
1 for 524 individuals (16.4%) 




























Supplemental Table S3. Description of GENDEP subjects included in TR study. 
 
Variable TR (n=109) Non-TR (n=668) 
Age  43.54±11.15 41.90±11.62 
Gender (F/M)  73/36 411/257 
Baseline MADRS 30.38±6.62 28.58±6.74 
Baseline HAMD 23.03±5.01 21.66±5.26 
Age at onset 32.10±11.88 31.86±10.38 








during longitudinal trial 
(yes/no) 
71/38 35/633 
N of previous SSRI 
treatments  
0 for 50 individuals (45.9%) 
1 for 39 individuals (35.8%) 
2 for 17 individuals (15.6%) 
3 for 3 individuals (2.8%) 
0 for 498 individuals (74.6%) 
1 for 145 individuals (21.7%) 
2 for 19 individuals (2.8%) 
3 for 6 individuals (0.9%) 
N of previous TCA 
treatments  
0 for 68 individuals (62.4%) 
1 for 28 individuals (25.7%) 
2 for 10 individuals (9.2%) 
3 for 3 individuals (2.8%) 
0 for 600 individuals (89.8%) 
1 for 58 individuals (8.9%) 
2 for 6 individuals (0.9%) 
3 for 3 individuals (0.4%) 
5 for 1 individuals (0.1%) 
N of previous treatments 
with dual antidepressants  
0 for 89 individuals (81.7%) 
1 for 19 individuals (17.4%) 
2 for 1 individuals (0.9%) 
0 for 637 individuals (95.4%) 
1 for 31 individuals (4.6%) 
 
N of previous MAOI 
treatments  
0 for 104 individuals (95.4%) 
1 for 5 individuals (4.6%) 
0 for 656 individuals (98.2%) 
1 for 12 individuals (1.8%) 
N of previous treatments 
with other antidepressants  
0 for 86 individuals (78.9%) 
1 for 20 individuals (18.3%) 
2 for 3 individuals (2.8%) 
0 for 635 individuals (95.1%) 
1 for 31 individuals (4.6%) 








































































































































































































































































































































































































































































































































































































































































































Supplemental Table S6. Power analysis for GWAS of Treatment Resistance and 
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Generation Scotland: Scottish Family Health Study (GS:SFHS): GS:SFHS is a 
family and population-based cohort that were recruited at random from medical 
practices. Individuals were recruited if they were aged 18 or over and had a first-degree 
relative willing to take part (age range=18-98, mean age=47.6, s.d.=15.4). At initial 
testing over 21,500 individuals were assessed for mood, cognition, personality and 
clinical measurements. DNA was also collected for 98% of the cohort (B. Smith et al., 
2006; B. H. Smith et al., 2013). In 2014, a follow-up questionnaire was issued which 
included information on coping style and resilience (all of which were used in this 
study). Over 9,000 individuals returned these questionnaires (Navrady et al., 2017).  
Record linkage in GS:SFHS 
98% of the cohort consented to linkage to National Health Service (NHS) records 
which included the Prescribing Information System (PIS) and the Scottish Morbidity 
Record (SMR). Individuals with schizophrenia, schizoaffective and bipolar disorder 
were identified using the SMR, general hospital inpatient, general hospital outpatient 
and psychiatric inpatient/outpatient data (SMR00, SMR01, SMR04). Prescribing 
information was obtained through the PIS which is a record of all prescriptions issued 
through general practitioners (GPs), nurses, pharmacists and hospitals where the 
medication was dispensed in the community (hospital dispensed prescriptions are not 
included). 
Defining antidepressant treatment resistance (TR) 
TR was obtained by extracting all individuals in the cohort on antidepressants (Table 
S1). Prescribing information included the dose per prescription, the amount of drug 
prescribed and the instructions for intake. Instructions for intake were sometimes given 
as a range (e.g. “1-2 tablets per day”); where this was the case the minimum amount 
was selected for daily dose (to ensure at least the minimum dose threshold was met) 
and the maximum amount was selected for duration (to ensure at least the minimum 
duration was met). Daily dose was calculated using dose per prescription and 
instructions for intake and carried forward to calculate duration using the amount of 
drug prescribed. British National Formulary (BNF) (Joint Formulary Committee, 
2017) dose recommendations for major depressive disorder (MDD) differed for adults 
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(aged 18-64) and the elderly (age>64) therefore age at prescription was taken into 
account when carrying out dose exclusions. Duration was calculated by summing 
continuous prescriptions of the same antidepressant. As only the month and not the 
day of prescription was given, a 31 day margin was given when calculating continuous 
prescriptions. 
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Supplemental Table S1. Antidepressant prescription frequency table for 
unrelated sample in Generation Scotland: Scottish Family Health Study. 
 


























































































































































































































































































































































































































































































































































































































































































































































Supplemental Table S3. Fit statistics for mediation models with direct association 
between neuroticism and treatment resistance. 
 
Highlighted rows indicate models with good fit statistics (CFI>0.95, TLI>0.95, 
RMSEA>0.06). Abbreviations: BRS, brief resilience scale; CFI, comparative fit index; 





































 Fit statistics 
Mediators CFI TLI RMSEA 
BRS 0.97 0.96 0.048 
Task-orientated coping 1.0 1.0 0.013 
Emotion-orientated coping 0.98 0.94 0.036 
Avoidance-orientated coping 0.81 0.79 0.071 
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Supplemental Table S4. Factor loadings for the Brief Resilience Scale acting as a 






Beta (SE) P value 
BRS=~ BRS1 1.00 (0.000)  
BRS=~ BRS2 0.87 (0.039) 2.0x10-110 
BRS=~ BRS3 0.95 (0.042) 3.8x10-114 
BRS=~ BRS4 0.97 (0.042) 1.2x10-118 
BRS=~ BRS5 0.93 (0.041) 2.0x10-112 
BRS=~ BRS6 1.04 (0.044) 8.3x10-124 
 






































Supplemental Table S5. Factor loadings for task-orientated coping acting as a 






Beta (SE) P value 
ToC=~ ToC1 1.00 (0.000)  
ToC=~ ToC2 1.25 (0.038) 4.7x10-244 
ToC=~ ToC3 0.91 (0.030) 7.7x10-210 
ToC=~ ToC4 1.28 (0.038) 1.3x10-249 
ToC=~ ToC5 1.14 (0.035) 1.2x10-232 
ToC=~ ToC6 1.39 (0.040) 6.0x10-267 
ToC=~ ToC7 1.31 (0.038) 7.6x10-258 
ToC=~ ToC8 1.17 (0.035) 1.7x10-244 
ToC=~ ToC9 1.20 (0.036) 1.4x10-243 
ToC=~ ToC10 1.18 (0.036) 9.0x10-239 
ToC=~ ToC11 1.16 (0.035) 1.3x10-241 
ToC=~ ToC12 1.27 (0.037) 7.1x10-259 
ToC=~ ToC13 1.26 (0.037) 2.3x10-253 
ToC=~ ToC14 1.28 (0.038) 1.8x10-250 
ToC=~ ToC15 1.03 (0.032) 4.0x10-221 
ToC=~ ToC16 1.27 (0.037) 1.6x10-250 
 




























Supplemental Table S6. Factor loadings for emotion-orientated coping acting as 



















































Beta (SE) P value 
EoC=~ EoC1 1.00 (0.000)  
EoC=~ EoC2 0.71 (0.026) 3.7x10-161 
EoC=~ EoC3 1.32 (0.039) 2.9x10-254 
EoC=~ EoC4 1.40 (0.040) 2.5x10-272 
EoC=~ EoC5 1.31 (0.037) 1.3x10-267 
EoC=~ EoC6 0.42 (0.020) 7.1x10-92 
EoC=~ EoC7 1.31 (0.039) 6.0x10-253 
EoC=~ EoC8 1.35 (0.039) 4.0x10-269 
EoC=~ EoC9 1.39 (0.040) 1.6x10-268 
EoC=~ EoC10 1.07 (0.033) 5.8x10-239 
EoC=~ EoC11 1.04 (0.032) 1.3x10-231 
EoC=~ EoC12 1.39 (0.039) 5.1x10-272 
EoC=~ EoC13 0.92 (0.019) 2.0x10-6 
EoC=~ EoC14 1.24 (0.036) 8.0x10-254 
EoC=~ EoC15 1.07 (0.033) 2.5x10-227 
EoC=~ EoC16 0.91 (0.030) 1.9x10-198 
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Supplemental Table S7. Factor loadings for avoidance-orientated coping acting 







Beta (SE) P value 
AoC=~ AoC1 1.00 (0.110)  
AoC=~ AoC2 1.72 (0.110) 1.1x10-54 
AoC=~ AoC3 1.22 (0.087) 7.4x10-45 
AoC=~ AoC4 0.91 (0.077) 3.8x10-32 
AoC=~ AoC5 1.80 (0.116) 3.9x10-54 
AoC=~ AoC6 1.81 (0.115) 1.8x10-55 
AoC=~ AoC7 1.66 (0.108) 5.8x10-53 
AoC=~ AoC8 0.64 (0.046) 3.1x10-43 
AoC=~ AoC9 2.45 (0.148) 1.8x10-61 
AoC=~ AoC10 2.52 (0.153) 6.1x10-61 
AoC=~ AoC11 1.23 (0.090) 6.8x10-43 
AoC=~ AoC12 1.91 (0.119) 5.7x10-58 
AoC=~ AoC13 2.34 (0.143) 4.3x10-60 
AoC=~ AoC14 1.27 (0.085) 3.8x10-50 
AoC=~ AoC15 0.98 (0.077) 2.2x10-37 
AoC=~ AoC16 1.01 (0.081) 8.4x10-36 
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